Anti-lewis y antibody drug conjugates and uses thereof

Antibody conjugates targeting Lewis Y antigen on cancer cells provide improved selective delivery and stability, addressing the limitations of existing therapies by enhancing tumor inhibition and minimizing toxicity.

WO2026234451A1PCT designated stage Publication Date: 2026-11-12LIGACHEM BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/000272
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing cancer therapies lack selectivity towards cancer cells, leading to adverse effects on healthy cells and development of treatment resistance, necessitating the development of novel antibody-drug conjugates that target Lewis Y antigen for improved efficacy and minimal toxicity.

Method used

Development of antibody conjugates comprising anti-Lewis Y antibodies or antigen-binding fragments that deliver active agents specifically to cancer cells, utilizing a structure represented by General Formula I, with improved stability and efficacy.

Benefits of technology

The antibody conjugates exhibit improved selective delivery and stability, effectively inhibiting tumor growth and reducing side effects by targeting Lewis Y expressed on cancer cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000011_0001
    Figure IMGF000011_0001
  • Figure IMGF000012_0001
    Figure IMGF000012_0001
  • Figure IMGF000013_0001
    Figure IMGF000013_0001
Patent Text Reader

Abstract

The present disclosure relates to an antibody conjugate targeting Lewis Y antigen (Lewis Y or LeY) and use thereof, and more particularly, to an antibody conjugate comprising an antibody or antigen-binding fragment thereof that binds to Lewis Y; and use of antibody conjugates for the treatment and / or prevention of diseases, more particularly, hyperproliferative and / or angiogenic diseases, such as cancer diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket: LCH-04525

[0002] ANTI-LEWIS Y ANTIBODY DRUG CONJUGATES AND USES THEREOF Related Applications

[0003] This application claims the benefit of priority to U. S. Provisional Application Serial No. 63 / 802582, filed May 8, 2025, the content of which is hereby incorporated by reference in its entirety.

[0004] Background

[0005] Cancer is a disease caused by abnormal and uncontrolled cell growth in the tissues of the body. Cancer therapies comprise a wide range of therapeutic approaches, including surgery, radiation, and chemotherapy. Existing therapeutics often suffer from a number of disadvantages, such as a lack of selectivity of targeting cancer cells over normal, healthy cells, and the development of resistance by the cancer to the treatment. Accordingly, the focus of development has been on developing novel therapeutics to achieve improved efficacy and minimal toxicity / adverse effects through improved and selective action of the therapeutics on tumor cells or immediately adjacent tissues.

[0006] An antibody-drug conjugate (ADC) is a targeted technology that involves bonding a toxin or drug to an antibody. The antibody specifically recognizes and binds to an antigen present on the surface of a cancer cell. Once bound, the drug is released into or near the target cancer cell causing its death. The technology has superior efficacy over antibody therapies and substantially reduces the risk of adverse effects compared to conventional anti-cancer treatments. This is because ADCs deliver drugs to the target cancer cells with minimal impact to healthy cells, and only releases drugs under specific conditions. Despite these advantages, there remains a continuous need to develop new antibody-drug conjugates for cancer treatment.

[0007] Summary

[0008] In certain aspects, the present disclosure provides antibody conjugates comprising antiLewis Y antibodies or antigen-binding fragments thereof that bind to Lewis Y. In certain embodiments, the antibodies disclosed herein bind to Lewis Y expressed in a cancer cell and may be used to deliver an active agent to the cell. In certain embodiments, the antibodies disclosed herein bind to Lewis Y on cell surface, enabling improved selective delivery of the active agent. In certain embodiments, the antibody conjugates disclosed herein have improved stability and efficacy as compared to antibody conjugates known in the art.

[0009] 1

[0010] FH30010281.1Attorney Docket: LCH-04525

[0011] In certain aspects, the present disclosure provides a conjugate having a structure represented by General Formula I, or a pharmaceutically acceptable salt thereof:

[0012] [General Formula I]

[0013] Ab-[LAb-(B)i]m

[0014] wherein,

[0015] Ab is an anti-Lewis Y antibody or antigen-binding fragment thereof, comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein

[0016] CDRH1 comprises an amino acid sequence of SEQ ID NO: 2,

[0017] CDRH2 comprises an amino acid sequence of SEQ ID NO: 4,

[0018] CDRH3 comprises an amino acid sequence of SEQ ID NO: 6,

[0019] CDRL1 comprises an amino acid sequence of SEQ ID NO: 11,

[0020] CDRL2 comprises an amino acid sequence of SEQ ID NO: 13, and

[0021] CDRL3 comprises an amino acid sequence of SEQ ID NO: 15;

[0022] each LAbis, independently, a linker;

[0023] each B is, independently an active agent; and

[0024] 1 and m are each independently 1 to 20.

[0025] Brief Description of the Drawings

[0026] FIGs. 1A-1E show hydrophobic interaction chromatography (HIC) results for: (a) antibody Clone 2, prenylated antibody Clone 2, ADC 01, ADC 02, ADC 03, ADC 04, ADC 05, and ADC 06 (FIG. 1A); (b) antibody Clone 3, prenylated antibody Clone 3, ADC 07, ADC 08, ADC 09, ADIC 01, ADIC 02, ADIC 03, ADIC 04, and ADIC 05 (FIG. IB); (c) antibody Clone 4, prenylated antibody Clone 4, ADC 10, ADC 11, ADC 12, ADC 13, ADC 14, ADC 15, and ADC 16 (FIG. 1C); (d) antibody Clone 4, prenylated antibody Clone 4, ADIC 06, ADIC 07, ADIC 08, ADIC 09, ADIC 10, ADIC 11, ADIC 12, ADIC 13, and ADIC 14 (FIG. ID); and (e) antibody Clone 4, prenylated antibody Clone 4, and AIC 01 (FIG. IE).

[0027] FIG. 2 shows that ADC 02 exhibited dose-dependent tumor growth inhibition in the HT29 model compared to the control group.

[0028] 2

[0029] FH30010281.1Attorney Docket: LCH-04525

[0030] FIG. 3 shows that both ADC 02 and ADC 03 exhibited dose-dependent tumor growth inhibition in the OVCAR3 model compared to the control group.

[0031] FIG. 4 shows that both ADC 07 and ADC 08 exhibited potent anti-cancer efficacy and dose-dependent tumor growth inhibition in the HCT15 model compared to the control group.

[0032] FIG. 5 shows that both ADC 10 and ADC 12 exhibited potent anti-cancer efficacy in the HCT15 model compared to the control group.

[0033] FIGs. 6A-6B show that ADC 10 demonstrated excellent anti-cancer efficacy and dosedependent tumor growth inhibition in the OVCAR3 model (FIG. 6A) and in the NCI-N87 model (FIG. 6B) compared to the respective control group in each model.

[0034] FIG. 7 shows that ADC 12 exhibited excellent anti-cancer efficacy and dose-dependent tumor growth inhibition in the OVCAR3 model compared to the control group.

[0035] FIGs. 8A-8C show that ADC 11, ADC 13, ADC 14, ADC 15, and ADC 16 exhibited marked tumor growth inhibition at tested dosages in the OVCAR3 model (FIG. 8A), in the HCT15 model (FIG. 8B), and in the NCI-N87 model (FIG. 8C) compared to the respective control group in each model.

[0036] FIG. 9 shows that ADIC 02 exhibited potent tumor growth inhibition in the HCT15 model compared to the control group.

[0037] FIG. 10 shows that both ADIC 06 and ADIC 07 exhibited potent and sustained anticancer efficacy in the HCT15 model.

[0038] FIG. 11 shows that ADIC 07 demonstrated dose-dependent tumor growth inhibition and potent anti-cancer efficacy in the SNU840 model of ovarian cancer cell line.

[0039] FIGs. 12A-12C show that ADIC 8, ADIC 11, ADIC 12, ADIC 13, ADIC 14, and AIC 01 exhibited marked tumor growth inhibition at tested dosages in the OVCAR3 model (FIG.

[0040] 12A), in the HCT15 model (FIG. 12B), and in the NCI-N87 model (FIG. 12C) compared to the respective control group in each model.

[0041] FIGs. 13A-13E show pharmacokinetic profiling of antibody conjugate and total antibody plasma concentrations in rats post-administration of ADC 01 (FIG. 13A), ADC 02 (FIG. 13B), ADC 03 (FIG. 13C), ADC 12 (FIG. 13D), and ADIC 08 (FIG. 13E).

[0042] Detailed Description

[0043] An antibody-drug conjugate (ADC) is a targeted technology for conjugating a toxin or a drug to an antibody that binds to an antigen, by which the toxin or drug is released in or near target cancer cells to cause cell death. The ADC enables a drug to be accurately delivered to target cancer cells while minimally affecting healthy cells, and to be released only under 3

[0044] FH30010281.1Attorney Docket: LCH-04525

[0045] specific conditions, and thus has excellent efficacy compared to antibody therapeutic agents themselves and can remarkably reduce the risk of side effects compared to existing anticancer agents.

[0046] The basic structure of these ADCs is “antibody-linker-small molecule drug (toxin).” In this structure, the linker plays a functional role in linking the antibody and the drug, but in some cases also ensures that the drug is released from the antibody at the appropriate time, for example after reaching target cells. That is, the stability of the linker can play a very important role in the efficacy and safety such as systemic toxicity of an antibody-drug conjugate (Discovery Medicine 2010, 10(53): 329-39).

[0047] The use of monoclonal antibodies for cancer treatment has had substantial success. For example, monoclonal antibodies are suitable for target-directed addressing of tumor tissue and cancer cells. ADCs have become a novel and powerful option for the treatment of lymphomas and solid cancers, and immunomodulatory antibodies also have recently had considerable success in clinical trials. The development of therapeutic antibodies is based on deep understanding of cancer serology, protein engineering technology and the action thereof, mechanisms of resistance, and interactions between immune systems and cancer cells.

[0048] Antigens which are expressed on the surface of human cancer cells are defined as a broad range of targets which are over-expressed compared to normal tissues, mutated and selectively expressed. The key challenge is to identify antigens suitable for antibody-based therapies. These therapeutic agents mediate changes in antigen or receptor function ( / .<?., function as a stimulant or an antagonist), regulate the immune system through Fc and T cell activation, and exhibit efficacy through the delivery of specific drugs that bind to antibodies targeting specific antigens. Molecular techniques that can alter antibody pharmacokinetics, action function, size and immune stimulation are emerging as key factors in the development of novel antibody-based therapies. Evidence from clinical trials of therapeutic antibodies in cancer patients highlights the importance of approaches for selecting optimized antibodies, including affinity and binding of target antigens and antibodies, selection of an antibody structure, and therapeutic approaches (signaling blockade or immune function).

[0049] Lewis Y is a type 2 blood group-related difucosylated oligosaccharide with the structure [Fucal^2Gaipi^4(Fucal^3) GlcNAc i— > R], and is fucosylated by al, 2-fucosyltransferase at the end of glycan chain (Hokke et al. Glycobiology. 8(4): 393-406. 1998; Kitamura et al. Proc Natl Acad Sci U S A. 91(26): 12957-12961. 1994). Lewis Y is primarily expressed during the embryonic period, with limited expression on the surface of granulocytes and epithelium in adults under the physiological condition (Dettke et al. J Leukoc Biol.

[0050] 4

[0051] FH30010281.1Attorney Docket: LCH-04525

[0052] 68(4):511-514. 2000). Nevertheless, Lewis Y is highly expressed in the majority of carcinomas, including breast, ovary, colon, stomach, and liver cancers (Hellstrbm et al. Cancer Res. 50(7): 2183-2190. 1990; Zhang et al. Int J Cancer. 73(1): 50-56. 1997). Studies revealed that expression of Lewis Y on ovarian cancers could promote cancer cell proliferation (Liu et al. Oncol Rep. 23(3): 833-841. 2010). Additionally, a significant percentage of breast carcinomas, gastric cancers, and small cell lung cancers is Lewis Y positive, and overexpression of Lewis Y is associated with a significantly decreased patient survival rate (Madjd et al. Breast Cancer Res. 7(5): R780-787. 2005; Baldus et al. Histol Histopathol.

[0053] 21(5):503-510. 2006; Krug et al. J Thorac Oncol. 2: 947-952. 2007).

[0054] In certain aspects, the present disclosure provides antibody conjugates comprising an anti -Lewis Y antibody or antigen-binding fragment thereof. In certain embodiments, the antibody or antigen-binding fragment disclosed herein binds to Lewis Y, or preferably binds specifically to Lewis Y expressed on cell surface, enabling improved selective delivery of active agents (e.g., toxins) to cancer cells expressing Lewis Y. In certain embodiments, the antibody conjugates disclosed herein have improved stability and efficacy as compared to antibody drug conjugates known in the art.

[0055] In certain aspects, the present disclosure provides a conjugate having a structure represented by General Formula I, or a pharmaceutically acceptable salt thereof:

[0056] [General Formula I]

[0057] Ab-[LAb-(B)i]m

[0058] wherein,

[0059] Ab is an anti-Lewis Y antibody or antigen-binding fragment thereof, comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); wherein

[0060] CDRH1 comprises an amino acid sequence of SEQ ID NO: 2,

[0061] CDRH2 comprises an amino acid sequence of SEQ ID NO: 4,

[0062] CDRH3 comprises an amino acid sequence of SEQ ID NO: 6,

[0063] CDRL1 comprises an amino acid sequence of SEQ ID NO: 11,

[0064] CDRL2 comprises an amino acid sequence of SEQ ID NO: 13, and

[0065] CDRL3 comprises an amino acid sequence of SEQ ID NO: 15;

[0066] 5

[0067] FH30010281.1Attorney Docket: LCH-04525

[0068] each LAbis independently a linker;

[0069] each B is independently an active agent; and

[0070] 1 and m are each independently 1 to 20.

[0071] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising: the amino acid sequence of SEQ ID NO: 8; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 8 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 8.

[0072] In some embodiments, Ab comprises a light chain variable region (VL) comprising: the amino acid sequence of SEQ ID NO: 17; a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 17 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 11, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 13, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 15; or a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 11, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 13, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, Ab comprises a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 17.

[0073] In some embodiments, Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 8 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 17. In some embodiments, Ab specifically binds to Lewis Y. In some embodiments, Ab is a humanized antibody or a human antibody. In some embodiments, Ab is selected from a monoclonal antibody, a single chain antibody (scAb), a Fab fragment, a Fab' fragment, a F(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single chain variable fragment (scFv), an scFv-Fc fragment, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.

[0074] In some embodiments, Ab comprises an IgA, IgG, IgM, IgE, or IgD constant domain or is an IgA, IgG, IgM, IgE, or IgD antibody. In some embodiments, Ab comprises an IgG 6

[0075] FH30010281.1Attorney Docket: LCH-04525

[0076] constant domain or is an IgG antibody. In some embodiments, Ab comprises an IgGl, IgG2, IgG3, or IgG4 constant domain or is an IgGl, IgG2, IgG3, or IgG4 antibody. In some embodiments, Ab comprises an IgGl constant domain or is an IgGl antibody. In some embodiments, Ab comprises LALA mutations in a heavy chain constant domain. In some embodiments, the LALA mutations comprise L234A and L235A substitutions according to EU numbering convention. In some embodiments, Ab comprises leucine-to-alanine substitutions in a heavy chain constant region in place of amino acids corresponding to amino acids 233-234 in SEQ ID NO: 9. In some embodiments, Ab comprises a P329G substitution according to EU numbering convention. In some embodiments, Ab comprises a proline-to-glycine substitution in a heavy chain constant region in place of an amino acid corresponding to amino acid 328 in SEQ ID NO: 9. In some embodiments, Ab comprises (a) L234A, L235A, and P329G substitutions according to EU numbering convention; or (b) leucine-to-alanine substitutions in a heavy chain constant region in place of amino acids corresponding to amino acids 233-234 in SEQ ID NO: 9 and a proline-to-glycine substitution in the heavy chain constant region in place of an amino acid corresponding to amino acid 328 in SEQ ID NO: 9.

[0077] In some embodiments, Ab at the C-terminus comprises an amino acid motif that is recognized by an isoprenoid transferase. In some embodiments, the isoprenoid transferase is farnesyl protein transferase (FTase) or geranylgeranyl transferase (GGTase). In some embodiments, LAbis covalently bonded to Ab by a thioether bond and the thioether bond comprises a sulfur atom of a cysteine of the amino acid motif. In some embodiments, the amino acid motif comprises a CYaYaX sequence, wherein: C is cysteine; each Yais independently an aliphatic amino acid; and X is selected from glutamine, glutamate, serine, cysteine, methionine, alanine, and leucine. In some embodiments, each Yais independently selected from alanine, isoleucine, leucine, methionine, and valine. In some embodiments, the amino acid motif comprises a CVIM (SEQ ID NO: 22) or CVLL (SEQ ID NO: 23). In some embodiments, at least one of the 1 to 20 amino acids preceding the amino acid motif is glycine. In some embodiments, the amino acid motif has the sequence GGGGGGGCVIM (SEQ ID NO: 24).

[0078] In some embodiments, Ab comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 19; (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and a light chain comprising the amino acid sequence of SEQ ID NO: 19; (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 21, and a light chain comprising the amino acid sequence of SEQ ID NO: 19; (d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 18; (e) a heavy 7

[0079] FH30010281.1Attorney Docket: LCH-04525

[0080] chain comprising the amino acid sequence of SEQ ID NO: 20, and a light chain comprising the amino acid sequence of SEQ ID NO: 18; or (f) a heavy chain comprising the amino acid sequence of SEQ ID NO: 21, and a light chain comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and a light chain comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 21, and a light chain comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and a light chain comprising the amino acid sequence of SEQ ID NO: 18. In some embodiments, Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 21, and a light chain comprising the amino acid sequence of SEQ ID NO: 18.

[0081] In various embodiments, the present disclosure provides linkers, and conjugates comprising those linkers, as well as methods for their synthesis and for their use in therapeutic applications. In particular, the disclosure describes conjugates comprising a structure represented by a formula disclosed herein (e.g., Formula la, or Formula X). These structures incorporate multiple attachment points for coupling to active agents, allowing for the delivery of multiple payloads or the combination of different functionalities within a single conjugate. The branched structure may enhance the therapeutic efficacy, improve pharmacokinetic properties, or allow for the co-delivery of synergistic agents. The conjugates described herein may be particularly useful in the context of antibody-drug conjugates, but the technology is broadly applicable to various targeting moieties and payloads. Indeed, the linkers disclosed herein may be used with existing linker technology in multiple ways, as it sits within a well-developed field with numerous available techniques for assembly of conjugates:

[0082] 1. Maleimide conjugation: This method utilizes the reaction between maleimide groups and thiol groups. For example, antibodies can be partially reduced to expose cysteine residues, which then react with maleimide-functionalized linkers or payloads.

[0083] 8

[0084] FH30010281.1Attorney Docket: LCH-04525

[0085] 2. Cysteine Re-bridging: This technology creates homogeneous and stable ADCs by re-bridging reduced interchain disulfide bonds with bifunctional linkers, without the need for antibody engineering.

[0086] 3. N-Hydroxysuccinimide (NHS) ester conjugation: NHS esters react with primary amines, such as lysine residues on proteins. This method is commonly used for attaching linkers or payloads to antibodies or other targeting moieties.

[0087] 4. Click chemistry: Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and strain-promoted azide-alkyne cycloaddition (SPAAC) are widely used for bioorthogonal conjugation. These reactions allow for site-specific attachment of payloads to modified targeting moieties. Click chemistry offers high specificity and can be performed under mild conditions, making it suitable for a wide range of biomolecules. Recently, metal-free SPAAC cycloaddition reactions have been investigated, including dibenzocyclooctyne (DBCO)-derived molecules covalently linked to the azide group of a functionalized phenylalanine such as para- azidophenlyalanine (pAzF) or para-azidomethylphenylalanine (pAMF). Metal-free SPAAC reactions have been shown as promising conjugation reactions for homogeneous, highly stable conjugates with desirable pharmacokinetics and controlled delivery of the potent payload. See e.g., Xenobiotica 2024, Vol. 54, No.

[0088] 8, 469-491.

[0089] 5. Enzymatic conjugation: Methods such as sortase-mediated ligation or transglutaminase-catalyzed conjugation enable site-specific attachment of payloads to targeting moieties under mild conditions. Sortase A (SrtA) catalyzes transpeptidation to insert recognition peptides at the C-terminus of antibody chains, followed by payload attachment. Bacterial transglutaminases (BTGs) form amide bonds between lysine and glutamine residues, enabling stable payload attachment. Additional examples include (i) conjugation via formyl glycine-generating enzyme, which inserts a specific sequence, converting cysteine to formyl glycine, that can then be conjugated to aldehyde-containing payloads; and (ii) prenyltransferase- mediated conjugation, wherein farnesyl transferase attaches a ketone-functionalized isoprenoid to a C-terminal CaaX motif, which is then linked to a hydroxylamine- bearing payload via oxime ligation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408.

[0090] 6. Hydrazone and oxime ligation: These methods involve the reaction between aldehydes or ketones with hydrazides or aminooxy groups, respectively. Exemplary 9

[0091] FH30010281.1Attorney Docket: LCH-04525

[0092] methods include using amino-terminal engineered serine at the N-terminus, which is oxidized to an aldehyde for oxime ligation.

[0093] 7. Thiol-ene and thiol-yne reactions: These photoinitiated reactions allow for the conjugation of thiol-containing molecules to alkene or alkyne-functionalized components. These methods offer rapid reaction kinetics and can be performed under mild conditions, making them suitable for sensitive biomolecules.

[0094] 8. Diels-Alder cycloaddition: This reaction between a diene and a dienophile can be used for bioconjugation, particularly when using cyclic dienes like transcyclooctene. The reaction proceeds rapidly and specifically under physiological conditions.

[0095] 9. Staudinger ligation: This method involves the reaction between an azide and a phosphine to form an amide bond; the method offers high chemoselectivity and can be performed in aqueous media, making it suitable for bioconjugation.

[0096] 10. Photoclick chemistry: Light-induced cycloadditions, such as the reaction between tetrazoles and alkenes, provide spatiotemporal control over the conjugation process. This can be particularly useful for in situ labeling or activation of conjugates. 11. Ligation to Fab nucleotide-binding sites: A method which uses indole-based linkers to target lysine residues in the Fab region’s nucleotide-binding pocket for sitespecific conjugation. See e.g., Biomedicine & Pharmacotherapy 161 (2023) 114408.

[0097] Each conjugation method offers unique advantages and presents specific challenges, and the choice of conjugation method may depend on factors, as readily appreciated by the skilled artisan, such as the nature of the targeting moiety, the payload, and the desired properties of the final conjugate. In many cases, the targeting moiety or payload may be modified to introduce specific functional groups that facilitate conjugation. For example, antibodies may be engineered to incorporate non-natural amino acids with bioorthogonal reactive groups, allowing for conjugation.

[0098] The assembly of conjugates, including antibody-drug conjugates, is a well-established process in the art which can readily be adapted and applied to the embodiments disclosed herein. Those of ordinary skill in the art can readily employ various existing chemistry methods to assemble conjugates efficiently and reliably; such methods allow for the controlled attachment of payloads to targeting moieties through linkers. Several known chemistry methods for assembling conjugates include:

[0099] 10

[0100] FH30010281.1Attorney Docket: LCH-04525

[0101] Simply put, notwithstanding the challenges associated with particular linker designs, the conjugation chemistry used to assemble targeting moieties, linkers, and payloads into functional conjugates is a mature field. Indeed, numerous well-characterized methods, such as the methods mentioned above (e.g., such as maleimide-thiol reactions, click chemistry, NHS ester conjugation, and enzymatic ligation) are available and routinely employed by those of skill in the art. Thus, once the structure and properties of a linker and a synthetic route to the linker are established, the selection and application of appropriate conjugation chemistry to assemble a conjugate is generally routine and predictable.

[0102] The skilled artisan can modulate reaction conditions, such as pH, temperature, and reagent concentrations, to achieve desired conjugation efficiencies and product homogeneity. The use of organic co-solvents, catalysts, or additives may be employed to enhance reaction rates or selectivity. In some cases, multiple conjugation steps may be used to assemble complex conjugates with multiple payloads or functionalities.

[0103] In some embodiments, the conjugate has a structure represented by Formula la or a pharmaceutically acceptable salt thereof:

[0104]

[0105] Formula la

[0106] wherein

[0107] each instance of G is independently a sugar or a sugar acid (e.g., a glucuronic acid or galactoside);

[0108] R1and R2are each independently hydrogen, Ci-s alkyl, or C3-8 cycloalkyl; or R1and R2combine to complete a (Cs-Cs) cycloalkyl ring;

[0109] each instance of W is independently -C(O)-, -C(O)N(R’)-, -C(O)O-, -SC>2N(R’)-, -P(O)(R”)N(R’)-, -SON(R’)-, or -PO2N(R’)-;

[0110] each instance of R’ and R” is independently H, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl or aryl;

[0111] each instance of Z is independently alkyl, halo, cyano, or nitro;

[0112] 11

[0113] FH30010281.1Attorney Docket: LCH-04525

[0114] nl and n2 are each independently 1 to 20;

[0115] each instance of n3 is independently 0, 1, 2, or 3; and

[0116] Y1is absent, C1-C50 alkylene, C1-C50 alkenylene, 1-50 atom heterocyclylene, or 1-50 atom heteroalkylene.

[0117] In some embodiments, R1is H or methyl. In some embodiments, R1is H. In some embodiments, R1is methyl. In some embodiments, R2is H or methyl. In some embodiments, R2is H. In some embodiments, R2is methyl. In some embodiments, G has a structure represented by Formula II or a pharmaceutically acceptable salt thereof:

[0118]

[0119] II

[0120] wherein

[0121] R3and each R4is independently H, alkyl, aralkyl, or an oxygen protecting group;

[0122] R3ais H or alkyl;

[0123] R3bis H or alkyl; or

[0124] R3aand R3bcombine to form an oxo;

[0125] R3Ais H or a hydroxyl protecting group; and

[0126] R3Bis H or a carboxyl protecting group.

[0127] In some embodiments, R3is H or methyl. In some embodiments, R3is H. In some embodiments, R4is H. In some embodiments, W is -C(O)N(R’)- and the C(O) is bonded to the phenyl ring and N(R’) is bonded to Y1. In some embodiments, R’ is H. In some embodiments, R” is H. In some embodiments, Z is halo (e.g., bromo) or cyano. In some embodiments, n3 is 0 or 1. In some embodiments, n3 is 1. In some embodiments, n3 is 0.

[0128] In some embodiments, Y1comprises an alkylene (e.g., a C1-50 alkylene). In some embodiments, Y1comprises a heteroalkylene (e.g., a C1-50 heteroalkylene). In some embodiments, Y1comprises an unsaturated bond (e.g., 1, 2, 3, 4 or 5 unsaturated bonds). In some embodiments, Y1is substituted with alkyl (e.g., a C1-20 alkyl). In some embodiments, Y1comprises an isoprenyl group having a structure represented by Formula III:

[0129] 12

[0130] FH30010281.1Attorney Docket: LCH-04525

[0131]

[0132] Ill

[0133] wherein n4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, n4 is 1, 2, 3, or 4.

[0134] In some embodiments, Y1comprises a C1-50 alkylene or C1-50 heteroalkylene wherein the Ci -50 alkylene or C1-50 heteroalkylene comprises one or more of:

[0135] (i) one or more unsaturated bonds;

[0136] (ii) a heteroarylene (e.g., a heteroarylene in the alkylene or heteroalkylene chain); (iii) at least one C1-20 alkyl substituent; and

[0137] (iv) at least one isoprenyl group having a structure represented Formula III:

[0138]

[0139] wherein n4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some embodiments, n4 is 1, 2, 3, or 4.

[0140] In some embodiments, Y1comprises a peptide comprising at least one hydrophilic amino acid. In some embodiments, the peptide comprises an amino acid having a side chain having a moiety that bears a charge at neutral pH in aqueous solution (e.g., an amine, guanidine, or carboxyl moiety). In some embodiments, the peptide comprises an amino acid selected from alanine, aspartate, asparagine, glutamate, glutamine, glycine, lysine, ornithine, proline, serine, histidine, arginine and threonine.

[0141] In some embodiments, Y1comprises a unit having a structure represented by Formula IVa or IVb:

[0142] -(CH2)r(V(CH2)p)q- Formula IVa,

[0143] -(CH2CH2X)W- Formula IVb;

[0144] wherein

[0145] V is a single bond, -O-, -S-, -NR5-, -C(O)NR6-, -NR7C(O)-, -NR8SO2-, or -SO2NR9-, preferably -O-;

[0146] 13

[0147] FH30010281.1Attorney Docket: LCH-04525

[0148] X is -0-, Ci-8 alkylene, or -NR5-, preferably -O-;

[0149] R5to R9are each independently H, Ci-6 alkyl, Ci-6 alkyl C6-20 aryl, or C1-6 alkyl C3-20 heteroaryl;

[0150] r is an integer of 1 to 10, preferably 2;

[0151] p is an integer of 0 to 12, preferably 2;

[0152] q is an integer of 1 to 20, preferably 2, 5, or 11; and

[0153] w is an integer of 1 to 20, preferably 6 to 20.

[0154] In some embodiments, V is -O-. In some embodiments, X is -O-. In some embodiments, R5is H. In some embodiments, R6is H. In some embodiments, R7is H. In some embodiments, R8is H. In some embodiments, R9is H. In some embodiments, each R5, R6, R7, R8, and R9is H. In some embodiments, r is 2. In some embodiments, p is 2. In some embodiments, q is 2, 5, or 11. In some embodiments, w is 6 to 20. In some embodiments, r is 2; p is 2; q is 2, 5, or 11; and w is 6 to 20.

[0155] In some embodiments, Y1further comprises a binding unit formed by a reaction between an alkyne and an azide or between an aldehyde or ketone group and hydrazine or hydroxylamine. In some embodiments, Y1comprises a unit having a structure represented by Formula Va, Vb, Vc, Vd, or Ve:

[0156]

[0157] wherein

[0158] L1is a single bond or C1-30 alkylene; and

[0159] R10is H or Ci-10 alkyl.

[0160] In some embodiments, L1is a single bond. In some embodiments, L1is C1-30 alkylene. In some embodiments, R10is H. In some embodiments, R10is C1-10 alkyl (e.g., methyl).

[0161] In some embodiments, Y1comprises an oxime. In some embodiments, the oxygen atom of the oxime is on the side of Y1that is linked to W and the carbon atom of the oxime is on the side of Y1that is linked to Ab. In some embodiments, the carbon atom of the oxime is on the side of Y1that is linked to W and the oxygen atom of the oxime is on the side of Y that is linked to Ab.

[0162] In some embodiments, the oxime has a structure represented by Formula Via:

[0163] 14

[0164] FH30010281.1Attorney Docket: LCH-04525

[0165]

[0166] wherein

[0167] R11is H, alkyl or cycloalkyl; and

[0168] R12is H, alkyl or cycloalkyl; or

[0169] R11and R12combine to form a cycloalkyl.

[0170] In some embodiments, each R11and R12is independently H or alkyl. In some embodiments, R11is alkyl, preferably methyl. In some embodiments, R11is H. In some embodiments, R12is alkyl, preferably methyl. In some embodiments, R12is H. In some embodiments, R11and R12combine to form a cycloalkyl, preferably cyclobutyl.

[0171] In some embodiments, the oxime has a structure represented by formula VIb:

[0172]

[0173] VIb

[0174] wherein

[0175] R11and R12are independently H, alkyl or cycloalkyl; or R11and R12combine to form a cycloalkyl;

[0176] X1and X2are each independently N(R13), O, or S; and R13is H, alkyl, aryl, or aralkyl. In some embodiments, X1is N(R13). In some embodiments, R13is H. In some embodiments, X1is N(R13), and R13is H. In some embodiments, X2is O.

[0177] In some embodiments, Y1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene

[0178] glycol moieties represented by

[0179]

[0180] (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol

[0181] 15

[0182] FH30010281.1Attorney Docket: LCH-04525

[0183] comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties represented

[0184] by

[0185]

[0186] (e.g, 1, 2, 3, or 4 ethylene glycol moieties).

[0187] In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, Y1comprises an oxime and the oligoethylene glycol covalently bonds the oxime to W. In some embodiments, Y1is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, Y1is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino). In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino).

[0188] In some embodiments, Y1further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, Y1further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, Y1further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine.

[0189] In some embodiments, Y1is linear. In some embodiments, Y1is branched. In some embodiments, Y1comprises:

[0190] i) a branching unit covalently coupled to Ab by a primary linker;

[0191] ii) a first branch, covalently coupled to W; and

[0192] iiia) a second branch which couples an active agent, via a cleavage group, to the branching unit; or

[0193] 16

[0194] FH30010281.1Attorney Docket: LCH-04525

[0195] iiib) a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.

[0196] In some embodiments, Y1comprises a second branch which couples an active agent, via a cleavage group, to the branching unit. In some embodiments, Y1comprises a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.

[0197] In some embodiments, Y1comprises:

[0198] i) a branching unit covalently coupled to Ab by a primary linker;

[0199] ii) a first branch which couples a first B to the branching unit; and

[0200] iiia) a second branch which couples a second B to the branching unit; or

[0201] iiib) a second branch comprising an alkyl or heteroalkyl e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) is covalently coupled to the branching unit.

[0202] In some embodiments, Y1comprises a second branch which couples a second B, via a cleavage group, to the branching unit. In some embodiments, Y1comprises a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.

[0203] In some embodiments, the branching unit comprises an amino acid. In some embodiments, the branching unit comprises a lysine residue. In some embodiments, the branching unit has a structure represented by Formula Vila, Vllb, Vile, or Vlld:

[0204]

[0205] wherein

[0206] 17

[0207] FH30010281.1Attorney Docket: LCH-04525

[0208] G1, G2, G3are each independently a bond,

[0209]

[0210]

[0211] R14is H or alkyl;

[0212] R15is H, alkyl or L5-CO2R16

[0213] R16is H or alkyl; and

[0214] L2, L3, L4, and L5are each independently a bond or alkylene.

[0215] In some embodiments, the branching unit has a structure represented by Formula Villa:

[0216]

[0217] Villa

[0218] wherein R14is H or alkyl.

[0219] In some embodiments, the branching unit has a structure represented by Formula Vlllb:

[0220]

[0221] Vlllb

[0222] wherein R14is H or alkyl.

[0223] In some embodiments, the cleavage group has a structure represented by Formula IX or a pharmaceutically acceptable salt thereof:

[0224] 18

[0225] FH30010281.1Attorney Docket: LCH-04525

[0226]

[0227] IX

[0228] wherein

[0229] Bw is an active agent;

[0230] each Rw2, Rw3, Rw4, and Rw5is independently H, alkyl, aralkyl, or an oxygen protecting group;

[0231] each Rw6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkyl sulfonyl, or sulfonamido;

[0232] each Ww1is independently -*C(O)-, -*C(O)N(Rw7)-, -*N(Rw7)C(O)-, - *(CH2)twiN(Rw7)C(O)-, -*C(O)O-, -*S(O2)N(RW7)-, -*P(O)( RW8)N(RW7)-, - *S(O)N(Rw7)-, or

[0233] -*P(O2)N(RW7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula IX;

[0234] Rw7and Rw8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0235] twl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0236] nwl is 0, 1, 2, or 3;

[0237] Jw1is H or alkyl;

[0238] Jw2is H or alkyl; or

[0239] Jw1and Jw2combine to form an oxo; and

[0240] Aw2represents a linkage to the secondary linker.

[0241] In some embodiments, at least one branched linker is covalently coupled to Ab; and at least two B are covalently coupled to the branched linker. The two B may be the same or are

[0242] 19

[0243] FH30010281.1Attorney Docket: LCH-04525

[0244] different from each other. In some embodiments, the conjugate comprises 1, 2, 3, or 4 branched linkers and each branched linker comprises two B.

[0245] In some embodiments, the conjugate comprises a structure represented by:

[0246]

[0247] or a pharmaceutically acceptable salt thereof; wherein

[0248] B' and B" are each an active agent;

[0249] nil, n22, and n33 are each independently 0 to 30;

[0250] AA is an amino acid group (e.g., a lysine); and

[0251] the wavy bond represents a connection to Ab.

[0252] In some embodiments, the conjugate comprises a structure represented by Formula X or a pharmaceutically acceptable salt thereof:

[0253] 20

[0254] FH30010281.1Attorney Docket: LCH-04525

[0255]

[0256] Formula X

[0257] wherein

[0258] L6comprises an alkylene;

[0259] Y2and Y4are each independently O, N(R17), or S;

[0260] Yxis H;

[0261] X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-,

[0262] -OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, -N(R19)P(O)(R18)-, -P(O)2N(R19)-, or -N(R19)P(O)2-;

[0263] R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;

[0264] each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0265] V1and V3are each independently a bond, N, NH, C, CH, or CH2;

[0266] L7and L9each independently comprise an alkylene;

[0267] T1and T3are each independently a bond, -O-, or a self-immolative moiety;

[0268] B1and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; or

[0269] V1, T1and B1or V3, T3and B3together represent a branched moiety; and

[0270] ml and m3 are each independently 1, 2, or 3.

[0271] In some embodiments, the conjugate has a structure represented by Formula XI or a pharmaceutically acceptable salt thereof:

[0272]

[0273] 21

[0274] FH30010281.1Attorney Docket: LCH-04525

[0275] Formula XI

[0276] wherein

[0277] L6comprises an alkylene;

[0278] Y2, Y3, and Y4are each independently O, N(R17), or S;

[0279] X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-,

[0280] -OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, -N(R19)P(O)(R18)-, -P(O)2N(R19)-, or -N(R19)P(O)2-;

[0281] R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;

[0282] each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0283] V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;

[0284] L7, L8, and L9each independently comprise an alkylene;

[0285] T1, T2, and T3are each independently a bond, -O-, or a self-immolative moiety;

[0286] B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, amido, guanidinyl, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; or

[0287] V1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety; and ml, m2, and m3 are each independently 1, 2, or 3.

[0288] Those of skill in the art will recognize that variables V1and ml, V2and m2, and V3and m3 are related. For example, those of skill in the art will understand that if ml is 3, then V3will have 3 open valencies. Likewise, if ml is 1, then V1will have at least one open valency. Simply put, the skilled artisan will understand that V1and ml, V2and m2, and V3and m3 will be combined in such a way that stable configurations are obtained based on the valencies required.

[0289] In some embodiments, Y2is O. In some embodiments, Y3is O. In some embodiments, Y4is O. In some embodiments, each of Y2, Y3, and Y4is O. In some embodiments, X1is -N(R18)C(O)-. In some embodiments, X1is -C(O)N(R18)-. In some embodiments, R18is H. In some embodiments, X1is -C(O)N(R18)-, and R18is H. In some embodiments, L6comprises a Ci-Cioo alkylene. In some embodiments, L6comprises a C1-C50 alkylene. In some embodiments, L6further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0290] 22

[0291] FH30010281.1Attorney Docket: LCH-04525

[0292] In some embodiments, L6is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, L6further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, L6further comprises a structure represented by Formula Xia:

[0293]

[0294] Xia

[0295] wherein

[0296] A1represents a linkage to X1;

[0297] A2represents a linkage to Ab;

[0298] X3and X4are each independently O, S, or N(R23);

[0299] R20and R21are each H or alkyl; or R20and R21combine to form a cycloalkyl;

[0300] R22is H or alkyl; and

[0301] R23is H, alkyl, aryl, or aralkyl.

[0302] In some embodiments, X3is N(R23). In some embodiments, R23is H. In some embodiments, X3is N(R23), and R23is H. In some embodiments, X4is O. In some embodiments, R20is alkyl (e.g., methyl). In some embodiments, R21is H. In some embodiments, R21is alkyl (e.g., methyl). In some embodiments, R20and R21combine to form a cycloalkyl (e.g., cyclobutyl). In some embodiments, R22is H. In some embodiments, R22is alkyl.

[0303] In some embodiments, L6further comprises a structure represented by formula Xlb:

[0304] At / O.

[0305] X N

[0306] R20R21! L

[0307] 2

[0308] Xlb

[0309] wherein

[0310] A1represents a linkage to X1;

[0311] A2represents a linkage to Ab;

[0312] R20and R21are each H or alkyl; or R20and R21combine to form a cycloalkyl; and

[0313] R22is H or alkyl.

[0314] 23

[0315] FH30010281.1Attorney Docket: LCH-04525

[0316] In some embodiments, R20is alkyl (e.g., methyl). In some embodiments, R21is H. In some embodiments, R21is alkyl (e.g., methyl). In some embodiments, R20and R21combine to form a cycloalkyl (e.g., cyclobutyl). In some embodiments, R22is H. In some embodiments, R22is alkyl.

[0317] In some embodiments, L6further comprises a structure represented by Formula Xia or Formula Xlb:

[0318]

[0319] Xlb.

[0320] In some embodiments, L6further comprises a structure represented by Formula Xlla, Xllb, or XIIc:

[0321]

[0322] Xlla Xllb XIIc wherein

[0323] each A1represents a linkage to X1;

[0324] each A2represents a linkage to Ab.

[0325] In some embodiments, L6further comprises a heteroaryl (e.g., pyrazolyl, triazolyl). In some embodiments, L6further comprises a structure represented by Formula Xllla or XIIIb:

[0326]

[0327] Xllla Xlllb

[0328] wherein

[0329] each A1represents a linkage to X1; and

[0330] 24

[0331] FH30010281.1Attorney Docket: LCH-04525

[0332] each A2represents a linkage to Ab.

[0333] In some embodiments, L6further comprises a structure represented by Formula XIV:

[0334]

[0335] XIV

[0336] wherein n5 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;

[0337] each A1represents a linkage to X1; and

[0338] each A2represents a linkage to Ab. In some embodiments, n5 is 1, 2, 3, 4, or 5.

[0339] In some embodiments, L6is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moi eties (e.g., 1, 2, 3, or 4 ethylene glycol moi eties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino e.g., dimethylamino). In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino). In some embodiments, L6further comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, L6comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl). In some embodiments, L6further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L6further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine. In some embodiments, L6further comprises a polypeptoid (e.g., polysarcosine).

[0340] In some embodiments, L7comprises a Ci-Cioo alkylene. In some embodiments, L7comprises a C1-C50 alkylene. In some embodiments, L7further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,

[0341] 25

[0342] FH30010281.1Attorney Docket: LCH-04525

[0343] 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In some embodiments, L7further comprises an amido moiety. In some embodiments, L7further comprises 1, 2, 3, 4, 5, or 6 amido moieties. In some embodiments, L7further comprises 1 or 2 amido moieties. In some embodiments, L7further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, L7further comprises a heteroaryl e.g., pyrazolyl, triazolyl). In some embodiments, L7further comprises a structure represented by Formula XVa or XVb:

[0344]

[0345] wherein:

[0346] each Ax1represents a linkage to V1; and

[0347] each Ax2represents a linkage to Y2.

[0348] In some embodiments, L7is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino). In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino). In some embodiments, L7is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, L7comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, L7further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L7further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some

[0349] 26

[0350] FH30010281.1Attorney Docket: LCH-04525

[0351] embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.

[0352] In some embodiments, V1is a bond. In some embodiments, V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIa or a pharmaceutically acceptable salt thereof:

[0353]

[0354] XVIa

[0355] wherein:

[0356] Ax3represents a linkage to L7;

[0357] Lx1and Lx2each independently comprise an alkylene;

[0358] Tx1and Tx2are each independently a bond or a self-immolative moiety; and

[0359] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0360] In some embodiments, V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIb, Formula XVIc, or Formula XVId, or a pharmaceutically acceptable salt thereof:

[0361]

[0362] 27

[0363] FH30010281.1Attorney Docket: LCH-04525

[0364] XVId,

[0365] wherein:

[0366] Ax3represents a linkage to L7;

[0367] Lx1, Lx2, and Lx3each independently comprise an alkylene;

[0368] Gx1, Gx2, and Gx3are each independently an alkylene,

[0369]

[0370] each Rx1is independently H, alkyl, or aralkyl;

[0371] Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; and

[0372] Bx1, Bx2, and Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0373] In some embodiments, V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIb or a pharmaceutically acceptable salt thereof:

[0374]

[0375] XVIb

[0376] wherein:

[0377] Ax3represents a linkage to L7;

[0378] Lx1and Lx2each independently comprise an alkylene;

[0379] Tx1and Tx2are each independently a bond or a self-immolative moiety; and

[0380] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0381] In some embodiments, V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIc or a pharmaceutically acceptable salt thereof:

[0382]

[0383] XVIc

[0384] wherein:

[0385] 28

[0386] FH30010281.1Attorney Docket: LCH-04525

[0387] Ax3represents a linkage to L7;

[0388] Lx1and Lx2each independently comprise an alkylene;

[0389] Gx1, Gx2, and Gx3are each independently an alkylene,

[0390]

[0391] each Rx1is independently H, alkyl, or aralkyl;

[0392] Tx1and Tx2are each independently a bond or a self-immolative moiety; and

[0393] Bx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0394] In some embodiments, V1is CH or C, valence permitting, and V1, T1and B1together represent a branched moiety having a structure represented by Formula XVId or a pharmaceutically acceptable salt thereof:

[0395]

[0396] XVId

[0397] wherein:

[0398] Ax3represents a linkage to L7;

[0399] Lx1, Lx2, and Lx3each independently comprise an alkylene;

[0400] Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; and

[0401] Bx1, Bx2, Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0402] In some embodiments, Lx1comprises a C1-C100 alkylene. In some embodiments, Lx1comprises a C1-C50 alkylene. In some embodiments, Lx1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol comprises 4 ethylene glycol moieties.

[0403] In some embodiments, Lx2comprises a C1-C100 alkylene. In some embodiments, Lx2comprises a C1-C50 alkylene. In some embodiments, Lx2further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,

[0404] 29

[0405] FH30010281.1Attorney Docket: LCH-04525

[0406] 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0407] In some embodiments, Lx3comprises a Ci-Cioo alkylene. In some embodiments, Lx3comprises a C1-C50 alkylene. In some embodiments, Lx3further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0408] In some embodiments, T1, Tx1, Tx2, or Tx3has a structure represented by Formula XVII or a pharmaceutically acceptable salt thereof:

[0409]

[0410] wherein

[0411] each Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group;

[0412] each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;

[0413] Wx1is -*C(O)-, -*C(O)N(Rx7)-, -*N(RX7)C(O)-, -*(CH2)tx1N(Rx7)C(O)-, -*C(O)O-, -*S(O2)N(Rx7)-, -*P(O)(Rx8)N(Rx7)-, -*S(O)N(Rx7)-, or -*P(O2)N(Rx7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XVII, Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0414] Ja1is H or alkyl;

[0415] Ja2is H or alkyl; or

[0416] 30

[0417] FH30010281.1Attorney Docket: LCH-04525

[0418] Ja1and Ja2combine to form an oxo;

[0419] tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0420] nxl is 0, 1, 2, or 3;

[0421] Ax4represents a linkage to B1, Bx1, Bx2, or Bx3; and

[0422] Ax5represents a linkage to L7, Lx1, Lx2, or Lx3.

[0423] In some embodiments, Rx2is H. In some embodiments, Rx3is H. In some embodiments, Rx4is H. In some embodiments, Rx5is H. In some embodiments, each Rx2, Rx3, Rx4, and Rx5is H. In some embodiments, nxl is 0. In some embodiments, Wx1is -*C(O)N(Rx7)-. In some embodiments, Rx7is H. In some embodiments, Wx1is -*C(O)N(Rx7)-, and Rx7is H. In some embodiments, Ja1is H. In some embodiments, Ja2is H. In some embodiments, Ja1and Ja2combine to form oxo.

[0424] In some embodiments, B1is an active agent. In some embodiments, ml is 1. In some embodiments, ml is 2. In some embodiments, ml is 3. In some embodiments, each T1is a bond. In some embodiments, each B1is H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0425] In some embodiments, L8comprises a Ci-Cioo alkylene. In some embodiments, L8comprises a C1-C50 alkylene. In some embodiments, L8further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In some embodiments, the oligoethylene glycol comprises 6 ethylene glycol moieties. In some embodiments, L8further comprises an amido moiety. In some embodiments, L8further comprises 1, 2, 3, 4, 5, or 6 amido moieties. In some embodiments, L8further comprises 1 or 2 optionally substituted amido moieties e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, L8further comprises a heteroaryl (e.g., pyrazolyl, triazolyl). In some embodiments, L8further comprises a structure represented by Formula XVIIIa or XVIIIb:

[0426]

[0427] XVIIIa XVIIIb

[0428] wherein:

[0429] each Ay1represents a linkage to V2; and

[0430] 31

[0431] FH30010281.1Attorney Docket: LCH-04525

[0432] each Ay2represents a linkage to Y3.

[0433] In some embodiments, L8is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino e.g., dimethylamino). In some embodiments, L8is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino). In some embodiments, L8further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L8further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.

[0434] In some embodiments, V2is a bond. In some embodiments, V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XIXa or a pharmaceutically acceptable salt thereof:

[0435]

[0436] XIXa

[0437] wherein:

[0438] Ay3represents a linkage to L8;

[0439] Ly1and Ly2each independently comprise an alkylene;

[0440] Ty1and Ty2are each independently a bond, or a self-immolative moiety; and

[0441] 32

[0442] FH30010281.1Attorney Docket: LCH-04525

[0443] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0444] In some embodiments, V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XlXb, Formula XIXc, or Formula XlXd, or a pharmaceutically acceptable salt thereof:

[0445]

[0446] XlXd,

[0447] wherein:

[0448] Ay3represents a linkage to L8;

[0449] Ly1, Ly2, and Ly3each independently comprise an alkylene;

[0450] Gy1, Gy2, and Gy3are each independently an alkylene,

[0451]

[0452] each Ry1is independently H, alkyl, or aralkyl;

[0453] Ty1, Ty2, andTy3are each independently a bond or a self-immolative moiety; and

[0454] By1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0455] In some embodiments, V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XlXb or a pharmaceutically acceptable salt thereof:

[0456] 33

[0457] FH30010281.1Attorney Docket: LCH-04525

[0458]

[0459] XlXb

[0460] wherein:

[0461] Ay3represents a linkage to L8;

[0462] Ly1and Ly2each independently comprise an alkylene;

[0463] Ty1and Ty2are each independently a bond or a self-immolative moiety; and

[0464] By1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0465] In some embodiments, V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XIXc or a pharmaceutically acceptable salt thereof:

[0466]

[0467] XIXc

[0468] wherein:

[0469] Ay3represents a linkage to L8; and

[0470] Ly1and Ly2each independently comprise an alkylene;

[0471] Gy1, Gy2, and Gy3are each independently an alkylene,

[0472]

[0473] each Ry1is independently H, alkyl, or aralkyl;

[0474] Ty1and Ty2are each independently a bond or a self-immolative moiety; and

[0475] By1and By2are each independently an active agent (e.g., a drug or a toxin).

[0476] In some embodiments, V2is CH or C, valence permitting, and V2, T2and B2together represent a branched moiety having a structure represented by Formula XlXd or a pharmaceutically acceptable salt thereof:

[0477] 34

[0478] FH30010281.1Attorney Docket: LCH-04525

[0479]

[0480] XlXd

[0481] wherein:

[0482] Ay3represents a linkage to L8;

[0483] Ly1, Ly2, and Ly3each independently comprise an alkylene;

[0484] Ty1, Ty2, and Ty3are each independently a bond or a self-immolative moiety; and

[0485] By1, By2, By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0486] In some embodiments, Ly1comprises a C1-C100 alkylene. In some embodiments, Ly1comprises a C1-C50 alkylene. In some embodiments, Ly1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, Ly2comprises a C1-C100 alkylene.

[0487] In some embodiments, Ly2comprises a C1-C50 alkylene. In some embodiments, Ly2further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0488] In some embodiments, Ly3comprises a C1-C100 alkylene. In some embodiments, Ly3comprises a C1-C50 alkylene. In some embodiments, Ly3further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0489] In some embodiments, T2, Ty1, Ty2, or Ty3has a structure represented by Formula XX or a pharmaceutically acceptable salt thereof:

[0490] 35

[0491] FH30010281.1Attorney Docket: LCH-04525

[0492]

[0493] XX

[0494] wherein

[0495] each Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group;

[0496] each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;

[0497] each Wy1is independently - -*C(O)O-, -*S(O2)N

[0498]

[0499] wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XX,

[0500] Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0501] Jb1is H or alkyl;

[0502] Jb2is H or alkyl; or

[0503] Jb1and Jb2combine to form an oxo;

[0504] tyl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0505] nyl is 0, 1, 2, or 3;

[0506] Ay4represents a linkage to B1, By1, By2, or By3; and

[0507] Ay5represents a linkage to L8, Ly1, Ly2, or Ly3.

[0508] In some embodiments, each Ry2is H. In some embodiments, each Ry3is H. In some embodiments, each Ry4is H. In some embodiments, each Ry5is H. In some embodiments, each of Ry2, Ry3, Ry4, and Ry5is H. In some embodiments, each nyl is 0. In some embodiments,

[0509] 36

[0510] FH30010281.1Attorney Docket: LCH-04525

[0511] each Wy1is -*C(O)N(Ry7)-. In some embodiments, each Ry7is H. In some embodiments, each Wy1is -*C(O)N(Ry7)-, and each Ry7is H. In some embodiments, Jb1is H. In some embodiments, Jb2is H. In some embodiments, Jb1and Jb2combine to form oxo. In some embodiments, B2is an active agent. In some embodiments, m2 is 1. In some embodiments, m2 is 2. In some embodiments, m2 is 3. In some embodiments, each T2is a bond. In some embodiments, each B2is H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0512] In some embodiments, L9comprises a Ci-Cioo alkylene. In some embodiments, L9comprises a C1-C50 alkylene. In some embodiments, L9further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 6 ethylene glycol moieties. In some embodiments, the oligoethylene glycol further comprises an amido moiety. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, or 6 amido moieties. In some embodiments, the oligoethylene glycol comprises 1 or 2 amido moieties. In some embodiments, L9further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, L9further comprises a heteroaryl (e.g., pyrazolyl, triazolyl). In some embodiments, L9further comprises a structure represented by Formula XXIa or XXIb:

[0513]

[0514] XXIa XXIb

[0515] wherein:

[0516] each Az1represents a linkage to V3; and

[0517] each Az2represents a linkage to Y4.

[0518] In some embodiments, L9is substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino). In some embodiments, L9is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl,

[0519] 37

[0520] FH30010281.1Attorney Docket: LCH-04525

[0521] acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino e.g., dimethylamino). In some embodiments, L9further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, L9further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.

[0522] In some embodiments, V3is a bond. In some embodiments, V3is N and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIa or a pharmaceutically acceptable salt thereof:

[0523]

[0524] XXIIa

[0525] wherein:

[0526] Az3represents a linkage to L9;

[0527] Lz1and Lz2each independently comprise an alkylene;

[0528] Tz1and Tz2are each independently a bond or a self-immolative moiety; and

[0529] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin).

[0530] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIb, Formula XXIIc, or Formula XXIId, or a pharmaceutically acceptable salt thereof:

[0531]

[0532] XXIIb,

[0533] 38

[0534] FH30010281.1Attorney Docket: LCH-04525

[0535]

[0536] XXIId,

[0537] wherein:

[0538] Az3represents a linkage to L9;

[0539] Lz1, Lz2, and Lz3each independently comprise an alkylene;

[0540] Gz1, Gz2, and Gz3are each independently an alkylene,

[0541]

[0542] each Rz1is independently H, alkyl, or aralkyl;

[0543] Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; and

[0544] Bz1, Bz2, andBz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0545] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIb or a pharmaceutically acceptable salt thereof:

[0546]

[0547] XXIIb

[0548] wherein:

[0549] Az3represents a linkage to L9;

[0550] Lz1and Lz2each independently comprise an alkylene;

[0551] Tz1and Tz2are each independently a bond or a self-immolative moiety; and

[0552] 39

[0553] FH30010281.1Attorney Docket: LCH-04525

[0554] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0555] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIc or a pharmaceutically acceptable salt thereof:

[0556]

[0557] XXIIc

[0558] wherein:

[0559] Az3represents a linkage to L9;

[0560] Lz1and Lz2each independently comprise an alkylene;

[0561] Gz1, Gz2, and Gz3are each independently an alkylene,

[0562]

[0563] each Rz1is independently H, alkyl, or aralkyl;

[0564] Tz1and Tz2are each independently a bond or a self-immolative moiety; and

[0565] Bz1and Bz2are each independently an active agent (e.g., a drug or a toxin).

[0566] In some embodiments, V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIId or a pharmaceutically acceptable salt thereof:

[0567]

[0568] XXIId

[0569] wherein:

[0570] Az3represents a linkage to L9;

[0571] Lz1, Lz2, and Lz3each independently comprise an alkylene;

[0572] Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; and

[0573] 40

[0574] FH30010281.1Attorney Docket: LCH-04525

[0575] Bz1, Bz2, Bz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

[0576] In some embodiments, Lz1comprises a C1-C100 alkylene. In some embodiments, Lz1comprises a C1-C50 alkylene. In some embodiments, Lz1further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, Lz1comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0577] In some embodiments, Lz2comprises a C1-C100 alkylene. In some embodiments, Lz2comprises a C1-C50 alkylene. In some embodiments, Lz2further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0578] In some embodiments, Lz3comprises a C1-C100 alkylene. In some embodiments, Lz3comprises a C1-C50 alkylene. In some embodiments, Lz3further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

[0579] In some embodiments, T3, Tz1, Tz2, or Tz3have a structure represented by Formula XXIII or a pharmaceutically acceptable salt thereof:

[0580]

[0581] XXIII

[0582] wherein

[0583] each Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group;

[0584] 41

[0585] FH30010281.1Attorney Docket: LCH-04525

[0586] each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;

[0587] Wz1is -*C(O)-, -*C(O)N(Rz7)-, -*N(RZ7)C(O)-, -*(CH2)tziN(Rz7)C(O)-, -*C(O)O-, -*S(O2)N(RZ7)-, -*P(O)( RZ8)N(RZ7)-, -*S(O)N(RZ7)-, or -*P(O2)N(RZ7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XXIII,

[0588] Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;

[0589] Jc1is H or alkyl;

[0590] Jc2is H or alkyl; or

[0591] Jc1and Jc2combine to form an oxo;

[0592] tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0593] nzl is 0, 1, 2, or 3;

[0594] Az4represents a linkage to B3, Bz1, Bz2, or Bz3; and

[0595] Az5represents a linkage to L9, Lz1, Lz2, or Lz3.

[0596] In some embodiments, Rz2is H. In some embodiments, Rz3is H. In some embodiments, Rz4is H. In some embodiments, Rz5is H. In some embodiments, each of Rz2, Rz3, Rz4, and Rz5is H. In some embodiments, nzl is 0. In some embodiments, Wz1is -*C(O)N(Rz7)-. In some embodiments, Rz7is H. In some embodiments, Wz1is -*C(O)N(Rz7)-, and Rz7is H. In some embodiments, Jc1is H. In some embodiments, Jc2is H. In some embodiments, Jc1and Jc2combine to form oxo. In some embodiments, B3is an active agent. In some embodiments, m3 is 1. In some embodiments, m3 is 2. In some embodiments, m3 is 3. In some embodiments, each T3is a bond. In some embodiments, each B3is H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0597] In some embodiments, each of L7, L8and L9independently comprises a C1-C100 alkylene. In some embodiments, each of L7, L8and L9independently comprises a C1-C50 alkylene. In some embodiments, each of L7, L8and L9independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, 4, 5, or 6 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 5 ethylene glycol moieties. In some embodiments, each of L7, L8and L9independently further comprises an amido moiety. In some embodiments, each of L7, L8and L9independently further comprises 1,

[0598] 42

[0599] FH30010281.1Attorney Docket: LCH-04525

[0600] 2, 3, 4, 5, or 6 amido moieties. In some embodiments, each of L7, L8and L9independently further comprises 1 or 2 amido moieties. In some embodiments, each of L7, L8and L9independently further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do). In some embodiments, each of L7, L8and L9independently further comprises a heteroaryl (e.g., pyrazolyl or triazolyl). In some embodiments, each of L7, L8and L9independentlyfurther comprises a structure represented by Formula XVa or XVb:

[0601]

[0602] wherein:

[0603] each Ax1represents a linkage to V1, V2or V3; and

[0604] each Ax2represents a linkage to Y2, Y3or Y4.

[0605] In some embodiments, each of L7, L8and L9is independently substituted with an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties). In some embodiments, the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g, carboxyethyl) or amino (e.g, dimethylamino). In some embodiments, each of L7, L8and L9is independently substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido. In some embodiments, the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl). In some embodiments, the oligoethylene glycol is substituted with amino (e.g., dimethylamino). In some embodiments, each of L7, L8and L9comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties). In some embodiments, each of L7, L8and L9further comprises an amino acid (e.g., a hydrophilic amino acid). In some embodiments, each of L7, L8and L9further comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids (e.g., hydrophilic amino acids). In some embodiments, the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine. In some embodiments, the amino acid(s) are selected from arginine, aspartate, glutamate, histidine, lysine, and ornithine. In some embodiments, the amino acid(s) are selected from aspartate and glutamate. In some

[0606] 43

[0607] FH30010281.1Attorney Docket: LCH-04525

[0608] embodiments, the amino acid(s) are sarcosine. In some embodiments, the amino acid(s) are selected from aspartate, glutamate, and sarcosine.

[0609] In some embodiments, each of Lx1, Lx2and Lx3independently comprises a C1-C100 alkylene, preferably a C1-C50 alkylene. In some embodiments, each of Lx1, Lx2and Lx3independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moi eties, preferably 1, 2, 3, or 4 ethylene glycol moi eties.

[0610] In some embodiments, each of Ly1, Ly2and Ly3independently comprises a C1-C100 alkylene, preferably a C1-C50 alkylene. In some embodiments, each of Ly1, Ly2and Ly3independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.

[0611] In some embodiments, each of Lz1, Lz2and Lz3comprises a C1-C100 alkylene, preferably a C1-C50 alkylene. In some embodiments, each of Lz1, Lz2and Lz3independently further comprises an oligoethylene glycol. In some embodiments, the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.

[0612] In some embodiments, each T1, T2, and T3is independently a bond. In some embodiments, each B1, B2, and B3is independently an active agent. In some embodiments, each B1, B2, and B3is independently H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

[0613] 44

[0614] FH30010281.1Attorney Docket: LCH-04525

[0615] In some embodiments, the conjugate comprises

[0616]

[0617] embodiments, the conjugate comprises

[0618]

[0619] . In some embodiments, the conjugate

[0620]

[0621] In some embodiments, each active agent is independently a drug or an immunomodulator (e.g., drugs and / or immunomodulators disclosed herein, such as those in Preparation Examples). In some embodiments, each active agent is independently a chemotherapeutic agent or a toxin. In some embodiments, each active agent is independently a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, or an antiparasitic agent.

[0622] In some embodiments, each active agent is independently selected from:

[0623] (a) a microtubule targeting agent (e.g., maytansinoid, maytansine, DM1, DM4, maytansinol, auristatin, dolastatin 10, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), eribulin, Halichondrin B, tubulysin, cryptophycin, EG5 inhibitors, SB- 715992 (ispinesib), orfilanesib (ARRY-520));

[0624] (b) a DNA damaging agent (e.g., enediyne, calicheamicin, uncialamycin, topoisomerase inhibitors, topotecan, camptothecin, SN-38, irinotecan (CPT-11), exatecan, Dxd, FL1 18, pyrrol obenzodiazepine (PBD), PBD dimer, duocarmycin, Duocarmycin A, CC-1065);

[0625] (c) an RNA targeting agent (e.g., thailanstatin, amatoxin, a-amanitin, P-amanitin); (d) an affinity ligand (e.g., the affinity ligand is a substrate, inhibitor, active agent, neurotransmitter, radioactive isotope, or mixtures thereof);

[0626] 45

[0627] FH30010281.1Attorney Docket: LCH-04525

[0628] (e) a radioactive label (e.g., 32P or 35S), a fluorescent dye, an electron dense reagent, an enzyme, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or mixtures thereof;

[0629] (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an anti-bacterial agent, an anti-fungal agent, an anti -parasitic agent, or mixtures thereof;

[0630] (g) an estrogen receptor modulator (e.g., tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone or toremifene);

[0631] (h) an aromatase inhibitor(e.g., 4(5)-imidazole, aminoglutethimide, megestrol acetate, exemestane, letrozole or anastrozole);

[0632] (i) a nonsteroidal antiandrogen (NSAA) (e.g., flutamide, nilutamide, bicalutamide);

[0633] (j) an aromatase inhibitor;

[0634] (k) a protein kinase inhibitor;

[0635] (l) a lipid kinase inhibitor;

[0636] (m) an antisense oligonucleotide;

[0637] (n) a ribozyme;

[0638] (o) a vaccine;

[0639] (p) an anti -angiogenic agent;

[0640] (q) a Bcl-xL inhibitor;

[0641] (r) a NAMPT inhibitor; and

[0642] (s) a Carmaphycin.

[0643] In some embodiments, each active agent is independently selected from:

[0644] (a) erlotinib, bortezomib, fulvestrant, sunitinib, letrozole, imatinib mesylate, PTK787 / ZK 222584, oxaliplatin, 5-fluorouracil, leucovorin, rapamycin, lapatinib, lonafarnib, sorafenib, gefitinib, AG1478, AG1571, thiotepa, cyclophosphamide, busulfan, improsulfan, piposulfan, benzodepa, carboquone, meturedepa, uredepa, ethylenimine, altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine, bullatacin, bullatacinone, camptothecin, topotecan, deruxtecan, SN-38, bryostatin, callystatin, CC-1065, adozelesin, carzelesin, bizelesin, cryptophy cin 1, cryptophy cin 8, dolastatin, duocarmycin, KW-2189, CB1-TM1, eleutherobin, pancrati statin, sarcodictyin, spongistatin, chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotoxin, fotemustine, lomustine, 46

[0645] FH30010281.1Attorney Docket: LCH-04525

[0646] nimustine, ranimustine, calicheamicin, calicheamicin gamma 1, calicheamicin omega 1, dynemicin, dynemicin A, clodronate, esperamicin, neocarzinostatin chromophore, aclacinomysins, actinomycin, antimycin, azaserine, bleomycins, carubicin, carninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, 6-diazo-5- oxo-L-norleucine, doxorubicin, morpholino-doxorubicin, cyanomorpholinodoxorubicin, 2-pyrrolino-doxorubucin, liposomal doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, marcellomycin, mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, methotrexate, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacytidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone, aminoglutethimide, mitotane, trilostane, folinic acid, aceglatone, aldophosphamide glycoside, aminolevulinic acid, eniluracil, amsacrine, bestrabucil, bisantrene, edatrexate, demecolcine, diaziquone, elfornithine, elliptinium acetate, etoglucid, gallium nitrate, hydroxyurea, lentinan, lonidamine, maytansine, ansamitocins, mitoguazone, mitoxantrone, mopidamol, pentostatin, phenamet, pirarubicin, losoxantrone, 2-ethylhydrazide, procarbazine, polysaccharide-k, razoxane, rhizoxin, sizofiran, spirogermanium, tenuazonic acid, triaziquone, 2,2 2” -tri chlorotri ethylamine, T-2 toxin, verracurin A, roridin A, anguidine, urethane, vindesine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, arabinoside, paclitaxel, albumin-engineered nanoparticle formulation of paclitaxel, docetaxel, gemcitabine, 6-thioguanine, mercaptopurine, cisplatin, carboplatin, vinblastine, platinum, etoposide, vincristine, vinorelbine, novantrone, teniposide, daunomycin, aminopterin, ibandronate, CPT-11, topoisomerase inhibitor RFS 2000, difluorom ethylornithine, retinoic acid, capecitabine, or pharmaceutically acceptable salts, solvates, or acids of any of the foregoing;

[0647] (b) monokine, a lymphokine, a traditional polypeptide hormone, parathyroid hormone, thyroxine, relaxin, prorelaxin, a glycoprotein hormone, follicle stimulating hormone, thyroid stimulating hormone, luteinizing hormone, hepatic growth factor, fibroblast growth factor, prolactin, placental lactogen, tumor necrosis factor-a, tumor necrosis factor-p, Mullerian inhibiting substance, mouse gonadotropin associated peptide, inhibin, activin, vascular endothelial growth factor, thrombopoietin, erythropoietin, an osteoinductive factor, an interferon, interferon-oc, interferon-P, interferon-y, a colony 47

[0648] FH30010281.1Attorney Docket: LCH-04525

[0649] stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage-CSF, granulocyte-CSF, an interleukin (IL), IL-1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, a tumor necrosis factor, polypeptide factor, LIF, kit ligand, or a combination of any of the foregoing;

[0650] (c) diphtheria toxin, botulinum toxin, tetanus toxin, dysentery toxin, cholera toxin, amanitin a-amanitin, pyrrolobenzodiazepine, tetrodotoxin, brevetoxin, ciguatoxin, ricin, AM toxin, an auristatin, tubulysin, geldanamycin, maytansinoid, SG2285, SG2057, cryptophycin, an enediyne antibiotic, epothilone, taltobulin, azonafide, a toxoid, or a combination of any of the foregoing;

[0651] (d) an affinity ligand, wherein the affinity ligand is a substrate, an inhibitor, a stimulating agent, a neurotransmitter, a radioisotope, or a combination of any of the foregoing; (e) a radioactive label,32P,35S, a fluorescent dye, an electron dense reagent, an enzyme, biotin, streptavidin, digoxigenin, a hapten, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or a combination of any of the foregoing;

[0652] (f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an antibacterial agent, an anti-fungal agent, and an anti-parasitic agent, or a combination of any of the foregoing;

[0653] (g) tamoxifen, raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, LY117018, onapri stone, or toremifene;

[0654] (h) 4(5)-imidazoles, megestrol acetate, exemestane, or anastrozole;

[0655] (i) flutamide, nilutamide, bicalutamide, leuprolide, goserelin, or troxacitabine;

[0656] (j) an aromatase inhibitor;

[0657] (k) a protein kinase inhibitor;

[0658] (l) a lipid kinase inhibitor;

[0659] (m) an antisense oligonucleotide;

[0660] (n) a ribozyme;

[0661] (o) a vaccine; and

[0662] (p) an anti -angiogenic agent.

[0663] In some embodiments, each active agent is independently selected from: Calicheamicin, Monomethyl auristatin E(MMAE), Monomethyl auristatin F(MMAF), Mertansine (DM1), Ravtansine (DM4), SN-38, Deruxtecan (Dxd), FL118, exatecan, pyrrolobenzodiazepines (PBD), PBD dimers, duocarmycin, Duocarmycin A, and Auristatin E.

[0664] 48

[0665] FH30010281.1Attorney Docket: LCH-04525 In some embodiments, the conjugate comprises a structure selected from:

[0666]

[0667] 49

[0668] FH30010281.1Attorney Docket: LCH-04525

[0669]

[0670] 50

[0671] FH30010281.1Attorney Docket: LCH-04525

[0672]

[0673] FH30010281.1Attorney Docket: LCH-04525

[0674]

[0675] 52

[0676] FH30010281.1Attorney Docket: LCH-04525

[0677]

[0678] 53

[0679] FH30010281.1Attorney Docket: LCH-04525

[0680]

[0681] 54

[0682] FH30010281.1Attorney Docket: LCH-04525

[0683]

[0684] 55

[0685] FH30010281.1Attorney Docket: LCH-04525

[0686]

[0687] 56

[0688] FH30010281.1Attorney Docket: LCH-04525

[0689]

[0690] 57

[0691] FH30010281.1Attorney Docket: LCH-04525

[0692]

[0693] 58

[0694] FH30010281.1Attorney Docket: LCH-04525

[0695]

[0696] 59

[0697] FH30010281.1Attorney Docket: LCH-04525

[0698]

[0699] 60

[0700] FH30010281.1Attorney Docket: LCH-04525

[0701]

[0702] 61

[0703] FH30010281.1Attorney Docket: LCH-04525

[0704]

[0705] 62

[0706] FH30010281.1Attorney Docket: LCH-04525

[0707]

[0708] 63

[0709] FH30010281.1Attorney Docket: LCH-04525

[0710]

[0711] wherein indicates a connection point to Ab.

[0712] 64

[0713] FH30010281.1Attorney Docket: LCH-04525

[0714] In certain aspects, the present disclosure provides a pharmaceutical composition comprising a conjugate disclosed herein and a pharmaceutically acceptable excipient.

[0715] In certain aspects, the present disclosure provides a pharmaceutical composition for use in preventing or treating a cancer, the composition comprising a conjugate disclosed herein. In some embodiments, the cancer is selected from lung cancer, colon cancer, colorectal cancer, breast cancer, ovarian cancer, gastric cancer, leukemia, lymphoma, multiple myeloma, head and neck cancer, pancreatic cancer, liver cancer, prostate cancer, and bladder cancer, and combinations thereof.

[0716] In certain aspects, the present disclosure provides a method of treating or preventing a cancer in a subject in need thereof comprising administering a conjugate disclosed herein or a pharmaceutically acceptable salt thereof to the subject. In some embodiments, the cancer is selected from lung cancer, colon cancer, colorectal cancer, breast cancer, ovarian cancer, gastric cancer, leukemia, lymphoma, multiple myeloma, head and neck cancer, pancreatic cancer, liver cancer, prostate cancer, and bladder cancer, and combinations thereof.

[0717] Antibody or Antigen-Binding Fragment thereof

[0718] The present disclosure provides an antibody or antigen-binding fragment thereof that binds to Lewis Y antigen (Lewis Y, or LeY). As described herein, the antibody or antigenbinding fragment thereof according to the present disclosure is a polypeptide comprising one or more complementarity-determining areas or regions (CDRs).

[0719] In some embodiments, the CDR is included in a “framework” region, and the framework orients the CDR(s) so that the CDR(s) can have appropriate antigen-binding properties.

[0720] In certain aspects, the present disclosure provides antibody-drug conjugates comprising an anti-Lewis Y antibody or antigen-binding fragment thereof that binds to Lewis Y. In certain embodiments, the antibody or antigen-binding fragment thereof disclosed herein binds to Lewis Y expressed in (e.g., on cell surface) a cancer cell and may be used to deliver a drug to the cell. In certain embodiments, the antibody drug conjugates disclosed herein have improved stability as compared to antibody drug conjugates known in the art.

[0721] In certain embodiments, the antibody comprises, but is not limited to, a monoclonal antibody, a bispecific antibody, a diabody, a multispecific antibody, a polyantibody, a minibody, a domain antibody, an antibody mimetic (or synthetic antibody), a chimeric antibody, a humanized antibody, a human antibody or an antibody fusion (or antibody conjugate), and a fragment thereof, and includes various forms of antibodies disclosed herein.

[0722] 65

[0723] FH30010281.1Attorney Docket: LCH-04525

[0724] In certain embodiments, an antibody fragment of the antibody according to the present disclosure includes Fab, Fab', F(ab')2, scFab, Fv, dsFv, scFV, scFV-Fc, a minibody, a diabody, sc Ab, or dAb.

[0725] In certain embodiments, the antibody or antigen-binding fragment thereof according to the present disclosure may consist of a polypeptide of only light chains or only heavy chains including the variable regions shown in Tables 1-4.

[0726] CDR sequences that may be included in the heavy and light chain variable regions of the antibody or antigen-binding fragment thereof according to an embodiment of the present disclosure are shown in Tables 1-4, respectively.

[0727] An antibody or antigen-binding fragment thereof according to the present disclosure shares certain regions or sequences with other antibodies disclosed herein. In certain embodiments, the constant region of the antibody or antigen-binding fragment thereof may be shared. In certain embodiments, Fc regions may be shared. In certain embodiments, the frame of a variable region may be shared.

[0728] The heavy chain variable region and the light chain variable region according to the present disclosure may be linked to at least a part of a human constant region. The selection of a constant region may be determined partially by whether or not antibody-dependent cell-mediated cytotoxicity, antibody-dependent cellular phagocytosis, and / or complementdependent cytotoxicity is required. For example, human isotypes IgGl and IgG3 have complement-dependent cytotoxicity, and human isotypes IgG2 and IgG4 do not have such cytotoxicity. In addition, human IgGl and IgG3 induce a cell-mediated effector function stronger than that of human IgG2 and IgG4. The light chain constant region may be lambda or kappa.

[0729] A variable region of an immunoglobulin chain generally has the same overall structure and includes a comparatively conserved framework region (FR) linked by three hypervariable regions called “complementarity determining areas or regions or domains” or complementarity determining regions (CDRs). The CDRs of a variable region derived from each chain including a heavy chain / light chain pair are typically aligned by a framework region to form a structure specifically binding to a specific epitope of a target protein. These factors of naturally occurring light chain and heavy chain variable regions are typically included from the N-terminus to the C-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The positions of amino acid sequences corresponding to each variable region, and the positions of the CDRs and FRs, may be determined using various well known definitions in the art, e.g., Kabat (Kabat et al., (1983) U. S. Dept, of Health and Human Services, “Sequences of Proteins 66

[0730] FH30010281.1Attorney Docket: LCH-04525

[0731] of Immunological Interest”), Chothia (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)), international ImMunoGeneTics database (IMGT) (on the worldwide web at imgt.cines.fr / ), AbM (see, e.g., Johnson et al., Nucleic Acids Res., 29:205-206 (2001), or in a manner related to the OPAL library (Hye Young Yang et. al., 2009 Mol. Cells 27: 225). The CDRs determined by each definition, when compared to each other, may be subsets which overlap or where one includes another. Those of ordinary skill in the art will be readily able to easily select CDR sequences according to the definitions above, given a variable region sequence of an antibody.

[0732] In certain embodiments, amino acid sequences of CDRs and FRs are defined according to Kabat definition. However, it is well known to those skilled in the art that CDRs of an antibody can be defined in the art according to a variety of methods, such as Chothia definition based on the location of a structural loop region (Al-Lazikani, B et al., J Mol Biol 273: 927-48 (1997)), and Kabat definition based on sequence variability (Kabat et al., “Sequences of proteins of immunological interest,” fifth edition, National Institutes of Health, Bethesda, MD. (1991)). It is also well known to those skilled in the art that CDR and FR sequences identified using one numbering scheme or definition may be converted or translated to corresponding sequences under a different numbering scheme or definition using tools available in the art. For example, the CDR and FR sequences may be converted using IMGT Scientific chart (imgt.org / IMGTScientificChart / Numbering / Hu_IGHGnber.html) or using the IgBLAST tool (ncbi.nlm.nih.gov / igblast).

[0733] In certain embodiments, amino acid residues in variable region sequences may also be determined using a Combined definition that incorporates both Kabat definition and Chothia definition. The Combined definition refers to the combination of the ranges of Kabat definition and Chothia definition. It should be understood by those skilled in the art that unless otherwise specified, the terms “CDR” and “complementarity determining region” of a given antibody or region thereof (e.g., a variable region) should be understood to encompass the complementarity determining region as defined according to any of the embodiments described in the present disclosure, or complementarity determining region sequences under corresponding numbering schemes. For example, CDR amino acid sequences defined by the Kabat definition for any specific antibody or antigen-binding fragment thereof of the present disclosure should be understood to encompass the amino acid sequences as identified by the sequence identifiers (SEQ ID NOs) of the present disclosure, and to encompass corresponding amino acid sequences that will be identified under, e.g., IMGT or Chothia definitions.

[0734] Although the scope of protection claimed in the claims of the present disclosure is based on the sequences defined according to Kabat definition, amino acid sequences defined 67

[0735] FH30010281.1Attorney Docket: LCH-04525

[0736] according to other CDRs definitions should also fall within the scope of protection of the present disclosure.

[0737] In certain embodiments, the antibody according to the present disclosure is a humanized antibody. A humanized antibody refers to any antibody in which the constant region of a nonhuman antibody is completely substituted with a human form of the constant region, and at least a portion of the variable region of a non-human antibody, except for the three loops of an amino acid sequence outside each variable region that binds to a target structure, is completely or partially substituted with the corresponding portion of a human antibody. In certain embodiments, the antibody according to the present disclosure is a human antibody.

[0738] Certain mutations may be introduced to the framework region to enhance the stability of antibodies while maintaining their antigen binding activity. Stabilization of therapeutic antibodies can result in improved serum half-life, lower dosage requirements, reduced sideeffects, improved shelf-life and reduced shipping and storage costs.

[0739] In certain embodiments, the present disclosure discloses one or more amino acid sequences having substantial sequence identity to one or more amino acid sequences disclosed herein. Substantial identity means that the effects disclosed herein are maintained in the presence of sequence variations. In certain embodiments, the amino acid sequence has about 90% identity, about 95% identity, or about 99% identity to the heavy chain variable regions shown in Tables 1-4. In another embodiment, the amino acid sequence has about 90% identity, about 95% identity, or about 99% identity to the light chain variable regions shown in Tables 1-4. For example, in the case of variants exhibiting 90% identity, 95% identity, or 99% identity to the sequence of the antibody or antigen-binding fragment thereof according to the present disclosure, any mutation occurs in the framework of the variable region rather than the CDRs.

[0740] In certain embodiments, a nucleic acid encoding the antibody or fragment thereof according to the present disclosure is a nucleic acid encoding a full-length antibody including the CDRs disclosed herein, the variable region including the CDRs, and the variable region, and the constant region. Once the amino acid sequence is determined, the nucleic acid sequence may be easily determined in consideration of a known reverse transcription program, codon usage, and the like.

[0741] Antigen Specificity and Affinity for Antibody

[0742] In certain preferred embodiments, the antibody or antigen-binding fragment thereof according to the present disclosure has specificity to a Lewis Y antigen and affinity suitable for use as an antibody therapeutic / diagnostic agent. In certain embodiments, the affinity for 68

[0743] FH30010281.1Attorney Docket: LCH-04525

[0744] aggregates may be KD < 1,000 nM, < 100 nM, < 10 nM, < 1 nM, < 0.1 nM, < 0.01 nM, or < 0.001 nM, and may be, for example, 10-6M to 10-12M.

[0745] Production of Antibody

[0746] In the present disclosure, a non-human antibody may be derived from, for example, any antibody-producing animal, for example, a mouse, a rat, a rabbit, a goat, a donkey, or non-human primates (e.g., monkeys such as cynomolgus or rhesus monkey) or apes (e.g., chimpanzees). A non-human antibody may be produced by immunizing an animal by using a method known in the art. For a method for producing a humanized antibody, according to an embodiment of the present disclosure, refer to US Patent No. 15 / 532,598. A fully human antibody may be produced by administering an antigen to a transformed animal including a human immunoglobulin gene locus, or by treating a phage display library expressing a human antibody repertory with an antigen, and then selecting the target antibody. The antibody may be polyclonal or monoclonal, or may be synthesized within a cell host through the expression of recombinant DNA.

[0747] A monoclonal antibody (mAb) may be produced using a conventional monoclonal antibody method, for example, a standard somatic hybridization technique in the literature (Kohler and Milstein, 1975, Nature 256:495).

[0748] Method for Expressing Antibody

[0749] The antibody disclosed herein may be expressed in a hybridoma cell line or an expression cell line other than a hybridoma. An expression construct encoding the antibody may be used to transform a mammalian, an insect or a microbial host cell. A construct such as a plasmid may be produced, as described in the foregoing description, using any of various known methods for introducing a polynucleotide into a host cell. The specific method may vary according to the type of host cell. Methods for introducing a heterogeneous polynucleotide into a mammalian cell are widely known in the art, and include, but are not limited to, for example, dextran-mediated transfer, calcium phosphate precipitation, polybrene-mediated transfer, protoplast fusion, electrophoresis, capsulation of a transferred polynucleotide using liposomes, mixing of a nucleic acid and a positively charged lipid, and direct microinjection of DNA into the nucleus.

[0750] Use of Anti-Lewis Y Antibody Drug-Conjugates for Therapeutic Purposes

[0751] 69

[0752] FH30010281.1Attorney Docket: LCH-04525

[0753] The expression of Lewis Y in cancer is associated with unfavorable prognosis of cancer patients and is known to also affect cancer metastasis. For example, Lewis Y is overexpressed in a majority of epithelial cancers on the surface of cancer cells. For anticancer antibody treatment, for example, the anti-Lewis Y antibody may, as described herein, be used in a form linked to various active agents (e.g., toxins) via a linker to remove Lewis Y-overexpressing cancer cells.

[0754] Treatment Method: Pharmaceutical Formulation and Administration Route

[0755] In some aspects, the present disclosure provides a treatment method using an antibodydrug conjugate or a pharmaceutically acceptable salt or solvate thereof. In certain embodiments, the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof is provided to a patient. The antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof inhibits cancer cell growth or metastasis by binding to Lewis Y expressed on the surface of cancer cells. In certain embodiments, the antibody binds to Lewis Y expressed on the surface of cancer cells in a form bonded to an active agent (e.g., a toxin), thereby specifically delivering the active agent bonded to the antibody to cancer cells, to induce the death of the cancer cells. In certain embodiments, the antibody binds to Lewis Y expressed on the surface of cancer cells in the form of an antibody specific to the same target or another target, thereby increasing specificity of multiple antibodies for cancer cells or inducing connections between cancer cells and other types of cells such as immune cells, to induce the death of the cancer cells.

[0756] Pharmaceutical Compositions

[0757] The compositions and methods disclosed herein may be utilized to treat an individual in need thereof. In certain embodiments, the individual is a mammal such as a human, or a nonhuman mammal. When administered to an animal, such as a human, the composition or the conjugate is preferably administered as a pharmaceutical composition comprising, for example, a conjugate described herein and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions such as water or physiologically buffered saline or other solvents or vehicles such as glycols, glycerol, oils such as olive oil, or injectable organic esters. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly for invasive routes of administration ( / .<?., routes, such as injection or implantation, that circumvent transport or diffusion through an epithelial barrier), the aqueous solution is pyrogen-free, or 70

[0758] FH30010281.1Attorney Docket: LCH-04525

[0759] substantially pyrogen-free. The excipients can be chosen, for example, to effect delayed release of an agent or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in dosage unit form such as tablet, capsule (including sprinkle capsule and gelatin capsule), granule, lyophile for reconstitution, powder, solution, syrup, suppository, injection or the like. The composition can also be present in a transdermal delivery system, e.g., a skin patch. The composition can also be present in a solution suitable for topical administration, such as a lotion, cream, or ointment. The composition may include a filler, an anticoagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifier, a preservative, or a combination thereof.

[0760] The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

[0761] A pharmaceutically acceptable carrier can contain physiologically acceptable agents that act, for example, to stabilize, increase solubility or to increase the absorption of a conjugate such as a conjugate described herein. Such physiologically acceptable agents include, for example, carbohydrates, such as glucose, sucrose or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers or excipients. The choice of a pharmaceutically acceptable carrier, including a physiologically acceptable agent, depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a selfemulsifying drug delivery system or a selfmicroemulsifying drug delivery system. The pharmaceutical composition (preparation) also can be a liposome or other polymer matrix, which can have incorporated therein, for 71

[0762] FH30010281.1Attorney Docket: LCH-04525

[0763] example, a conjugate described herein. Liposomes, for example, which comprise phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.

[0764] A pharmaceutical composition (preparation) can be administered to a subject by any of a number of routes of administration including, for example, orally (for example, drenches as in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue); absorption through the oral mucosa (e.g., sublingually); subcutaneously; transdermally (for example as a patch applied to the skin); and topically (for example, as a cream, ointment or spray applied to the skin). The conjugate may also be formulated for inhalation. In certain embodiments, a conjugate may be simply dissolved or suspended in sterile water. Details of appropriate routes of administration and compositions suitable for same can be found in, for example, U. S. Pat. Nos. 6,110,973, 5,763,493, 5,731,000, 5,541,231, 5,427,798, 5,358,970 and 4,172,896, as well as in patents cited therein.

[0765] The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the conjugate which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent. The dosage of the pharmaceutical composition may range, for example, from 10 pg / kg to about 30 mg / kg, optionally from 0.1 mg / kg to about 30 mg / kg, or alternatively from 0.3 mg / kg to about 20 mg / kg per adult. The pharmaceutical composition may be administered once a day, multiple times a day, once every 1 to 4 weeks, or once to 12 times a year.

[0766] Methods of preparing these formulations or compositions include the step of bringing into association an active conjugate, such as a conjugate described herein, with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a conjugate described herein with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0767] Formulations of the disclosed conjugates suitable for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets,

[0768] 72

[0769] FH30010281.1Attorney Docket: LCH-04525

[0770] lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), lyophile, powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of a conjugate described herein as an active ingredient. Compositions or conjugates may also be administered as a bolus, electuary or paste.

[0771] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium conjugates; (7) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; (10) complexing agents, such as, modified and unmodified cyclodextrins; and (11) coloring agents. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

[0772] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surfaceactive or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered conjugate moistened with an inert liquid diluent.

[0773] The tablets, and other solid dosage forms of the pharmaceutical compositions, such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as 73

[0774] FH30010281.1Attorney Docket: LCH-04525

[0775] to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

[0776] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, cyclodextrins and derivatives thereof, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[0777] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0778] Suspensions, in addition to the active conjugates, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0779] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active conjugate may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.

[0780] The ointments, pastes, creams and gels may contain, in addition to an active conjugate, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth,

[0781] 74

[0782] FH30010281.1Attorney Docket: LCH-04525

[0783] cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0784] Powders and sprays can contain, in addition to an active conjugate, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0785] Transdermal patches have the added advantage of providing controlled delivery of a conjugate described herein to the body. Such dosage forms can be made by dissolving or dispersing the active conjugate in the proper medium. Absorption enhancers can also be used to increase the flux of the conjugate across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the conjugate in a polymer matrix or gel.

[0786] The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion. Pharmaceutical compositions suitable for parenteral administration comprise one or more active conjugates in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

[0787] Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the disclosed conjugates include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0788] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be 75

[0789] FH30010281.1Attorney Docket: LCH-04525

[0790] ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.

[0791] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

[0792] Injectable depot forms are made by forming microencapsulated matrices of the subject conjugates in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.

[0793] For use in the methods described herein, active conjugates can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.

[0794] Methods of introduction may also be provided by rechargeable or biodegradable devices. Various slow-release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biopharmaceuticals. A variety of biocompatible polymers (including hydrogels), including both biodegradable and non-degradable polymers, can be used to form an implant for the sustained release of a conjugate at a particular target site.

[0795] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0796] The selected dosage level will depend upon a variety of factors including the activity of the particular conjugate or combination of conjugates employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the 76

[0797] FH30010281.1Attorney Docket: LCH-04525

[0798] particular conjugate(s) being employed, the duration of the treatment, other drugs, conjugates and / or materials used in combination with the particular conjugate(s) employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0799] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the pharmaceutical composition or conjugate at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. By “therapeutically effective amount” is meant the concentration of a conjugate that is sufficient to elicit the desired therapeutic effect. It is generally understood that the effective amount of the conjugate will vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective amount may include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the conjugate, and, if desired, another type of therapeutic agent being administered with the conjugate described herein. A larger total dose can be delivered by multiple administrations of the agent. Methods to determine efficacy and dosage are known to those skilled in the art (Isselbacher et al. (1996) Harrison’s Principles of Internal Medicine 13 ed., 1814-1882, herein incorporated by reference).

[0800] In general, a suitable daily dose of an active conjugate used in the compositions and methods described herein will be that amount of the conjugate that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

[0801] If desired, the effective daily dose of the active conjugate may be administered as one, two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain embodiments, the active conjugate may be administered two or three times daily. In preferred embodiments, the active conjugate will be administered once daily.

[0802] The patient receiving this treatment is any animal in need, including primates, in particular humans; and other mammals such as equines, cattle, swine, sheep, cats, and dogs; poultry; and pets in general.

[0803] In certain embodiments, conjugates described herein may be used alone or conjointly administered with another type of therapeutic agent.

[0804] The present disclosure includes the use of pharmaceutically acceptable salts of conjugates described herein in the compositions and methods described herein. In certain 77

[0805] FH30010281.1Attorney Docket: LCH-04525

[0806] embodiments, contemplated salts described herein include, but are not limited to, alkyl, dialkyl, trialkyl or tetra-alkyl ammonium salts. In certain embodiments, contemplated salts described herein include, but are not limited to, L-arginine, benethamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, IH-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, l-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, contemplated salts described herein include, but are not limited to, Na, Ca, K, Mg, Zn or other metal salts. In certain embodiments, contemplated salts described herein include, but are not limited to, 1 -hydroxy -2 -naphthoic acid, 2, 2-di chloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, 1-ascorbic acid, 1-aspartic acid, benzenesulfonic acid, benzoic acid, (+)-camphoric acid, (+)-camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), caprylic acid (octanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-l,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, d-glucoheptonic acid, d-gluconic acid, d-glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, 1-malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, 1 -pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, 1-tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, and undecylenic acid salts.

[0807] The pharmaceutically acceptable acid addition salts can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent.

[0808] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.

[0809] Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium 78

[0810] FH30010281.1Attorney Docket: LCH-04525

[0811] metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal-chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0812] Definitions

[0813] Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, cell and tissue culture, molecular biology, cell and cancer biology, neurobiology, neurochemistry, virology, immunology, microbiology, pharmacology, genetics and protein and nucleic acid chemistry, described herein, are those well-known and commonly used in the art.

[0814] The methods and techniques of the present disclosure are generally performed, unless otherwise indicated, according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout this specification. See, e.g. “Principles of Neural Science”, McGraw-Hill Medical, New York, N. Y. (2000); Motulsky, “Intuitive Biostatistics”, Oxford University Press, Inc. (1995); Lodish et al., “Molecular Cell Biology, 4th ed.”, W. H. Freeman & Co., New York (2000); Griffiths et al., “Introduction to Genetic Analysis, 7th ed.”, W. H. Freeman & Co., N. Y. (1999); and Gilbert et al., “Developmental Biology, 6th ed.”, Sinauer Associates, Inc., Sunderland, MA (2000).

[0815] Chemistry terms used herein, unless otherwise defined herein, are used according to conventional usage in the art, as exemplified by “The McGraw-Hill Dictionary of Chemical Terms”, Parker S., Ed., McGraw-Hill, San Francisco, C. A. (1985).

[0816] The term “agent” is used herein to denote a chemical compound (such as an organic or inorganic compound, a mixture of chemical compounds), a biological macromolecule (such as a nucleic acid, an antibody, including parts thereof as well as humanized, chimeric and human antibodies and monoclonal antibodies, a protein or portion thereof, e.g., a peptide, a lipid, a carbohydrate), or an extract made from biological materials such as bacteria, plants, fungi, or animal (particularly mammalian) cells or tissues. Agents include, for example, agents whose structure is known, and those whose structure is not known.

[0817] A “patient,” “subject,” or “individual” are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (including bovines, porcines, etc.), companion animals (e.g., canines, felines, etc.) and rodents (e.g., mice and rats).

[0818] 79

[0819] FH30010281.1Attorney Docket: LCH-04525

[0820] “Treating” a condition or patient refers to taking steps to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.

[0821] The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and / or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and / or clinically significant amount.

[0822] “Administering” or “administration of’ a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods.

[0823] Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age and / or the physical condition of the subject and the chemical and biological properties of the compound or agent (e.g., solubility, digestibility, bioavailability, stability and toxicity). In some embodiments, a compound or an agent is administered orally, e.g., to a subject by ingestion. In some embodiments, the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.

[0824] 80

[0825] FH30010281.1Attorney Docket: LCH-04525

[0826] As used herein, the phrase “conjoint administration” refers to any form of administration of two or more different therapeutic agents such that the second agent is administered while the previously administered therapeutic agent is still effective in the body (e.g., the two agents are simultaneously effective in the patient, which may include synergistic effects of the two agents). For example, the different therapeutic compounds can be administered either in the same formulation or in separate formulations, either concomitantly or sequentially. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic agents.

[0827] As used herein, the terms “optional” or “optionally” mean that the subsequently described event or circumstance may occur or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances in which it does not. For example, “optionally substituted alkyl” refers to situations where the alkyl may be substituted as well as where the alkyl is not substituted.

[0828] It is understood that substituents and substitution patterns on the compounds described herein can be selected by one of ordinary skilled person in the art to result chemically stable compounds which can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.

[0829] As used herein, the term “optionally substituted” refers to the optional replacement of one to six hydrogen radicals in a given structure with the radical of a specified substituent including, but not limited to: hydroxyl, hydroxyalkyl, alkoxy, halogen, alkyl, nitro, silyl, acyl, acyloxy, aryl, cycloalkyl, heterocyclyl, amino, aminoalkyl, cyano, haloalkyl, haloalkoxy, -OCO-CH2-O-alkyl, -OP(O)(O-alkyl)2 or -CH2-OP(O)(O-alkyl)2. Preferably, “optionally substituted” refers to the optional replacement of one to four hydrogen radicals in a given structure with the substituents mentioned above. More preferably, one to three hydrogen radicals are optionally replaced by the substituents as mentioned above. It is understood that the substituent can be further substituted.

[0830] In the present disclosure, “linker” refers to a compound which covalently bonds a cytotoxic compound to an antibody.

[0831] The term “conjugates” as used herein refers to cell binding agents that are covalently bonded to one or more molecules of a cytotoxic compound. In this regard, "cell binding agent" is a molecule having affinity for a biological target, and may be, for example, an antibody, particularly a monoclonal antibody, or an antibody fragment, and the binding agent functions 81

[0832] FH30010281.1Attorney Docket: LCH-04525

[0833] to direct a biologically active compound to a biological target. In certain embodiments, the conjugate may be designed to target tumor cells through cell surface antigens. The antigen may be a cell surface antigen that is overexpressed or expressed in an abnormal cell type. Specifically, the target antigen may be expressed only on proliferative cells (e.g., tumor cells). The target antigen may be selected on the basis of different expression, usually between proliferative tissues and normal tissues. In the present disclosure, the antibody is bonded to the linker.

[0834] In the present disclosure, a “variant” of a polypeptide, for example, an antigen-binding fragment, a protein, or an antibody, is a polypeptide in which insertion, deletion, addition, and / or substitution have occurred at one or more amino acid residues compared to other polypeptide sequences, and includes fusion polypeptides. Protein variants also include those modified by protein enzymatic cleavage, phosphorylation or other post-translational modifications, but retaining the biological activity of the antibody disclosed herein, such as binding and specificity to Lewis Y. Variants may have about 99% identity, about 98% identity, about 97% identity, about 96% identity, about 95% identity, about 94% identity, about 93% identity, about 92% identity, about 91% identity, about 90% identity, about 89% identity, about 88% identity, about 87% identity, about 86% identity, about 85% identity, about 84% identity, about 83% identity, about 82% identity, about 81% identity, or about 80% identity to the sequence of the antibody or antigen-binding fragment thereof according to the present disclosure. Percent identity (%) or homology may be calculated by methods known in the art.

[0835] In certain embodiments, the percent homology or identity can be calculated by 100X[(same position) / min(TGA, TGB)], wherein TGA and TGB are the sum of the number of residues and internal gap positions in sequences A and B to be compared (Russell et al., J. Mol Biol., 244: 332-350 (1994).

[0836] The term “derivative” of a polypeptide as used herein refers to a polypeptide that has chemical modification at one or more residues through conjugation with other chemical moi eties, different from insertion, deletion, addition or substitution variants.

[0837] The term “percent sequence identity” or “percent identity” between two polynucleotide or polypeptide sequences refers to the number of identical matched positions shared by the sequences over a comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where an identical nucleotide or amino acid is presented in both the target and reference sequence. Gaps presented in the target sequence are not counted since gaps are not nucleotides or amino acids. Likewise, gaps presented in the reference sequence are not counted 82

[0838] FH30010281.1Attorney Docket: LCH-04525

[0839] since target sequence nucleotides or amino acids are counted, not nucleotides or amino acids from the reference sequence. The percentage of sequence identity is calculated by determining the number of positions at which the identical amino-acid residue or nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. The comparison of sequences and determination of percent sequence identity between two sequences can be accomplished using readily available software programs. Suitable software programs are available from various sources, and for alignment of both protein and nucleotide sequences. One suitable program to determine percent sequence identity is bl2seq, part of the BLAST suite of program available from the U. S. government's National Center for Biotechnology Information BLAST web site (at world wide web at blast.ncbi.nlm.nih.gov). B12seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, e.g., Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at world wide web at ebi.ac.uk / Tools / psa.

[0840] As used herein, “homology” with respect to a peptide, polypeptide or antibody sequence refers to the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGN™ (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms known in the art needed to achieve maximal alignment over the full length of the sequences being compared.

[0841] The term “affinity” or “avidity” refers to the strength of interaction between an antibody or its antigen-binding fragment and an antigen, determined by characteristics of the antigen such as size, shape, and / or charge, and the CDR sequences of the antibody or antigen-binding fragment. Methods for determining such affinities are known in the art and may also be referenced herein.

[0842] 83

[0843] FH30010281.1Attorney Docket: LCH-04525

[0844] Antibodies or their antigen-binding fragments used herein are said to “specifically bind” to the target, such as the antigen, when the dissociation constant (KD) is <10'6M. Antibodies bind “with high affinity” to the target when KD is <lx 10'8M.

[0845] As used in the present disclosure, the “antigen-binding fragment” of a chain (heavy chain or light chain) of an antibody or immunoglobulin includes a part of an antibody which lacks some amino acids compared to a full-length chain, but can specifically bind to an antigen. This fragment can be considered as having biological activity, in that the fragment can specifically bind to a target antigen, or can compete with other antibodies or antigen binding fragments thereof to bind to a specific epitope. In certain embodiments, such a fragment includes at least one CDR present in a full-length light chain or heavy chain, and in some embodiments, includes a short-chain heavy chain and / or light chain, or part thereof. This biological active fragment may be produced by a recombinant DNA technique or may be produced, for example, by cleaving an intact antibody enzymatically or chemically. An immunologically functional immunoglobulin fragment includes, but is not limited to, Fab, Fab', F(ab')2, scFab, dsFv, Fv, scFV, scFV-Fc, diabody, minibody, scAb, and dAb, and may be derived from any mammal, including, but not being limited to, a human, a mouse, a rat, a camelid, or a rabbit. The functional parts of antibodies such as the one or more CDRs disclosed in the present disclosure may be linked with a secondary protein or a small compound by a covalent bond, and thereby used as a targeted therapeutic agent for a specific target.

[0846] In the present disclosure, the “Fc” region includes two heavy chain fragments including CH2 and CH3 domains of an antibody. These two heavy chain fragments are linked to each other by hydrophobic interaction of two or more of disulfide bonds and a CH3 domain.

[0847] In the present disclosure, the “Fab fragment” consists of one light chain and one heavy chain including a variable region and CHI only. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. In an scFab, two molecules of Fab are linked by a flexible linker.

[0848] In the present disclosure, the “Fab' fragment” includes a Fab fragment and additionally a region between CHI and CH2 domains of a heavy chain. A disulfide bond may form between two heavy chains of Fab' fragments of two molecules, forming a F(ab')2 molecule.

[0849] In the present disclosure, as described above, the “F(ab')2 fragment” includes two light chains and two heavy chains including a variable region CHI and part of a constant region between the CHI and CH2 domains, with an inter-chain disulfide bond formed between the two heavy chains. Accordingly, a F(ab')2 fragment consists of two Fab' fragments, and the two Fab' fragments are joined to each other by the disulfide bond therebetween.

[0850] 84

[0851] FH30010281.1Attorney Docket: LCH-04525

[0852] In the present disclosure, the “Fv region” is a fragment of an antibody which includes each variable region of a heavy chain and a light chain, but does not include constant regions. In an sdFV, a heavy chain and a light chain are linked by a disulfide bond. In an scFc, the Fv is linked by a flexible linker. In a scFv-Fc, a Fc is linked to a scFV. In a minibody, CH3 is linked to a scFV. A diabody includes the scFVs of two molecules.

[0853] In the present disclosure, the “single chain Fv” or “scFv” antibody fragment includes the VH and VL domains of an antibody, and these domains are present within a single polypeptide chain. An Fv polypeptide may additionally include a polypeptide linker between a VH domain which enables the scFv to form the target structure for antigen binding, and a VL domain.

[0854] In the present disclosure, the “single-chain antibody (scAb)” is a single polypeptide chain including one constant region of a heavy chain or a light chain constant region in which heavy chain and light chain variable regions are linked by a flexible linker. For a single-chain antibody, U. S. Pat. No. 5,260,203 may be referred to, and short-chain antibody is disclosed herein by reference.

[0855] In the present disclosure, the “domain antibody (dAb)” is an immunologically functional immunoglobulin fragment including only a variable region of a heavy chain or a variable region of a light chain. In certain embodiments, two or more VH regions are linked by a covalent bond via a peptide linker, to form a bivalent domain antibody. Two VH regions of this bivalent domain antibody may target the same or different antigens.

[0856] In the present disclosure, “complementarity determining region” (CDR; that is, CDR1, CDR2, and CDR3) denotes amino acid residues of the variable region of an antibody, which are necessary for binding to antigen. Each variable region typically has three CDR domains, identified as CDR1, CDR2, and CDR3.

[0857] In the present disclosure, the “framework region” (FR) is a variable region residue other than the CDR residues. Each variable region typically has four FRs, identified as FR1, FR2, FR3, and FR4.

[0858] In the present disclosure, the “bivalent antigen-binding protein” or “bivalent antibody” includes two antigen-binding sites. The two antigen-binding sites included in a bivalent antibody may have the same antigen specificity, or may be a bispecific antibody where the antigen-biding sites bind to different antigens.

[0859] In the present disclosure, the “multispecific antigen-binding protein” or “multispecific antibody” targets two or more antigens or epitopes.

[0860] 85

[0861] FH30010281.1Attorney Docket: LCH-04525

[0862] As used herein, a “chimeric antibody” refers to an antibody (immunoglobulin) in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U. S. Patent No. 4,816,567; Morrison et al., Proc. Nat’l Acad. Sci. USA, 81:6851-55 (1984)). Chimeric antibodies of interest herein include PRIMATIZED® antibodies wherein the antigen-binding region of the antibody is derived from an antibody produced by, e.g., immunizing macaque monkeys with an antigen of interest.

[0863] “Humanized” forms of non-human (e.g., murine) antibodies, are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In one embodiment, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from an CDR of the recipient are replaced by residues from an CDR of a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and / or capacity. In some instances, FR residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody performance, such as binding affinity. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence, and all or substantially all of the FR regions are those of a human immunoglobulin sequence, although the FR regions may include one or more individual FR residue substitutions that improve antibody performance, such as binding affinity, isomerization, immunogenicity, and the like. The number of these amino acid substitutions in the FR is typically no more than 6 in the H chain, and in the L chain, no more than 3. The humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see, e.g., Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, for example, Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994); and U. S. Patent Nos. 6,982,321 and 7,087,409.

[0864] 86

[0865] FH30010281.1Attorney Docket: LCH-04525

[0866] A “human antibody” is one that possesses an amino-acid sequence corresponding to that of an antibody, produced by a human and / or has been made using any of the techniques for making human antibodies as disclosed herein. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phagedisplay libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991). Also available for the preparation of human monoclonal antibodies are methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p.

[0867] 77 (1985); Boerner et al., J. Immunol., 147(l):86-95 (1991). See also van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74 (2001). Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U. S. Patent Nos. 6,075,181 and 6,150,584 regarding XENOMOUSETM technology). See also, for example, Li et al., Proc. Nat’l Acad. Sci. USA, 103:3557-3562 (2006) regarding human antibodies generated via a human B-cell hybridoma technology.

[0868] A “human consensus framework” is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991). Examples include for the VL, the subgroup may be subgroup kappa I, kappa II, kappa III or kappa IV as in Kabat et al., supra. Additionally, for the VH, the subgroup may be subgroup I, subgroup II, or subgroup III as in Kabat et al., supra.

[0869] An “affinity-matured” antibody is one with one or more alterations in one or more CDRs thereof that result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody that does not possess those alteration(s). In one embodiment, an affinity-matured antibody has nanomolar or even picomolar affinities for the target antigen. Affinity -matured antibodies are produced by procedures known in the art. For example, Marks et al., Bio / Technology 10:779-783 (1992) describes affinity maturation by VH- and VL-domain shuffling. Random mutagenesis of CDR and / or framework residues is described by, for example: Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al. Gene

[0870] 87

[0871] FH30010281.1Attorney Docket: LCH-04525

[0872] 169:147- 155 (1995); Yelton et al. J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al, J. Mol. Biol. 226:889-896 (1992).

[0873] As used herein, the term “alkyl” refers to saturated aliphatic groups, including but not limited to Ci-Cio straight-chain alkyl groups or Ci-Cio branched-chain alkyl groups. Preferably, the “alkyl” group refers to Ci-Ce straight-chain alkyl groups or Ci-Ce branched-chain alkyl groups. Most preferably, the “alkyl” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkyl groups. Examples of “alkyl” include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, n-butyl, sec-butyl, tert-butyl, 1 -pentyl, 2-pentyl, 3 -pentyl, neo-pentyl, 1 -hexyl, 2-hexyl, 3 -hexyl, 1 -heptyl, 2-heptyl, 3 -heptyl, 4-heptyl, 1 -octyl, 2-octyl, 3 -octyl or 4-octyl and the like. Moreover, the term “alkyl” as used throughout the specification, examples, and claims is intended to include both unsubstituted and substituted alkyl groups, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, including haloalkyl groups such as trifluoromethyl and 2,2,2-trifluoroethyl, etc.

[0874] As used herein, the term “alkylene” refers to a bivalent saturated aliphatic groups, including but not limited to C1-C10 straight-chain alkyl groups or C1-C10 branched-chain alkylene groups. Preferably, the “alkylene” group refers to Ci-Ce straight-chain alkylene groups or Ci-Ce branched-chain alkyl groups. Most preferably, the “alkylene” group refers to C1-C4 straight-chain alkyl groups or C1-C4 branched-chain alkylene groups. Examples of “alkylene” include, but are not limited to, methylene, ethylene, 1 -propylene, 2-propylene, n-butylene, sec-butylene, tert-butylene, 1 -pentylene, 2-pentylene, 3 -pentylene, neo-pentylene, 1-hexylene, 2-hexylene, 3 -hexylene, 1 -heptylene, 2-heptylene, 3 -heptylene, 4-heptylene, 1-octylene, 2-octylene, 3 -octylene or 4-octylene and the like. The “alkylene” group may be optionally substituted.

[0875] The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)-, preferably alkylC(O)-.

[0876] The term “acylamino” is art-recognized and refers to an amino group substituted with an acyl group and may be represented, for example, by the formula hydrocarbylC(O)NH-.

[0877] The term “acyloxy” is art-recognized and refers to a group represented by the general formula hydrocarbylC(O)O-, preferably alkylC(O)O-.

[0878] The term “alkoxy” refers to an alkyl group having an oxygen attached thereto. Representative alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.

[0879] The term “alkoxyalkyl” refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula alkyl-O-alkyl.

[0880] 88

[0881] FH30010281.1Attorney Docket: LCH-04525

[0882] The term “Cx-y” or “Cx-Cy”, when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups that contain from x to y carbons in the chain. Coalkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. A Ci-ealkyl group, for example, contains from one to six carbon atoms in the chain.

[0883] The term “alkylamino”, as used herein, refers to an amino group substituted with at least one alkyl group.

[0884] The term “alkylthio”, as used herein, refers to a thiol group substituted with an alkyl group and may be represented by the general formula alkylS-.

[0885] The term “amido”, as used herein, refers to a group such as

[0886]

[0887] wherein R9and R10each independently represent a hydrogen or hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0888] The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by

[0889]

[0890] wherein R9, R10, and R10’ each independently represent a hydrogen or a hydrocarbyl group, or R9and R10taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure.

[0891] The term “aminoalkyl”, as used herein, refers to an alkyl group substituted with an amino group.

[0892] The term “aralkyl”, as used herein, refers to an alkyl group substituted with an aryl group.

[0893] The term “aryl” as used herein include substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. Preferably the ring is a 5- to 7-membered ring, more preferably a 6-membered ring. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls,

[0894] 89

[0895] FH30010281.1Attorney Docket: LCH-04525

[0896] cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.

[0897] The term “carbamate” is art-recognized and refers to a group

[0898]

[0899] wherein R9and R10independently represent hydrogen or a hydrocarbyl group.

[0900] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

[0901] The term “carbocycle” includes 5-7 membered monocyclic and 8-12 membered bicyclic rings. Each ring of a bicyclic carbocycle may be selected from saturated, unsaturated and aromatic rings. Carbocycle includes bicyclic molecules in which one, two or three or more atoms are shared between the two rings. The term “fused carbocycle” refers to a bicyclic carbocycle in which each of the rings shares two adjacent atoms with the other ring. Each ring of a fused carbocycle may be selected from saturated, unsaturated and aromatic rings. In an exemplary embodiment, an aromatic ring, e.g., phenyl, may be fused to a saturated or unsaturated ring, e.g., cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated and aromatic bicyclic rings, as valence permits, is included in the definition of carbocyclic. Exemplary “carbocycles” include cyclopentane, cyclohexane, bicyclo[2.2.1]heptane, 1,5-cyclooctadiene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]oct-3-ene, naphthalene and adamantane. Exemplary fused carbocycles include decalin, naphthalene, 1,2,3,4-tetrahydronaphthalene, bicyclo[4.2.0]octane, 4,5,6,7-tetrahydro-lH-indene and bicyclo[4.1.0]hept-3-ene. “Carbocycles” may be substituted at any one or more positions capable of bearing a hydrogen atom.

[0902] The term “carbocyclylalkyl”, as used herein, refers to an alkyl group substituted with a carbocycle group.

[0903] The term “carbonate” is art-recognized and refers to a group -OCO2-.

[0904] The term “carboxy”, as used herein, refers to a group represented by the formula -CO2H.

[0905] The term “cleavage group” refers to a chemical moiety which dissociates when subjected to a stimulus, such as acidic conditions, basic conditions, reducing conditions, oxidizing conditions, light, or heat, or an enzyme, such as an esterase.

[0906] The term “cycloalkyl” includes substituted or unsubstituted non-aromatic single ring structures, preferably 4- to 8-membered rings, more preferably 4- to 6-membered rings. The

[0907] 90

[0908] FH30010281.1Attorney Docket: LCH-04525

[0909] term “cycloalkyl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is cycloalkyl and the substituent (e.g., R100) is attached to the cycloalkyl ring, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, pyrimidine, denzodioxane, tetrahydroquinoline, and the like.

[0910] The term “ester”, as used herein, refers to a group -C(O)OR9wherein R9represents a hydrocarbyl group.

[0911] The term “ether”, as used herein, refers to a hydrocarbyl group linked through an oxygen to another hydrocarbyl group. Accordingly, an ether substituent of a hydrocarbyl group may be hydrocarbyl-O-. Ethers may be either symmetrical or unsymmetrical. Examples of ethers include, but are not limited to, heterocycle-O-heterocycle and aryl-O-heterocycle. Ethers include “alkoxyalkyl” groups, which may be represented by the general formula alkyl-O-alkyl.

[0912] The term “guanidinyl”, as used herein, refers to a group of the formula -NRa-C(=NRb)-NRbRc, wherein Ra, Rb, and Rcare each independently H or hydrocarbyl.

[0913] The terms “halo” and “halogen” as used herein means halogen and includes chloro, fluoro, bromo, and iodo.

[0914] The terms “hetaralkyl” and “heteroaralkyl”, as used herein, refers to an alkyl group substituted with a hetaryl group.

[0915] The terms “heteroaryl” and “hetaryl” include substituted or unsubstituted aromatic single ring structures, preferably 5- to 7-membered rings, more preferably 5- to 6-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heteroaryl” and “hetaryl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.

[0916] The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, and sulfur.

[0917] The term “heterocyclylalkyl”, as used herein, refers to an alkyl group substituted with a heterocycle group.

[0918] 91

[0919] FH30010281.1Attorney Docket: LCH-04525

[0920] The terms “heterocyclyl”, “heterocycle”, and “heterocyclic” refer to substituted or unsubstituted non-aromatic ring structures, preferably 3- to 10-membered rings, more preferably 3- to 7-membered rings, whose ring structures include at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. The terms “heterocyclyl” and “heterocyclic” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

[0921] The term “hydrocarbyl”, as used herein, refers to a group that is bonded through a carbon atom that does not have a =0 or =S substituent, and typically has at least one carbonhydrogen bond and a primarily carbon backbone, but may optionally include heteroatoms. Thus, groups like methyl, ethoxyethyl, 2-pyridyl, and even trifluoromethyl are considered to be hydrocarbyl for the purposes of this application, but substituents such as acetyl (which has a =0 substituent on the linking carbon) and ethoxy (which is linked through oxygen, not carbon) are not. Hydrocarbyl groups include, but are not limited to aryl, heteroaryl, carbocycle, heterocycle, alkyl, alkenyl, alkynyl, and combinations thereof.

[0922] The term “hydroxyalkyl”, as used herein, refers to an alkyl group substituted with a hydroxy group.

[0923] The term “hydroxylamino” is art-recognized and refers to a group

[0924]

[0925] ix

[0926] RX, wherein Rx, Ry, and Rzindependently represent hydrogen or a hydrocarbyl group.

[0927] The term “lower” when used in conjunction with a chemical moiety, such as, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy is meant to include groups where there are ten or fewer atoms in the substituent, preferably six or fewer. A “lower alkyl”, for example, refers to an alkyl group that contains ten or fewer carbon atoms, preferably six or fewer. In certain embodiments, acyl, acyloxy, alkyl, alkenyl, alkynyl, or alkoxy substituents defined herein are respectively lower acyl, lower acyloxy, lower alkyl, lower alkenyl, lower alkynyl, or lower alkoxy, whether they appear alone or in combination with other substituents, such as in the recitations hydroxyalkyl and aralkyl (in which case, for example, the atoms within the aryl group are not counted when counting the carbon atoms in the alkyl substituent).

[0928] 92

[0929] FH30010281.1Attorney Docket: LCH-04525

[0930] The terms “polycyclyl”, “polycycle”, and “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and / or heterocyclyls) in which two or more atoms are common to two adjoining rings, e.g., the rings are “fused rings”. Each of the rings of the polycycle can be substituted or unsubstituted. In certain embodiments, each ring of the poly cycle contains from 3 to 10 atoms in the ring, preferably from 5 to 7.

[0931] The term “sulfate” is art-recognized and refers to the group -OSO3H, or a pharmaceutically acceptable salt thereof.

[0932] The term “sulfonamido” is art-recognized and refers to the group represented by the general formulae

[0933]

[0934] wherein R9and R10independently represents hydrogen or hydrocarbyl.

[0935] The term “sulfoxide” is art-recognized and refers to the group-S(O)-.

[0936] The term “sulfonate” is art-recognized and refers to the group SO3H, or a pharmaceutically acceptable salt thereof.

[0937] The term “sulfone” is art-recognized and refers to the group -S(O)2-.

[0938] The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. The heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include any substituents described herein, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido,

[0939] 93

[0940] FH30010281.1Attorney Docket: LCH-04525

[0941] a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.

[0942] The term “thioalkyl”, as used herein, refers to an alkyl group substituted with a thiol group.

[0943] The term “thioester”, as used herein, refers to a group -C(O)SR9or -SC(O)R9wherein R9represents a hydrocarbyl.

[0944] The term “thioether”, as used herein, is equivalent to an ether, wherein the oxygen is replaced with a sulfur.

[0945] The term “urea” is art-recognized and may be represented by the general formula

[0946]

[0947] wherein R9and R10independently represent hydrogen or a hydrocarbyl.

[0948] The term “modulate” as used herein includes the inhibition or suppression of a function or activity (such as cell proliferation) as well as the enhancement of a function or activity.

[0949] The term “DBCO” used herein refers to an optionally substituted dibenzocyclooctyne moiety, e.g., the following structure:

[0950]

[0951] The term “sugar moiety” used herein refers to a naturally occurring sugar or a modified sugar which is part of a larger molecule and is connected to the remainder of the larger molecule through, for example, one of the hydroxyl groups present on the sugar. For example, in some embodiments the sugar is connected to the remainder of the larger molecule via the hydroxyl group on the anomeric carbon. Examples of sugar moieties include, but are not limited to, glucuronosyl and galactosyl.

[0952] A “glycosidase” is an enzyme that breaks down glycosidic bonds in carbohydrates, glycoproteins, and glycolipids. Examples of glycosidases are P-glucuronidase and P-galactosidase. P-glucuronidase is a type of glucuronidase that catalyzes hydrolysis of P-D-glucuronic acid or P-glucuronosyl residues. P-Galactosidase is a glycoside hydrolase enzyme that catalyzes hydrolysis of terminal non-reducing P-D-galactose or P-galactosyl residues in P-D-galactosides.

[0953] 94

[0954] FH30010281.1Attorney Docket: LCH-04525

[0955] The phrase “pharmaceutically acceptable” is art-recognized. In certain embodiments, the term includes compositions, excipients, adjuvants, polymers and other materials and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0956] “Pharmaceutically acceptable salt” or “salt” is used herein to refer to an acid addition salt or a basic addition salt which is suitable for or compatible with the treatment of patients.

[0957] The term “pharmaceutically acceptable acid addition salt” as used herein means any non-toxic organic or inorganic salt of any base compounds represented by Formula la. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acids, as well as metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids that form suitable salts include mono-, di-, and tricarboxylic acids such as glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic and salicylic acids, as well as sulfonic acids such as p-toluene sulfonic and methanesulfonic acids. Either the mono or di-acid salts can be formed, and such salts may exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of compounds of Formula la are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection of the appropriate salt will be known to one skilled in the art. Other non-pharmaceutically acceptable salts, e.g., oxalates, may be used, for example, in the isolation of compounds of Formula la for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.

[0958] The term “pharmaceutically acceptable basic addition salt” as used herein means any non-toxic organic or inorganic base addition salt of any acid compounds represented by Formula la or any of their intermediates. Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium, or barium hydroxide. Illustrative organic bases which form suitable salts include aliphatic, alicyclic, or aromatic organic amines such as methylamine, trimethylamine and picoline or ammonia. The selection of the appropriate salt will be known to a person skilled in the art.

[0959] Many of the compounds useful in the methods and compositions of this disclosure have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration, said R and S notation is used in correspondence with the rules described in Pure Appl. Chem. (1976), 45, 11-30. The disclosure contemplates all stereoisomeric forms 95

[0960] FH30010281.1Attorney Docket: LCH-04525

[0961] such as enantiomeric and diastereoisomeric forms of the compounds, salts, prodrugs or mixtures thereof (including all possible mixtures of stereoisomers). See, e.g., WO 01 / 062726.

[0962] Furthermore, certain compounds which contain alkenyl groups may exist as Z (zusammen) or E (entgegen) isomers. In each instance, the disclosure includes both mixture and separate individual isomers.

[0963] “Prodrug” or “pharmaceutically acceptable prodrug” refers to a compound that is metabolized, for example hydrolyzed or oxidized, in the host after administration to form the compound of the present disclosure (e.g., compounds of formula la). Typical examples of prodrugs include compounds that have biologically labile or cleavable (protecting) groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, or dephosphorylated to produce the active compound. Examples of prodrugs using ester or phosphoramidate as biologically labile or cleavable (protecting) groups are disclosed in U. S. Patents 6,875,751, 7,585,851, and 7,964,580, the disclosures of which are incorporated herein by reference. The prodrugs of this disclosure are metabolized to produce a compound of Formula la. The present disclosure includes within its scope, prodrugs of the compounds described herein. Conventional procedures for the selection and preparation of suitable prodrugs are described, for example, in “Design of Prodrugs” Ed. H. Bundgaard, Elsevier, 1985.

[0964] The term “Log of solubility”, “LogS” or “logS” as used herein is used in the art to quantify the aqueous solubility of a compound. The aqueous solubility of a compound significantly affects its absorption and distribution characteristics. A low solubility often goes along with a poor absorption. LogS value is a unit stripped logarithm (base 10) of the solubility measured in mol / liter.

[0965] Examples

[0966] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and are not intended to limit the invention.

[0967] Preparation of Compounds

[0968] < Preparation Example 1> Preparation of Compound 2

[0969] 96

[0970] FH30010281.1Attorney Docket: LCH-04525

[0971]

[0972] Preparation of Compound 1

[0973] To a solution of l-ethyl-3-methyl-7J / -pyrazole-5-carboxylic acid (8.0 g, 51.9 mmol) in dichloromethane (50 mL), oxalyl chloride (4.97 mL, 57.1 mmol) and a catalytic amount of A A -di methyl form am ide (0.1 mL) were added at 0 °C. After stirring at room temperature for 2 hours, the solvent was removed under reduced pressure to afford Compound 1 as a crude product.

[0974] Preparation of Compound 2

[0975] To a solution of crude Compound 1 in acetone (100 mL), potassium thiocyanate (6.5 g, 67.5 mmol) was added at 0 °C. After stirring at room temperature for 30 minutes, the reaction mixture was diluted with hexane (100 mL). The resulting solid was removed by filtration, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 2 (9.7 g, 95%). 'H-NMR (400 MHz, CDCI3), 6 7.78 (d, 1H), 7.41 (s, 1H), 7.38 (d, 1H), 3.88 (s, 3H), 2.57 (s, 3H). ESI-MS m / z: [M+H]+196.00.

[0976] ^Preparation Example 2> Preparation of Compound 5

[0977]

[0978] Preparation of Compound 3

[0979] To a solution of methyl 4-chl oro-3 -m ethoxy-5 -nitrobenzoate (15.0 g, 61.1 mmol), aqueous ammonia solution (28-30% NH3, 200 mL) was added. After stirring at 50 °C for 6 hours and cooled to room temperature, the resulting precipitate was collected by filtration, washed with water, and lyophilized to afford Compound 3 (9.51 g, 68%).1H-NMR (400 MHz, CDC13) 8 8.29 (s, 1H), 8.04 (d, 1H), 7.87 (d, 1H), 7.78 (s, 1H), 4.01 (s, 3H).

[0980] Preparation of Compound 4

[0981] To a solution of Compound 3 (300 mg, 1.30 mmol) in dichloromethane (9 mL), aluminum chloride (1.04 g, 7.81 mmol) was added at 0 °C under N2. After stirring at room temperature for 21 hours, the mixture was poured into ice water, and the resulting solid was

[0982] 97

[0983] FH30010281.1Attorney Docket: LCH-04525

[0984] collected by filtration and lyophilized to afford Compound 4 (223 mg, 79%). 'H-NMR (400 MHz, CDC13), 6 11.73 (s, 1H), 8.21 (s, 1H), 7.92 (s, 1H), 7.80 (s, 1H), 7.66 (s, 1H).

[0985] Preparation of Compound 5

[0986] To a solution of Compound 4 (2.0 g, 9.23 mmol) and cesium carbonate (3.61 g, 11.08 mmol) in A, A-di methyl form am ide (15 mL), the mixture was cooled to 0 °C under N2. After stirring for 5 minutes, trans- l,4-dibromo-2 -butene (5.93 g, 27.70 mmol) was then added at room temperature under N2, and the reaction mixture was stirred for an additional 2 hours. The mixture was extracted with ethyl acetate (3 x 20 mL), washed with distilled water (2 x 15 mL) and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting crude product was solidified using di chloromethane and hexane to afford Compound 5 (2.53 g, 78%).1H-NMR (400 MHz, CDCI3), 8 8.23 (s, 2H), 8.02 (d, J= 1.8 Hz, 2H), 7.84 (d, J= 1.8 Hz, 2H), 7.73 (s, 2H), 6.16-5.98 (m, 4H), 5.70 (s, 1H), 4.83 (d, J= 3.5 Hz, 4H), 4.25 (d, J= 5.4 Hz, 1H), 4.20-4.14 (m, 3H). ESI-MS m / z: [M+H]+350.98.

[0987] ^Preparation Example 3 > Preparation of Compound 9

[0988]

[0989] 8 9

[0990] Preparation of Compound 6

[0991] To a solution of tert-butyl (E)-(4-aminobut-2-en-l-yl)carbamate (11.4 g, 61.57 mmol) in ethanol (100 mL), Compound 3 (10.0 g, 43.4 mmol) and A, A-diisopropylethylamine (14.9 mL, 86.7 mmol) were added. After stirring at 120 °C for 12 hours, the solvent was removed

[0992] 98

[0993] FH30010281.1Attorney Docket: LCH-04525

[0994] under reduced pressure, and the resulting residue was diluted with diethyl ether (40 mL). The resulting solid was collected by filtration and dried to afford Compound 6 (12.6 g, 76%).1H-NMR (400 MHz, DMSO-d6), 6 8.18 (d, 1H), 8.01(s, 1H), 7.73 (t, 1H), 7.55 (d, 1H), 7.31 (s, 1H), 6.92 (s, 1H), 5.53 (s, 2H), 4.08 (s, 2H), 3.47 (s, 2H), 1.35 (m, 9H).

[0995] Preparation of Compound 7

[0996] To a solution of Compound 6 (10.0 g, 26.28 mmol) in methanol (90 mL), aqueous ammonia solution (28-30% NHs, 90 mL) and sodium hydrosulfite (Na2S2O4, 45 g, 262.8 mmol) were sequentially added at 0 °C. After stirring at room temperature for 1 hour and 30 minutes, methanol (100 mL) was added, and the resulting solid was removed by filtration. The filtrate was concentrated under reduced pressure, diluted with dichloromethane (100 mL), and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford Compound 7 (6.9 g, 75%). 'H-NMR(400 MHz, DMSO-d6), 87.62 (br s, 1H), 6.98 (br s, 1H), 6.92 (t, 1H), 6.87 (d, 1H), 6.79 (d, 1H), 5.57 (q, 2H), 4.67 (br s, 2H), 3.82 (br s, 1H), 3.76 (s, 3H), 3.51 (dd, 4H), 1.37 (s, 9H).

[0997] Preparation of Compound 8

[0998] To a solution of Compound 7 (6.9 g, 19.7 mmol) in A, A-di methyl form am ide (50 mL), Compound 2 (4.9 g, 25.59 mmol) was added at 0 °C, and the mixture was stirred at room temperature for 30 minutes. Triethylamine (5.4 mL, 39.38 mmol) and N-(3-dimethylaminopropyl)-A'-ethylcarbodiimide (4.2 g, 27.56 mmol) were then added at 0 °C. After stirring at room temperature for 17 hours, the mixture was concentrated under reduced pressure, diluted with diethyl ether (20 mL), and the resulting solid was collected by filtration to afford Compound 8 (7.7 g, 76%). ‘H-NMR (400 MHz, DMSO-d6), 6 12.86 (s, 1H), 8.02 (s, 1H), 7.67 (s, 1H), 7.40 (m, 2H), 6.93 (m, 1H), 6.65 (s, 1H), 5.67 (m, 2H), 4.93 (d, 2H), 4.61 (q, 2H), 3.98 (s, 3H), 3.51 (m, 2H), 2.55 (m, 2H), 2.18 (s, 3H), 1.35 (t, 3H), 1.32 (s, 9H).

[0999] Preparation of Compound 9

[1000] To a solution of Compound 8 (7.7 g, 15.05 mmol) in dichloromethane (25 mL) and methanol (25 mL), hydrochloric acid (4 M in 1,4-di oxane, 27 mL) was added, and the mixture was stirred for 2 hours and 30 minutes at room temperature. After stirring, the reaction mixture was concentrated under reduced pressure, diluted with diethyl ether (20 mL), and the resulting solid was collected by filtration to afford Compound 9 (5.6 g, 76%). 'H-NMR. (400 MHz, DMSO-de) 6 8.02 (s, 1H), 8.67(d, 1H), 7.41 (d, 1H), 7.37 (s, 1H), 6.66 (s, 1H), 6.01 (m, 1H), 5.65 (m, 1H), 4.97 (d, 2H), 4.60 (q, 2H), 3.98 (s, 3H), 2.66 (m, 5H), 2.33 (m, 3H), 1.35 (m, 3H). ESI-MS m / z: [M+H]+823.0.

[1001] 99

[1002] FH30010281.1Attorney Docket: LCH-04525

[1003]

[1004] Preparation of Compound 10

[1005] To a solution of Compound 5 (265 mg, 0.76 mmol) in A -di methyl form am ide (4 mL), tert-butyl piperidin-4-ylcarbamate (167 mg, 0.83 mmol) and cesium carbonate (296 mg, 0.91 mmol) were added under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL), washed with distilled water (2 x 50 mL), and dried over anhydrous sodium sulfate. After filtering and concentrating under reduced pressure, the mixture was diluted with dichloromethane and hexane, and the resulting solid was collected by filtration and dried to afford Compound 10 (248 mg, 70%). ESI-MS m / z: [M+H]+469.06.

[1006] Preparation of Compound 11

[1007] To a solution of Compound 9 (628 mg, 1.30 mmol) and Compound 10 (304 mg, 0.65 mmol) in / / -butanol (5 mL), AA-diisopropylethylamine (0.56 mL, 3.24 mmol) was added at room temperature. After stirring at 120 °C for 24 hours and cooled to room temperature, the mixture was diluted with di chloromethane (100 mL) and methanol (20 mL), then washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was diluted with dichloromethane and hexane, and the solid was collected by filtration and dried to afford Compound 11 (124 mg, 23%). ESI-MS m / z: [M+H]+844.02.

[1008] 100

[1009] FH30010281.1Attorney Docket: LCH-04525

[1010] Preparation of Compound 12

[1011] To a solution of Compound 11 (124 mg, 0.15 mmol) in methanol (4 mL) and distilled water (0.5 mL), aqueous ammonia solution (28-30% NH₃, 0.4 mL) and sodium hydrosulfite (Na2S2O4, 218 mg, 2.94 mmol) were added under N2. After stirring at room temperature for 1 hour, the reaction mixture was diluted with methanol (50 mL) and filtered. The filtrate was concentrated under reduced pressure, diluted with di chloromethane (100 mL) and methanol (20 mL), and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford Compound 12 (119 mg, crude). ES MS m / z: [M+H]+814.81.

[1012] Preparation of Compound 13

[1013] To a solution of crude Compound 12 (119 mg, 0.15 mmol) in A^A-dimethylformamide (1 mL), a solution of Compound 2 (32 mg, 0.16 mmol) in A^A-dimethylformamide (1 mL) was added under N2. After stirring at room temperature for 1 hour, N-(3 -di methyl ami nopropyl )-A-ethylcarbodiimide hydrochloride (35 mg, 0.18 mmol) and triethylamine (0.06 mL, 0.44 mmol) were added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure and purified by column chromatography to afford Compound 13 (36 mg, 25%). ESLMS m / z: [M+H]+975.15.

[1014] Preparation of Compound 14

[1015] To a solution of Compound 13 (36 mg, 0.04 mmol) in dichloromethane (1 mL) and trifluoroacetic acid (1 mL) was added at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 14 (15.2 mg, 47%). ESLMS m / z: [M+H]+875.06.

[1016] 101

[1017] FH30010281.1Attorney Docket: LCH-04525

[1018] ^Preparation Example 5> Preparation of Compound 42

[1019]

[1020] Preparation of Compound 36

[1021] To a solution of 4-nitropyrazole (1.0 g, 6.13 mmol) in methanol (20 mL), aqueous ammonia solution (28-30%, 2.2 mL) and sodium hydrosulfite (7.7 g) were added. After stirring at room temperature for 1 hour, the mixture was filtered through Celite and the filtrate was concentrated under reduced pressure. To the resulting residue, methanol (15 mL) was added, followed by di- / c / 7-butyl dicarbonate (2.24 mL, 9.73 mmol) and triethylamine (1.86 mL, 13.27 mmol) at room temperature. The mixture was stirred for 16 hours, then diluted with ethyl acetate (50 mL) and washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford

[1022] 102

[1023] FH30010281.1Attorney Docket: LCH-04525

[1024] Compound 36 (0.7 g, 43%). 'H-NMR (400 MHz, DMSO-d6) 69.05 (s, 1H), 7.44 (s, 1H), 1.42 (s, 9H).

[1025] Preparation of Compound 37

[1026] To a solution of Compound 36 (0.7 g, 3.82 mmol) in A A-di methyl form am ide (15 mL), cesium carbonate (3.7 g, 11.46 mmol) and trans- l,4-dibromo-2 -butene (2.45 g, 11.46 mmol) were added. After stirring at room temperature for 2 hours, the mixture was diluted with ethyl acetate (50 mL) and washed with saturated aqueous ammonium chloride solution (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 37 (867 mg, 71%). 'H-NMR (400 MHz, CDC13) 8 7.66 (s, 1H), 7.33 (s, 1H), 6.24 (s, 1H), 6.00 - 5.90 (m, 1H), 5.87 (td, J = 13.2, 5.9 Hz, 1H), 4.69 (d, J = 5.6 Hz, 2H), 3.94 (d, J = 6.9 Hz, 2H), 1.50 (s, 9H). ESI-MS m / z: [M+H]+317.26.

[1027] Preparation of Compound 38

[1028] To a solution of Compound 4 (540 mg, 2.5 mmol) in A A -di methyl form am ide (15 mL), cesium carbonate (894 mg, 2.75 mmol) and Compound 37 (867 mg, 2.75 mmol) were added. After stirring at room temperature for 2 hours, the mixture was diluted with ethyl acetate (50 mL) and washed with saturated aqueous ammonium chloride solution (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 38 (830 mg, 73%). 'H-NMR (400 MHz, DMSO-d6) 6 9.12 (s, 1H), 8.24 (s, 1H), 8.05 (s, 1H), 7.88 (s, 1H), 7.75 (s, 1H), 7.65 (s, 1H), 7.30 (s, 1H), 6.08 (d, J= 15.4 Hz, 1H), 5.86 (d, J= 15.8 Hz, 1H), 4.82 (d, J= 5.4 Hz, 2H), 4.74 (d, J= 5.9 Hz, 2H), 1.44 (d, J= 2.3 Hz, 9H). ESI-MS m / z: [M+H]+452.31.

[1029] Preparation of Compound 39

[1030] To a solution of Compound 38 (830 mg, 1.83 mmol) and Compound 9 (1.13 g, 2.76 mmol) in / / -butanol (11 mL), AA-diisopropylethylamine (1.6 mL, 9.18 mmol) was added. After stirring at 0 °C for 5 minutes and heated to 120 °C, the reaction mixture was stirred for 24 hours. After cooling to room temperature, the mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 39 (420 mg, 28%). ESI-MS m / z: [M+H]+827.39.

[1031] Preparation of Compound 40

[1032] To a solution of Compound 39 (420 mg, 0.51 mmol) in methanol (5 mL), aqueous ammonia solution (28-30%, 1.8 mL, 12.66 mmol) and sodium hydrosulfite (882 mg, 5.06 mmol) were added. After stirring at room temperature for 2.5 hours, the mixture was filtered 103

[1033] FH30010281.1Attorney Docket: LCH-04525

[1034] through Celite and washed with methanol. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by reversed-phase column chromatography to afford Compound 40 (400 mg). ESI-MS m / z: [M+H]+797.48.

[1035] Preparation of Compound 41

[1036] To a solution of Compound 40 (400 mg, 0.51 mmol) in A A -di methyl form am ide (1.5 mL), a solution of Compound 2 (109 mg, 0.55 mmol) in A, A-di methyl form am ide (1 mL) was added at 0 °C. After stirring for 30 minutes, 7V-(3-dimethylaminopropyl)-7V’-ethylcarbodiimide (0.1 mL, 0.61 mmol) and triethylamine (0.35 mL, 2.53 mmol) were added. The reaction mixture was stirred at room temperature for 15 hours, filtered, and concentrated under reduced pressure. The resulting residue was purified by reversed-phase column chromatography to afford Compound 41 (97 mg, 20%).

[1037] Preparation of Compound 42

[1038] To a solution of Compound 41 (30 mg, 0.03 mmol) in dichloromethane (1 mL), trifluoroacetic acid (0.2 mL) was added at 0 °C. After stirring at room temperature for 30 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 42 (10 mg, 27%). 'H-NMR (400 MHz, CD3OD) 87.80 (s, 1H), 7.57 (d, J= 11.4 Hz, 3H), 7.29 (s, 1H), 7.23 (s, 1H), 6.62 (d, J = 1.7 Hz, 1H), 6.56 (s, 1H), 5.85 (d, J= 18.0 Hz, 3H), 5.70 (d, J= 15.6 Hz, 1H), 5.01 (s, 4H), 4.63 (s, 3H), 4.61 - 4.52 (m, 2H), 4.45 (s, 2H), 3.74 (s, 2H), 3.31 (m, 3H), 2.65 (s, 1H), 2.20 (d, J= 12.3 Hz, 6H), 1.34 (dt, J= 21.7, 6.9 Hz, 6H). ESI-MS m / z: [M+H]+858.54.

[1039] 104

[1040] FH30010281.1Attorney Docket: LCH-04525

[1041]

[1042] Preparation of Compound 49

[1043] To a solution of Compound 4 (5.0 g, 23.08 mmol) in A A -di methyl form am ide (30 mL), cesium carbonate (11.2 g, 34.62 mmol) was added at 0 °C under N2. After 5 minutes, ethyl 4- bromobutyrate (5.4 g, 27.70 mmol) was added at room temperature under N2. After stirring for 2 hours, the mixture was diluted with ethyl acetate (60 mL) and washed with distilled water (2 x 15 mL) and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate,

[1044] 105

[1045] FH30010281.1Attorney Docket: LCH-04525

[1046] filtered, and concentrated under reduced pressure. The resulting residue was solidified using dichloromethane and hexane, and the resulting solid was collected by filtration and dried to afford Compound 49 (4.7 g, 61%), which was used without further purification. 'H-NMR (400 MHz, CDC13) 68.29 (s,lH), 8.05 (s, 1H), 7.87 (s, 1H), 7.77 (s, 1H), 4.28 (m, 2H), 3.61 (s, 2H), 2.56-2.54 (m, 2H), 2.21-2.03(m, 2H). ESI-MS m / z: [M+H]+331.20.

[1047] Preparation of Compound 50

[1048] To a solution of Compound 49 (4.5 g, 13.60 mmol) in ethanol (30 mL) were added tertbutyl (£)-(4-aminobut-2-en-l-yl)carbamate (2.5 g, 13.60 mmol) and N, N-diisopropylethylamine (2.37 mL, 27.21 mmol) at 120 °C under N2. After stirring for 12 hours, the reaction mixture was cooled to room temperature, diluted with ethyl acetate (60 mL), and washed with distilled water (2 x 15 mL) and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 50 (4.5 g, 68%). 'H-NMR(400MHz, CDCI3) 88.15 (d, J= 1.9 Hz, 1H), 8.10 (s, 1H), 7.50 (d, J = 2.0 Hz, 1H), 5.71 (dt, J= 4.7, 2.8 Hz, 2H), 4.73 (s, 1H), 4.27 (ddd, J= 5.8, 4.1, 1.5 Hz, 2H), 4.09 (t, J= 6.4 Hz, 2H), 3.75 (s, 2H), 3.72 (s, 3H), 2.52 (t, J= 7.2 Hz, 2H), 2.18 (p, J= 6.8 Hz, 2H), 1.44 (s, 9H). ESI-MS m / z: [M+H]+467.79

[1049] Preparation of Compound 51

[1050] To a solution of Compound 50 (4.4 g, 9.156 mmol) in methanol (20 mL), aqueous ammonia solution (28-30%, 10 mL) and sodium hydrosulfite (Na2S2O4, 15 g, 91.6 mmol) were added at 0 °C. After stirring at room temperature for 1.5 hours, the mixture was filtered through Celite using methanol. The filtrate was concentrated under reduced pressure to afford Compound 51 (4 g, 96%). ESI-MS m / z: [M+H]+437.31.

[1051] Preparation of Compound 52

[1052] To a solution of Compound 51 (4.0 g, 8.87 mmol) in N, A -di methyl form am ide (30 mL), Compound 2 (1.9 g, 9.76 mmol) was added at 0 °C. After stirring at room temperature for 30 minutes, triethylamine (3.7 mL, 26.63 mmol) and A-(3-dimethylaminopropyl)-A’-ethylcarbodiimide (2.7 g, 17.75 mmol) were added at 0 °C. The mixture was stirred at room temperature for 17 hours, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 52 (3.8 g, 71%). 'H-NMR (400 MHz, DMSO-d6) 6 12.86 (s, 1H), 7.99 (s, 1H), 7.66 (s, 1H), 7.37-7.35 (m, 2H), 6.89 (m, 1H), 6.63 (s, 1H), 5.79-5.72 (d, J= 16 Hz, 1H), 5.58-5.54 (d, J= 16 Hz, 1H) 4.94 (s, 2H), 4.22 (s, 3H), 4.20 (m, 6H), 3.61 (s, 3H), 2.11 (s, 2H), 1.36 (m, 9H), 1.17 (m, 4H). ESI-MS m / z: [M+H]+598.31.

[1053] 106

[1054] FH30010281.1Attorney Docket: LCH-04525

[1055] Preparation of Compound 53

[1056] To a solution of Compound 52 (3.8 g, 6.21 mmol) in dichloromethane (50 mL), hydrochloric acid (4 M solution in 1,4-dioxane, 11.5 mL) was added. After stirring for 2 hours, the reaction mixture was concentrated under reduced pressure and diluted with diethyl ether (20 mL). The resulting solid was collected by filtration to afford Compound 53 (3.9 g, 99%). 'H-NMR (400 MHz, DMSO-d6) 6 8.04 (s, 1H), 7.88 (m, 2H), 7.68 (s, 1H), 7.39 (s, 2H), 6.67 (s, 1H), 6.08-6.04 (d, J= 16 Hz, 1H), 5.59-5.55 (d, J= 16 Hz, 1H), 5.00 (s, 2H), 4.22 (m, 2H), 3.65 (s, 3H), 1.37 (s, 3H), 2.19 (s, 3H), 2.11 (m, 2H). ESI-MS m / z: [M+H]+498.31.

[1057] Preparation of Compound 54

[1058] To a solution of Compound 53 (3.8 g, 6.63 mmol) and Compound 38 (2.0 g, 4.42 mmol) in / / -butanol (13 mL), A, A-diisopropylethylamine (3.85 mL, 22.13 mmol) was added at room temperature. After stirring at 100 °C for 21 hours and cooled to room temperature, the mixture was diluted with dichloromethane (100 mL), methanol (20 mL) and washed with distilled water (50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 54 (1.6 g, 38%). ESLMS m / z: [M+H]+913.98.

[1059] Preparation of Compound 55

[1060] To a solution of Compound 54 (1.6 g, 1.83 mmol) in methanol (8 mL), aqueous ammonia solution (28-30%, 3.2 mL) and sodium hydrosulfite (Na2S2O4, 3.1 g, 18.3 mmol) were added under N2. After stirring at room temperature for 1 hour, methanol (50 mL) was added and the resulting solid was collected by filtration. The filtrate was concentrated under reduced pressure, diluted with dichloromethane (100 mL), and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford Compound 55 (1.4 g, 85%). ESLMS m / z: [M+H]+883.05.

[1061] Preparation of Compound 56

[1062] To a solution of Compound 55 (1.35 g, 1.51 mmol) in / A-dimethylformamide (10 mL), a solution of Compound 2 (324 mg, 1.66 mmol) in N, A -di methyl form am ide (1 mL) was added under N2. After stirring at room temperature for 1 hour, A-(3-dimethylaminopropyl)-A’-ethylcarbodiimide hydrochloride (465 mg, 3.02 mmol) and triethylamine (0.63 mL, 4.53 mmol) were added. The mixture was stirred at room temperature for 16 hours, then concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 56 (560 mg, 35%). ESLMS m / z: [M+H]+1045.96.

[1063] Preparation of Compound 57

[1064] 107

[1065] FH30010281.1Attorney Docket: LCH-04525

[1066] To a solution of Compound 56 (100 mg, 0.094 mmol) in methanol (2 mL), lithium hydroxide monohydrate (13.8 mg, 0.28 mmol) in distilled water (1 mL) was added at -50 °C under N2. After stirring at 0 °C for 2 hours, the mixture was acidified to pH 4~5 with acetic acid. The mixture was concentrated and lyophilized to afford crude Compound 57 (100 mg), which was used without further purification. ESLMS m / z: [M+H]+1031.95.

[1067] Preparation of Compound 58

[1068] To a solution of crude Compound 57 (100 mg, 0.097 mmol) in dichloromethane (5 mL), trifluoroacetic acid (1 mL) was added at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 58 (42 mg, 34%). 'H-NMR (400 MHz, DMSO-d6) 6 12.80 (s, 1H), 9.77 (s, 2H), 7.96 (s, 1H), 7.87 (m, 2H), 7.65 (s, 2H), 7.53 (s, 1H), 7.34 (s, 2H), 7.28 (s, 2H), 6.53 (s, 2H), 5.79 (m, 3H), 5.65 (m, 1H), 4.90 (s, 4H), 4.62 (m, 2H), 4.50 (m, 6H), 3.92 (m, 3H), 2.24 (s, 2H), 2.11 (m, 6H), 1.74 (m, 2H), 1.26 (m, 6H). ESLMS m / z: [M+H]+929.98.

[1069] ^Preparation Example 7> Preparation of Compound 66

[1070]

[1071] Preparation of Compound 59

[1072] To a solution of 4-aminopyrazole (5.89 g, 70.8 mmol) in tetrahydrofuran (200 mL), triethylamine (15 mL, 106.13 mmol) and di- / c / 7-butyl dicarbonate (48.8 mL, 212.26 mmol) were added under N2. After stirring at room temperature for 20 hours, ethyl acetate (50 mL) was added and the mixture was washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The

[1073] 108

[1074] FH30010281.1Attorney Docket: LCH-04525

[1075] resulting residue was purified by column chromatography to afford Compound 59 (5.9 g, 29%). 'H-NMR (400 MHz, CDC13) 68.19 (s, 1H), 7.63 (s, lH), 6.34 (s, 1H), 1.64 (d, J = 3.9 Hz, 9H), 1.52 (s, 9H).

[1076] Preparation of Compound 60

[1077] To a solution of Compound 59 (1.1 g, 3.88 mmol) in acetonitrile (30 mL), potassium carbonate (590 mg, 4.27 mmol), 18-crown-6 (513 mg, 1.94 mmol), and methyl acrylate (367 mg, 4.27 mmol) were added. After stirring at room temperature for 30 minutes, ethyl acetate (50 mL) was added and the mixture was washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 60 (1.38 g, 96%). 'H-NMR (400 MHz, CDC13) 87.77 (s, 1H), 7.27 (d, J = 3.1 Hz, 1H), 3.92 (dt, J = 9.4, 5.8 Hz, 2H), 3.71 - 3.65 (m, 3H), 2.68 - 2.59 (m, 2H), 1.65 (q, J = 2.4 Hz, 9H), 1.54 - 1.48 (m, 9H). ESLMS m / z: [M+H]+370.32.

[1078] Preparation of Compound 61

[1079] To a solution of Compound 60 (1.38 g, 3.73 mmol) in methanol (20 mL), potassium carbonate (770 mg, 5.6 mmol) was added at 0 °C. After stirring at room temperature for 30 minutes, ethyl acetate (50 mL) was added and the mixture was washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 61 (950 mg, 94%). 'H-NMR (400 MHz, CDC13) 67.66 (s, 1H), 7.53 (s, 1H), 3.96 - 3.87 (m, 2H), 3.67 (s, 3H), 2.64 (p, J = 5.0 Hz, 2H), 1.50 (s, 9H).

[1080] Preparation of Compound 62

[1081] To a solution of Compound 61 (167 mg, 0.62 mmol) in N, A -di methyl form am ide (30 mL), cesium carbonate (303 mg, 0.93 mmol) and trans- l,4-dibromo-2 -butene (397 mg, 1.86 mmol) were added. After stirring at room temperature for 3 hours, ethyl acetate (50 mL) was added and the mixture was washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 62 (177 mg, 71%). ESLMS m / z: [M+H]+402.24.

[1082] Preparation of Compound 64

[1083] To a solution of Compound 63 (300 mg, 0.32 mmol; Compound 63 was prepared by the method described in WO 2022 / 155518 Al the content of which is hereby incorporated by reference) in A( A -di methyl form am ide (2 mL), cesium carbonate (179 mg, 0.43 mmol) and Compound 62 (177 mg, 0.44 mmol) were added. After stirring at room temperature for 12

[1084] 109

[1085] FH30010281.1Attorney Docket: LCH-04525

[1086] hours, ethyl acetate (50 mL) was added and the mixture was washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 64 (133 mg, 34%). ES MS m / z: [M+H]+1045.34.

[1087] Preparation of Compound 65

[1088] To a solution of Compound 64 (150 mg, 0.14 mmol) in dichloromethane (1 mL), trifluoroacetic acid (0.25 mL) was added at 0 °C. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure to afford crude Compound 65 (135 mg, crude), which was used without further purification. ESLMS m / z: [M+H]+945.06.

[1089] Preparation of Compound 66

[1090] To a solution of Compound 65 (135 mg, crude) in methanol (1 mL), lithium hydroxide monohydrate (11.7 mg, 0.28 mmol) in water (1 mL) was added at -45 °C. After stirring at 0 °C for 2 hours, the mixture was adjusted to pH 4~5 with acetic acid. The mixture was concentrated under reduced pressure, and the resulting residue was purified by HPLC and lyophilized to afford Compound 66 (34 mg, 42% for 2 steps). ESLMS m / z: [M+H]+902.

[1091]

[1092] 110

[1093] FH30010281.1Attorney Docket: LCH-04525

[1094] Preparation of Compound 70

[1095] To a solution of 3-(N-methyl-4-(trimethylsilyl)butanamido)propyl methanesulfonate (1.03 g, 3.30 mmol) and Compound 4 (476 mg, 2.20 mmol) in / A-dimethylformamide (6 mL), potassium carbonate (334 mg, 2.42 mmol) was added at 60 °C under N2. After stirring for 16 hours, the mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (2 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 70 (811 mg, 85%). 'H-NMR (400 MHz, CDCI3) 8 7.77 (d, J= 33.1 Hz, 2H), 4.18 (t, J= 6.1 Hz, 2H), 4.10 (dt, J= 9.7, 5.0 Hz, 2H), 3.50 (t, J = 6.7 Hz, 2H), 2.91 (s, 3H), 2.10 (q, J= 6.3 Hz, 2H), 1.00 - 0.78 (m, 2H).

[1096] Preparation of Compound 71

[1097] To a solution of tert-butyl (E)-(4-aminobut-2-en-l-yl)carbamate (454 mg, 2.44 mmol) in ethanol (7 mL), Compound 70 (811 mg, 1.88 mmol) and M / Ldiisopropylethylamine (0.67 mL, 3.76 mmol) were added. After stirring at 120 °C for 21 hours, the mixture was diluted with dichloromethane (200 mL) and washed with distilled water (2 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 71 (971 mg, 88%). ESLMS m / z: [M+H]+582.31.

[1098] Preparation of Compound 72

[1099] To a solution of Compound 71 (3.53 g, 6.06 mmol) in methanol (8 mL), hydrogen chloride (4 M in 1,4-di oxane, 15 mL) was added. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure to afford crude Compound 72 (3.69 g), which was used without further purification. ESLMS m / z: [M+H]+482.25.

[1100] Preparation of Compound 73

[1101] To a solution of Compound 38 (1 g, 2.21 mmol) and Compound 72 (1.62 g, 3.36 mmol) in ethanol (20 mL), tri ethylamine (1.55 mL, 3.36 mmol) was added at room temperature. After stirring at 100 °C for 49 hours and cooled to room temperature, the mixture was diluted with dichloromethane (100 mL), methanol (20 mL) and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 73 (845 mg, 42%). ESLMS m / z: [M+H]+898.48.

[1102] 111

[1103] FH30010281.1Attorney Docket: LCH-04525

[1104] Preparation of Compound 74

[1105] To a solution of Compound 73 (930 mg, 1.04 mmol) in methanol (15 mL), aqueous ammonia solution (28-30%, 3 mL) and sodium hydrosulfite (Na2S2O4, 2.7 g, 15.55 mmol) were added under N2. After stirring at room temperature for 2 hours, the mixture was diluted with dichloromethane (50 mL) and filtered. The filtrate was concentrated under reduced pressure, then diluted with dichloromethane (100 mL) and methanol (20 mL), and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude Compound 74 (900 mg), which was used without further purification. ES MS m / z: [M+H]+837.12.

[1106] Preparation of Compound 74a

[1107] To a solution of Compound 74 (846 mg, 1.01 mmol) in A Mdi methyl form am ide (4 mL), a solution of Compound 2 (434 mg, 2.22 mmol) in 7\(A-dimethylformamide (1 mL) was added under N2. After stirring at room temperature for 1 hour, A-(3-dimethylaminopropyl)-A’-ethylcarbodiimide (0.45 mL, 2.53 mmol) and triethylamine (0.71 mL, 5.05 mmol) were added. The mixture was stirred at room temperature for 16 hours, then concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 74a (304 mg, 66%). ESLMS m / z: [M+H]+1159.65.

[1108] Preparation of Compound 75

[1109] To a solution of Compound 74a (110 mg, 0.12 mmol) in dichloromethane (3 mL), trifluoroacetic acid (1 mL) was added at 0 °C under N2. After stirring at 0 °C for 40 minutes, the reaction mixture was concentrated under reduced pressure and purified by HPLC and lyophilized to afford Compound 75 (8.2 mg, 9%). ESLMS m / z: [M+H]+916.45.

[1110] 112

[1111] FH30010281.1Attorney Docket: LCH-04525

[1112] ^Preparation Example 9> Preparation of Compound 81

[1113]

[1114] Preparation of Compound 76

[1115] To a solution of Compound 4 (3.8 g, 17.55 mmol) in A A-di methyl form am ide (80 mL), cesium carbonate (8.6 g, 26.32 mmol) and Compound 62 (8.5 g, 21.13 mmol) were added. After stirring at room temperature for 15 hours, the mixture was diluted with ethyl acetate (50 mL) and washed with saturated aqueous ammonium chloride solution (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 76 (867 mg, 71%). ESLMS m / z: [M+H]+538.13.

[1116] 113

[1117] FH30010281.1Attorney Docket: LCH-04525

[1118] Preparation of Compound 77

[1119] To a solution of Compound 50 (5 g, 9.29 mmol) in dichloromethane (50 mL), trifluoroacetic acid (10 mL) was added at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure. A solution of Compound 76 (6.12 g, 13.94 mmol) in dimethyl sulfoxide (32 mL) was added to the resulting residue, followed by the addition of A, A-diisopropylethylamine (8.1 mL, 46.47 mmol) at room temperature. After stirring at 100 °C for 93 hours and cooled to room temperature, the mixture was diluted with dichloromethane (100 mL), methanol (20 mL) and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 77 (4.53 g, 56%). ESLMS m / z: [M+H]+868.13.

[1120] Preparation of Compound 78

[1121] To a solution of Compound 77 (3.59 g, 4.13 mmol) in methanol (60 mL), ammonia solution (28-30%, 2.4 mL) and sodium hydrosulfite (Na2S2O4, 10.8 g, 123.9 mmol) were added under N2. After stirring at room temperature for 4 hours, the mixture was diluted with di chloromethane (100 mL) and filtered. The filtrate was concentrated under reduced pressure, then diluted with dichloromethane (100 mL) and methanol (50 mL), and washed with distilled water (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to afford crude Compound 78 (3.4 g), which was used without further purification. ESLMS m / z: [M+H]+808.23.

[1122] Preparation of Compound 79

[1123] To a solution of Compound 78 (884 mg, 1.1 mmol) in N, A -di methyl form am ide (4 mL), a solution of Compound 2 (470 mg, 2.41 mmol) in N, A -di methyl form am ide (1 mL) was added under N2. After stirring at room temperature for 1 hour, A-(3-dimethylaminopropyl)-Afethylcarbodiimide (0.43 mL, 2.41 mmol) and triethylamine (0.77 mL, 5.47 mmol) were added. The mixture was stirred at room temperature for 16 hours, then concentrated under reduced pressure. The solid afforded by diluting with dichloromethane and diethyl ether was filtered and dried to afford crude Compound 79 (1.24 g). ESLMS m / z: [M+H]+1131.06.

[1124] Preparation of Compound 80

[1125] To a solution of Compound 79 (1.24 g, crude) in dichloromethane (15 mL), trifluoroacetic acid (5 mL) was added at 0 °C under N2. After stirring at 0 °C for 2 hours, the reaction mixture was concentrated under reduced pressure to afford crude Compound 80 (1.08 g), which was used without further purification. ESLMS m / z: [M+H]+1030.14.

[1126] 114

[1127] FH30010281.1Attorney Docket: LCH-04525

[1128] Preparation of Compound 81

[1129] To a solution of Compound 80 (100 mg, 0.1 mmol) in tetrahydrofuran (2 mL), lithium hydroxide monohydrate (40.1 mg, 0.97 mmol) in distilled water (1 mL) was added at room temperature. After stirring for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 81 (5 mg, 5%). ESLMS m / z: [M+H]+1002.89.

[1130] ^Preparation Example 10> Preparation of Compound 90

[1131]

[1132] Preparation of Compound 82

[1133] To a solution of aluminum chloride (2.96 g, 22.2 mmol) and sodium azide (4.59 g, 70.6 mmol) in tetrahydrofuran (40 mL) was stirred at room temperature for 15 minutes. After stirring, 4-chlorobutyronitrile (2.0 mL, 20.9 mmol) was added, and the reaction mixture was refluxed for 24 hours. Upon completion, the mixture was extracted with ethyl acetate and water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford crude Compound 82 (3.1 g), which was used without further purification.

[1134] 115

[1135] FH30010281.1Attorney Docket: LCH-04525

[1136] Preparation of Compound 83

[1137] To a solution of crude Compound 82 (3.1 g, crude) in acetonitrile (40 mL), potassium carbonate (4.3 g, 31.29 mmol) and methyl iodide (2 mL, 27.34 mmol) were added. After refluxing for 16 hours, the mixture was diluted with ethyl acetate (50 mL) and washed sequentially with saturated brine (50 mL) and distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 83 (308 mg, 9 % for 2 steps). 'H-NMR (400 MHz, CDC13) 8 3.72 - 3.61 (m, 3H), 3.07 (t, J= 7.3 Hz, 1H), 2.59 (t, J= 7.0 Hz, 2H), 2.32 - 2.21 (m, 1H), 2.19 - 2.08 (m, 2H).

[1138] Preparation of Compound 84

[1139] To a solution of Compound 83 (308 mg, 1.92 mmol) and Compound 4 (346 mg, 1.6 mmol) in A A-di methyl form am ide (12 mL) was added potassium carbonate (331 mg, 2.4 mmol) at 60 °C under N2. After stirring for 16 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (2 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 84 (300 mg, 55%). ‘H-NMR (400 MHz, DMSO) 6 8.29 (s, 1H), 8.05 (d, J= 1.6 Hz, 1H), 7.86 (d, J= 1.8 Hz, 1H), 7.78 (s, 1H), 4.36 - 4.28 (m, 3H), 3.05 (t, J= 7.4 Hz, 1H), 2.52 (d, J= 1.9 Hz, 1H), 2.24 (p, J= 6.6 Hz, 1H).

[1140] Preparation of Compound 85

[1141] To a solution of tert-butyl (E)-(4-aminobut-2-en-l-yl)carbamate (327 mg, 1.76 mmol) in dimethyl sulfoxide (5 mL), Compound 84 (500 mg, 1.88 mmol) and N, N-diisopropylethylamine (0.77 mL, 4.4 mmol) were added. After stirring at 90 °C for 50 hours, the reaction mixture was diluted with dichloromethane (200 mL) and washed with distilled water (2 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 85 (431 mg, 99%). ESLMS m / z: [M+H]+491.03.

[1142] Preparation of Compound 86

[1143] To a solution of Compound 85 (431 mg, 0.88 mmol) in dichloromethane (8 mL) was added hydrogen chloride (4 M in 1,4-dioxane, 2.2 mL). After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure to afford crude Compound 86 (560 mg), which was used without further purification. ESLMS m / z: [M+H]+391.06.

[1144] 116

[1145] FH30010281.1Attorney Docket: LCH-04525

[1146] Preparation of Compound 87

[1147] To a solution of Compound 86 (240 mg, 0.58 mmol) and Compound 38 (468 mg, 1.04 mmol) in dimethyl sulfoxide (2.5 mL) was added M / Ldiisopropylethylamine (0.45 mL, 2.59 mmol) at room temperature. After heating to 100 °C and stirred for 48 hours, the reaction mixture was cooled to room temperature, diluted with di chloromethane (100 mL) and methanol (20 mL), and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 87 (88 mg, 21%). ES MS m / z:

[1148] [M+H]+805.94.

[1149] Preparation of Compound 88

[1150] To a solution of Compound 87 (88 mg, 0.11 mmol) in methanol (1 mL) were added ammonia solution (28-30%, 0.02 mL) and sodium hydrosulfite (Na2S2O4, 190 mg, 1.1 mmol) under N2. After stirring at room temperature for 4 hours, the reaction mixture was diluted with dichloromethane (50 mL) and filtered. The filtrate was concentrated under reduced pressure, then diluted with dichloromethane (50 mL) and methanol (5 mL), and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford crude Compound 88 (82 mg, crude), which was used without further purification. ESLMS m / z: [M+H]+746.11.

[1151] Preparation of Compound 89

[1152] To a solution of Compound 88 (82 mg, crude) in N, A -di methyl form am ide (1 mL) was added Compound 2 (53 mg, 0.27 mmol) in A Mdi methyl form am ide (1 mL) under N2. After stirring at room temperature for 1 hour, A-(3-dimethylaminopropyl)-A’-ethylcarbodiimide (0.18 mL, 2.41 mmol) and triethylamine (0.05 mL, 0.33 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 89 (13 mg, 11% for 2 steps). ESLMS m / z: [M+H]+1067.94.

[1153] Preparation of Compound 90

[1154] To a solution of Compound 89 (13 mg, 0.01 mmol) in dichloromethane (1 mL), trifluoroacetic acid (0.2 mL) was added at 0 °C under N2. After stirring at 0 °C for 30 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 90 (6.8 mg, 57%). ESLMS m / z:

[1155] [M+H]+968.89.

[1156] 117

[1157] FH30010281.1Attorney Docket: LCH-04525

[1158]

[1159] Preparation of Compound 91

[1160] To a solution of Compound 72 (3.77 g, 7.82 mmol) and Compound 76 (3 g, 5.57 mmol) in dimethyl sulfoxide (10 mL) was added A A-diisopropylethylamine (4.85 mL, 27.88 mmol) at room temperature. After heating to 100 °C and stirring for 48 hours, the reaction mixture was cooled to room temperature, diluted with di chloromethane (100 mL) and methanol (20 mL), and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 91 (3 g, 54%). 'H-NMR (400 MHz, DMSO) 6 8.29 (s, 2H), 8.13 (d, J= 9.4 Hz, 2H), 7.87 (s, 3H), 7.63 (d, J= 18.9 Hz, 3H), 7.46 (s, 2H), 6.14 (dd, J= 14.0, 7.6 Hz, 1H), 5.96 (s, 1H), 5.88 (s, 1H), 5.74 (s, 2H), 4.84 (d, J= 5.8 Hz, 2H), 4.71 (d, J= 5.4 Hz, 2H), 4.23 (d, J= 11.8 Hz, 3H), 4.15 (q, J= 7.1 Hz, 14H), 3.89 (s, 2H), 3.67 (s, 3H), 2.94 (d, J= 19.7 Hz, 4H), 2.66 (s, 4H), 2.11 (s, 13H), 1.52 (s, 10H), 1.29 (t, J= 7.1 Hz, 14H), 0.17 - -0.13 (m, 14H). ESLMS m / z: [M+H]+984.04.

[1161] Preparation of Compound 92

[1162] To a solution of Compound 91 (3 g, 3.05 mmol) in methanol (20 mL) were added ammonia solution (28-30%, 8.7 mL) and sodium hydrosulfite (Na2S2O4, 7.96 g, 45.77 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with di chloromethane (100 mL) and filtered. The filtrate was concentrated under reduced pressure, then diluted with dichloromethane (100 mL) and methanol (50 mL), and washed with distilled water (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and

[1163] 118

[1164] FH30010281.1Attorney Docket: LCH-04525

[1165] concentrated under reduced pressure to afford crude Compound 92 (2.8 g, crude), which was used without further purification. ESI-MS m / z: [M+H]+924.13.

[1166] Preparation of Compound 93

[1167] To a solution of Compound 92 (2.5 g, crude) in A( A -di methyl form am ide (15 mL) was added Compound 2 (2.38 g, 12.19 mmol) in A( A -di methyl form am ide (5 mL) under N2. After stirring at room temperature for 1 hour, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.6 g, 13.54 mmol) and tri ethylamine (1.9 mL, 13.54 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 93 (2 g, 59% for 2 steps). ES MS m / z: [M+H]+1245.04.

[1168] Preparation of Compound 94

[1169] To a solution of Compound 93 (43 mg, 0.03 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) at 0 °C under N2. After stirring at room temperature for 1 hour, the reaction mixture was concentrated under reduced pressure to afford crude Compound 94 (32 mg), which was used without further purification. ESLMS m / z: [M+H]+1001.95.

[1170] Preparation of Compound 95

[1171] To a solution of Compound 94 (32 mg, crude) in tetrahydrofuran (2 mL) was added lithium hydroxide monohydrate (13.5 mg, 0.32 mmol) in distilled water (1 mL) at room temperature. After stirring for 3 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 95 (9.5 mg, 30% for 2 steps). ESLMS m / z: [M+H]+987.96.

[1172] 119

[1173] FH30010281.1Attorney Docket: LCH-04525

[1174]

[1175] Preparation of Compound 103

[1176] To a solution of 2-(2-(2-chloroethoxy)ethoxy)ethan-l-ol (15 g, 88.96 mmol) in tetrahydrofuran (30 mL) was added methylamine solution (40 wt.% in H2O, 90 mL, 889.57 mmol) at 0 °C. After stirring at 80 °C for 20 hours, the reaction mixture was concentrated under reduced pressure and diluted with di chloromethane (300 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford crude Compound 103 (20 g), which was used without further purification. 'H-NMR (400 MHz, CDCI3) 65.31 (d, J= 1.0 Hz, 1H), 3.91 (t, J= 5.1 Hz, 2H), 3.79 (t, J = 4.0 Hz, 2H), 3.77 - 3.59 (m, 8H), 3.23 - 3.16 (m, 2H), 2.78 (s, 3H).

[1177] Preparation of Compound 104

[1178] To a solution of Compound 103 (8.8 g, 44.01 mmol) in di chloroethane (100 mL) were added (4-nitrophenyl) 2-trimethylsilylethyl carbonate (15.0 g, 52.89 mmol) and triethylamine

[1179] 120

[1180] FH30010281.1Attorney Docket: LCH-04525

[1181] (12.4 mL, 88.14 mmol) at 0 °C. After stirring at room temperature for 18 hours, the reaction mixture was diluted with dichloroethane (300 mL) and washed with 2 wt.% aqueous sodium hydroxide solution (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 104 (10.2 g, 75%). 'H-NMR (400 MHz, CDCh) 6 4.21 - 4.12 (m, 2H), 3.73 (t, J= 5.9 Hz, 2H), 3.69 - 3.57 (m, 8H), 3.45 (d, J= 7.8 Hz, 2H), 2.95 (d, J= 3.9 Hz, 3H), 1.04 - 0.96 (m, 2H), 0.04 (s, 9H).

[1182] Preparation of Compound 105

[1183] To a solution of Compound 104 (5.0 g, 16.26 mmol) in dichloromethane (100 mL) were added triethylamine (3.4 mL, 24.39 mmol) and methanesulfonyl chloride (1.5 mL, 19.52 mmol) at 0 °C. After stirring at room temperature for 3 hours, the reaction mixture was diluted with di chloromethane (100 mL) and washed with distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford crude Compound 105 (6.8 g), which was used without further purification. 'H-NMR. (400 MHz, CDCh) 6 4.41 - 4.34 (m, 2H), 4.21 - 4.12 (m, 2H), 3.80 - 3.73 (m, 2H), 3.67 -3.56 (m, 6H), 3.47 - 3.39 (m, 2H), 3.07 (s, 3H), 2.95 (s, 3H), 1.00 (t, J= 8.2 Hz, 2H), 0.04 (s, 9H).

[1184] Preparation of Compound 106

[1185] To a solution of Compound 4 (5.1 g, 23.62 mmol) in A A-di methyl form am ide (20 mL) were added cesium carbonate (6.1 g, 18.61 mmol) and Compound 105 (6.1 g, 15.74 mmol). After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 106 (4.1 g, 51%). ESLMS m / z: [M+H]+506.06.

[1186] Preparation of Compound 107

[1187] To a solution of Compound 106 (4.1 g, 8.10 mmol) in dimethyl sulfoxide (30 mL) were added tert-butyl (E)-(4-aminobut-2-en-l-yl)carbamate (3.0 g, 16.20 mmol) and N, N-diisopropylethylamine (5.6 mL, 32.41 mmol). After stirring at 80 °C for 20 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 107 (4.5 g, 84%). ESLMS m / z: [M+H]+656.43.

[1188] 121

[1189] FH30010281.1Attorney Docket: LCH-04525

[1190] Preparation of Compound 108

[1191] To a solution of Compound 107 (4.5 g, 6.86 mmol) in methanol (25 mL) was added hydrogen chloride solution (4M in 1,4-dioxane, 25 mL, 102.93 mmol) at 0 °C. After stirring at 0 °C for 7 hours, the reaction mixture was neutralized with sodium carbonate aqueous solution, filtered, and concentrated under reduced pressure. The resulting residue was purified by Cl 8 reverse phase column chromatography to afford Compound 108 (3.2 g, 83%). ESLMS m / z:

[1192] [M+H]+556.09.

[1193] Preparation of Compound 109

[1194] To a solution of Compound 76 (1.0 g, 1.86 mmol) and Compound 108 (1.5 g, 2.79 mmol) in dimethyl sulfoxide (20 mL) was added 7V,7V-diisopropylethylamine (1.6 mL, 9.29 mmol). After stirring at 100 °C for 70 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 109 (830 mg, 42%). ESIMS m / z: [M+H]+1057.06

[1195] Preparation of Compound 110

[1196] To a solution of Compound 109 (830 mg, 0.79 mmol) in methanol (8 mL) and distilled water (2 mL) were added ammonia solution (28-30% ammonia, 2 mL) and sodium hydrosulfite (Na2S2O4, 2.7 g, 15.70 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with methanol (50 mL) and filtered. The filtrate was concentrated under reduced pressure to afford Compound 110 (1.0 g, crude), which was used without further purification. ESLMS m / z: [M+H]+997.05.

[1197] Preparation of Compound 111

[1198] To a solution of Compound 110 (1.0 g, crude) in M / Ldi methyl form am ide (3 mL) at 0 °C was added Compound 2 (458 mg, 2.34 mmol) in A Mdi methyl form am ide (2 mL). After stirring for 2 hours, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC HC1, 374 mg, 2.00 mmol) and triethylamine (0.55 mL, 3.91 mmol) were added to the reaction mixture. After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL) and distilled water (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 111 (330 mg, 32% for 2 steps). ESLMS m / z: [M+H]+1319.83.

[1199] 122

[1200] FH30010281.1Attorney Docket: LCH-04525

[1201] Preparation of Compound 112

[1202] To a solution of Compound 111 (110 mg, 0.08 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (0.5 mL) at 0 °C under N2. After stirring at room temperature for 3 hours under N2, the reaction mixture was concentrated and diluted with diethyl ether (40 mL). The resulting solid was filtered and dried to afford Compound 112 (113 mg, 95%). ES MS m / z: [M+H]+1075.08.

[1203] Preparation of Compound 113

[1204] To a solution of Compound 112 (40 mg, 0.03 mmol) in methanol (0.5 mL) was added lithium hydroxide monohydrate (11.5 mg, 0.28 mmol) in distilled water (1 mL) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was acidified with acetic acid to pH 4~5. The resulting residue was purified by HPLC and lyophilized to afford Compound 113 (14 mg, 48%). 'H-NMR (400 MHz, MeOD) 6 7.66 (s, 1H), 7.63 - 7.57 (m, 2H), 7.50 (s, 1H), 7.27 (s, 1H), 7.21 (s, 1H), 6.65 (d, J= 11.0 Hz, 2H), 5.92 - 5.76 (m, 3H), 5.62 (d, J= 15.6 Hz, 1H), 5.02 (s, 3H), 4.67 - 4.36 (m, 6H), 4.36 (d, J= 5.3 Hz, 2H), 3.98 (s, 2H), 3.68 - 3.61 (m, 2H), 3.58 - 3.49 (m, 5H), 3.44 (d, J= 6.6 Hz, 2H), 2.68 (d, J= 4.9 Hz, 5H), 2.23 (d, J= 7.9 Hz, 6H), 1.41 - 1.34 (m, 6H). ESLMS m / z: [M+H]+1060.85.

[1205] ^Preparation Example 13 > Preparation of Compound 122

[1206]

[1207] 123

[1208] FH30010281.1Attorney Docket: LCH-04525

[1209] Preparation of Compound 119

[1210] To a solution of Compound 118 (2 g, 2.76 mmol; prepared by the method described in WO 2017 / 089890 Al, the content of which is hereby incorporated by reference) in dichloromethane (30 mL), were added bis(pentafluorophenyl)carbonate (1.3 g, 3.31 mmol) and pyridine (0.44 mL, 5.51 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with di chloromethane (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL) and distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 119 (1.6 g, 61%). ESLMS m / z: [M+H]+941.17.

[1211] Preparation of Compound 120

[1212] To a solution of Compound 119 (74.4 mg, 0.08 mmol) and Compound 14 (96 mg, 0.07 mmol) in A Mdi methyl form am ide (1 mL) was added AA'-diisopropylethylamine (0.05 mL, 0.29 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 120 (117 mg, crude), which was used without further purification. ESLMS m / z: [M+H]+1632.36.

[1213] Preparation of Compound 121

[1214] To a solution of Compound 120 (117 mg, crude) in methanol (0.45 mL) and tetrahydrofuran (0.3 mL) was added lithium hydroxide monohydrate (15 mg, 0.36 mmol) in distilled water (0.3 mL) at -50 °C. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4~5 with acetic acid. The reaction mixture was concentrated under reduced pressure to afford Compound 121 (107 mg, crude), which was used without further purification. ESLMS m / z: [M+H]+1491.99, [M / 2+H]+746.39.

[1215] Preparation of Compound 122

[1216] To a solution of Compound 121 (107 mg, crude) in di chloromethane (1 mL) was added trifluoroacetic acid (0.25 mL) at 0 °C under N2. After stirring at room temperature for 1 hour under N2, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC and lyophilized to afford Compound 122 (35 mg, 26% for 3 steps). ESL MS m / z: [M+H]+1391.02, [M / 2+H]+696.39.

[1217] 124

[1218] FH30010281.1Attorney Docket: LCH-04525

[1219] ^Preparation Example 14> Preparation of Compound 141

[1220]

[1221] Preparation of Compound 138

[1222] To a solution of Compound 56 (560 mg, 0.52 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2 mL) under N2 at 0°C. After stirring at room temperature for 1.5 hour, the reaction mixture was concentrated under reduced pressure. The solid was triturated with dichloromethane and diethyl ether. The reaction mixture was filtered and dried to afford Compound 138 (680 mg, 98%). ESLMS m / z: [M+H]+958.99.

[1223] Preparation of Compound 139

[1224] To a solution of Compound 119 (57.8 mg, 0.06 mmol) and Compound 138 (80 mg, 0.06 mmol) in A, A-di methyl form am ide (3 mL) were added AA’-diisopropylethylamine (0.05 mL, 0.31 mmol) at 0 °C under N2. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure. The solid was triturated with dichloromethane and diethyl ether. The reaction mixture was filtered and dried to afford Compound 139 (80 mg, 75%), which was used without further purification. ESLMS m / z:

[1225] [M+H]+1714.06, [M / 2+H]+857.82.

[1226] Preparation of Compound 140

[1227] To a solution of Compound 139 (74 mg, 0.04 mmol) in methanol (1.0 mL) and THF (1.0 mL) was added lithium hydroxide monohydrate (16.2 mg, 0.37 mmol) in distilled water

[1228] 125

[1229] FH30010281.1Attorney Docket: LCH-04525

[1230] (2.5 mL) at -50 °C. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4~5 with acetic acid. The reaction mixture was concentrated under reduced pressure to afford Compound 140 (70 mg, crude), which was used without further purification. ESI-MS m / z:

[1231] [M+H]+1546.86, [M / 2+H]+773.78.

[1232] Preparation of Compound 141

[1233] To a solution of Compound 140 (70 mg, crude) in dichloromethane (3 mL) was added trifluoroacetic acid (0.6 mL) at 0 °C under N2. After stirring at room temperature for 2 hours under N2, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 141 (34 mg, 42% for 2 steps). ESLMS m / z:

[1234] [M+H]+1467.91, [M / 2+H]+723.84.

[1235]

[1236] Preparation of Compound 145

[1237] To a solution of A-Boc-hydroxylamine (5.0 g, 37.55 mmol) in

[1238]

[1239] -di methyl form am ide (20 mL) were added potassium carbnonate (8.8 g, 63.84 mmol) and ethyl-2-bromoisobutyrate (15.38 g, 78.86 mmol). After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. NH4CI solution (50 mL), distilled water (50 mL), and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 145 (10.5 g, 100%). 'H-NMR. (400 MHz, CDCI3) 84.21 (p, J= 6.8 Hz, 2H), 1.49 (s, 6H), 1.47 (s, 9H), 1.31 (q, J= 6.9 Hz, 3H).

[1240] 126

[1241] FH30010281.1Attorney Docket: LCH-04525

[1242] Preparation of Compound 146

[1243] To a solution of Compound 145 (47 g, 190.1 mmol) in methanol (400 mL) was added lithium hydroxide monohydrate (16 g, 380 mmol) in water (100 mL). After stirring at room temperature for 3 hours, the reaction mixture was adjusted to pH 3.0 with 1 M HC1 solution and concentrated. Then the reaction mixture was extracted with ethyl acetate (3 x 200 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and triturated with ether. The resulting solid was filtered to afford Compound 146 (38 g, 91%) as a white solid. 'H-NMR (400 MHz, CDCh) 6 7.32 (s, 1H), 1.53 (s, 6H), 1.49 (s, 9H).

[1244] Preparation of Compound 147

[1245] To a solution of bi s(2 -hydroxy ethyl)ether (20 g, 188.5 mmol) in dichloromethane (400 mL) were added -toluenesulfonyl chloride (79 g, 414.6 mmol) and potassium hydroxide (42 g, 753.9 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was washed with saturated aq. NH4CI solution (2 x 100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 147 (78 g, 99%) as a white solid. 'H-NMR (400 MHz, CDCh) 87.79-7.77 (m, 4H), 7.36-7.34 (m, 4H), 4.10-4.08 (m, 4H), 3.62-3.60 (m, 4H), 2.45 (s, 6H).

[1246] Preparation of Compound 148

[1247] To a solution of Compound 147 (78 g, 188.2 mmol) in

[1248]

[1249] -di methyl form am ide (470 mL) was added sodium azide (61 g, 940.9 mmol) under N2. After stirring at 80 °C for 18 hours, the reaction mixture was diluted with ethyl acetate (I L) and washed with saturated aq. NH4CI solution (2 x 500 mL) and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 148 (24 g, 83%) as a pale yellow oil. 'H-NMR (400 MHz, CDCh) 63.70-3.67 (m, 4H), 3.43-3.40 (m, 4H).

[1250] Preparation of Compound 149

[1251] To a solution of Compound 148 (24 g, 153.7 mmol) in ethyl acetate (500 mL) were added triphenylphosphine (40 g, 153.7 mmol) and 1 M HC1 solution (284 mL) at 0 °C under N2. After stirring at room temperature for 17 hours, the reaction mixture was concentrated under reduced pressure and then the resulting residue was adjusted to pH 10 with 1 M sodium hydroxide solution. The resulting residue was extracted with di chloromethane (2 x 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate 127

[1252] FH30010281.1Attorney Docket: LCH-04525

[1253] was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 149 (9.6 g, 48%) as a colorless oil. 'H-NMR (400 MHz, CDC13) 63.68 (t, J= 4.8 Hz, 2H), 3.54 (t, J= 4.8 Hz, 2H), 3.40 (t, J= 4.8 Hz, 2H), 3.90 (t, J = 4.8 Hz, 2H), 1.37 (bs, 2H).

[1254] Preparation of Compound 150

[1255] To a solution of Compound 149 (8.9 g, 68.4 mmol) in dichloromethane (150 mL) were added Compound 146 (15 g, 68.4 mmol), / A, A’, A’-tetramethyl-O-(U7-benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 33.8 g, 88.95 mmol), and N, N-diisopropylethylamine (23.8 mL, 137 mmol) under N2. After stirring at room temperature for 14 hours, the reaction mixture was washed with saturated aq. NH4CI solution (20 mL), saturated aq. NaHCCf solution (20 mL), and brine (40 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 150 (20 g, 88%) as a yellow oil. ‘H-NMR (400 MHz, CDCI3) 87.04 (s, 1H), 3.66 (t, J= 5.0 Hz, 2H), 3.58 (s, 2H), 3.47 (t, J= 5.6 Hz, 2H), 3.41 (t, J= 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H). ESLMS m / z: [M+H]+332.249.

[1256] Preparation of Compound 151

[1257] To a solution of Compound 150 (21 g, 63.3 mmol) in tetrahydrofuran (150 mL) were added triphenylphosphine (18 g, 69.7 mmol) and distilled water (22 mL) at 0 °C under N2. After stirring at 80 °C for 20 hours, the reaction mixture was concentrated and the resulting residue was purified by column chromatography to afford Compound 151 (15 g, 77%) as a yellow oil. 'H-NMR (400 MHz, CDCI3) 63.56 (t, J= 5.4 Hz, 2H), 3.53-3.48 (m, 4H), 3.46 (q, J= 5.5 Hz, 2H), 2.90 (t, J= 5.0 Hz, 2H), 1.48 (s, 9H), 1.46 (s, 6H). ESLMS m / z: [M+H]+306.279.

[1258] Preparation of Compound 153

[1259] To a solution of Compound 151 (1.38 g, 4.54 mmol) in di chloromethane (20 mL) were added Compound 152 (2 g, 4.12 mmol; prepared by the method described in US Patent No.

[1260] 11,173,214 B2), 1 -(3 -dimethylaminopropyl)-3 -ethylcarbodiimide hydrochloride (EDC HC1, 831 mg, 4.33 mmol), 1 -hydroxybenzotriazole (HOBt, 613 mg, 4.54 mmol) and N-methylmorpholine (0.91 mL, 8.25 mmol) under N2. After stirring at room temperature for 12 hours, the reaction mixture was washed with saturated aq. sodium bicarbonate solution (30 mL) and saturated aq. ammonium chloride solution (30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 153 (2.2

[1261] 128

[1262] FH30010281.1Attorney Docket: LCH-04525

[1263] g, 69%) as a colorless oil. 'H-NMR (400 MHz, DMSO-d6) 6 9.82 (s, 1H), 7.93-7.86 (m, 2H), 7.57 (d, J= 2.3 Hz, 1H), 7.39 (dd, J= 8.6, 2.3 Hz, 1H), 7.11 (d, J= 8.5 Hz, 1H), 5.78-5.66 (m, 2H), 5.49 (t, J= 9.7 Hz, 1H), 5.27-5.15 (m, 2H), 5.07 (t, J= 9.8 Hz, 1H), 4.74 (d, J= 9.9 Hz, 1H), 4.45 (d, J= 4.3 Hz, 2H), 3.64 (s, 3H), 3.48 (dt, J= 21.5, 6.4 Hz, 6H), 3.25 (q, J= 6.0 Hz, 3H), 2.01 (d, J= 6.0 Hz, 9H), 1.42 (s, 9H), 1.26 (s, 6H). ESI-MS m / z: [M+H]+772.74.

[1264] Preparation of Compound 154

[1265] To a solution of Compound 153 (1 g, 1.29 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (613 mg, 1.55 mmol) and pyridine (0.21 mL, 2.59 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with di chloromethane (100 mL) and washed with saturated aq. NaHCCL solution (50 mL), 0.5 N aq. HC1 solution (50 mL), and 2% aq. NaOH solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 154 (1 g, crude), which was used without further purification. 'H-NMR (400 MHz, DMSO-d6) 8 7.99 (t, J= 5.6 Hz, 1H), 7.92 (s, 1H), 7.71 (d, J= 2.3 Hz, 1H), 7.59 (d, J= 8.9 Hz, 1H), 7.22 (d, J= 8.6 Hz, 1H), 5.76 (d, J= 7.8 Hz, 1H), 5.49 (t, J= 9.6 Hz, 1H), 5.38 (s, 2H), 5.26-5.17 (m, 1H), 5.08 (t, J= 9.8 Hz, 1H), 4.76 (d, J = 9.9 Hz, 1H), 3.64 (s, 3H), 3.53-3.51 (m, 4H), 3.30-3.22 (m, 4H), 2.01 (d, J= 6.1 Hz, 9H), 1.41 (s, 9H), 1.26 (s, 6H). ESI-MS m / z: [M+H]+982.60.

[1266] ^Preparation Example 16> Preparation of Compound 191

[1267]

[1268] Preparation of Compound 185

[1269] To a mixture of hexaethylene glycol (30 g, 106 mmol), silver (I) oxide (29.55 g, 128 mmol) and potassium iodide (1.76 g, 10.6 mmol) in dichloromethane (2 mL) was added p-toluenesulfonyl chloride (20.26 g, 106 mmol) at 0 °C. The reaction mixture was warmed to room temperature under N2. After stirring for 16 hours, the reaction mixture was filtered through a celite pad, concentrated under reduced pressure and purified by column chromatography to yield Compound 185 (28.5 g, 61%) as a colorless oil. 'H-NMR (400 MHz,

[1270] 129

[1271] FH30010281.1Attorney Docket: LCH-04525

[1272] CDC13) 67.80 (d, J= 8.4 Hz, 2H), 7.34 (d, J= 8.4 Hz, 2H), 4.16 (m, 2H), 3.72-3.58 (m, 22H), 2.97 (br, 1H), 2.45 (s, 3H). ESI-MS m / z: [M+H]+437.79.

[1273] Preparation of Compound 186

[1274] Compound 185 (28 g, 64.1 mmol) and sodium azide (6.25 g, 96.2 mmol) were dissolved in N, N-dimethylformamide (70 mL). Then the reaction mixture was heated to 100 °C. After stirring for 3 hours, the reaction mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography to yield Compound 186 (11.3 g, 57%) as a colorless oil. 'H-NMR (400 MHz, CDC13) 8 3.77-3.69 (m, 2H), 3.71-3.63 (m, 18H), 3.67-3.58 (m, 2H), 3.40 (t, J= 5.1 Hz, 2H). ESI-MS m / z: [M+H]+308.65.

[1275] Preparation of Compound 187

[1276] To a solution of Compound 186 (10 g, 32.5 mmol) in tetrahydrofuran (60 mL) were added triphenylphosphine (9.39 g, 35.8 mmol) and distilled water (5.9 mL, 325 mmol) at 0 °C under N2. The reaction mixture was heated to 85 °C and stirred for 4 hours. After the completion of reaction, the reaction mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography to yield Compound 187 (7.7 g, 84%) as a colorless oil. 'H-NMR (400 MHz, CDCI3) 63.75-3.57 (m, 22H), 3.56-3.49 (m, 2H), 2.92-2.83 (m, 2H). ESI-MS m / z: [M+H]+282.34.

[1277] Preparation of Compound 188

[1278] To a solution of Compound 187 (7.7 g, 27.4 mmol) in acetonitrile (50 mL) were added benzyl chloroformate (4.7 mL, 32.8 mmol) and a solution of sodium bicarbonate (6.9 g, 82.1 mmol) in distilled water (60 mL). After stirring at room temperature for 16 hours, the reaction mixture was diluted with dichloromethane (100 mL) and washed with distilled water (3 x 30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to yield Compound 188 (9.27 g, 82%). 'H-NMR (400 MHz, CDCI3) 6 7.35 (d, J= 4.7 Hz, 5H), 5.10 (d, J= 3.8 Hz, 2H), 3.77-3.50 (m, 22H), 3.40 (t, J= 5.6 Hz, 2H), 3.01 (d, J= 6.5 Hz, 1H). ESI-MS m / z: [M+H]+416.34.

[1279] Preparation of Compound 189

[1280] To a solution of Compound 188 (2.2 g, 5.30 mmol) in dichloromethane (50 mL) were added triethylamine (2.23 mL, 15.89 mmol) and -toluenesulfonyl chloride (1.31 g, 6.88 mmol) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with aq. 10% citric acid solution (3 x 30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and

[1281] 130

[1282] FH30010281.1Attorney Docket: LCH-04525

[1283] concentration under reduced pressure, the resulting residue was purified by column chromatography to yield Compound 189 (1.9 g, 63%) as a colorless oil. ESI-MS m / z: [M+H]+570.07.

[1284] Preparation of Compound 190

[1285] To a solution of hexaethylene glycol (65.37 g, 232 mmol) in tetrahydrofuran (100 mL) was added sodium hydride (60% dispersion in mineral oil, 151 mg, 6.29 mmol) at 0 °C. After 30 minutes, tert-butyl acrylate (10 mL, 68.7 mmol) was added to the reaction mixture. After stirring at room temperature for 16 hours, the reaction mixture was quenched by adding acetic acid (1 mL) and concentrated under reduced pressure. Then, the resulting residue was diluted with distilled water (500 mL) and extracted with ethyl acetate (4 x 500 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 190 (28 g, 100%) as a colorless oil, which was used without further purification. ES MS m / z: [M+Na]+433.18.

[1286] Preparation of Compound 191

[1287] To a solution of Compound 190 (900 mg, 2.19 mmol) in dichloromethane (20 mL) were added triethylamine (0.92 mL, 6.58 mmol) and -toluenesulfonyl chloride (627 mg, 3.29 mmol) at 0 °C. After stirring at room temperature for 25 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. ammonium chloride solution (3 x 30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to yield Compound 191 (900 mg, 73%) as a pale yellow oil. 'H-NMR (400 MHz, CDC13) 8 7.83-7.76 (m, 2H), 7.37-7.31 (m, 2H), 4.19-4.12 (m, 2H), 3.75-3.66 (m, 4H), 3.66-3.43 (m, 22H), 2.50 (t, J= 6.6 Hz, 2H), 2.45 (s, 4H), 1.45 (s, 9H). ESI-MS m / z:

[1288] [M+Na]+587.33.

[1289] 131

[1290] FH30010281.1Attorney Docket: LCH-04525

[1291]

[1292] Preparation of Compound 192

[1293] To a solution of methyl 3,4,5-trihydroxybenzoate (methyl gallate, 70 g, 380.1 mmol) in A A -di methyl form am ide (600 mL) were added 4-methoxybenzyl chloride (51.8 mL, 380.1 mmol), potassium bicarbonate (114.17 g, 1140.4 mmol), and potassium iodide (0.38 g, 0.006 mmol). The reaction mixture was heated to 60 °C under N2. After stirring for 16 hours, the reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting mixture was diluted with water (300 mL) and extracted with di chloromethane (2 x 300 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered,

[1294] 132

[1295] FH30010281.1Attorney Docket: LCH-04525

[1296] and concentrated under reduced pressure to afford Compound 192 (58.17 g, 50%) as a white solid. 'H-NMR (400 MHz, CDC13) 67.30 (d, J= 8.0 Hz, 2H), 7.19 (s, 2H), 6.90 (d, J= 8.0 Hz, 2H), 5.40 (s, 2H), 5.05 (s, 2H), 3.88 (s, 3H), 3.82 (s, 3H). ESLMS m / z: [M+H]+305.31.

[1297] Preparation of Compound 193

[1298] To a solution of Compound 192 (1.5 g, 4.93 mmol) in A -di methyl form am ide (10 mL) were added potassium bicarbonate (3.41 g, 24.6 mmol) and Compound 189 (6.46 g, 11.34 mmol) under N2. After stirring at 80 °C for 17 hours, the reaction mixture was concentrated under reduced pressure, and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. ammonium chloride solution (30 mL), saturated aq. sodium bicarbonate solution (30 mL), and brine (30 mL), then dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and purified by column chromatography to afford Compound 193 (5.6 g, 100%) as a yellow oil. ESLMS m / z: [M+H]+1100.46.

[1299] Preparation of Compound 194

[1300] To a solution of Compound 193 (3.6 g, 3.28 mmol) in dichloromethane (30 mL) were added anisole (5.3 mL, 49.1 mmol) and trifluoroacetic acid (1.3 mL) at 0 °C under N2. After stirring at room temperature for 40 minutes, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 194 (3.6 g, 100%) as a pale yellow oil. ESLMS m / z: [M+H]+979.45.

[1301] Preparation of Compound 195

[1302] To a solution of Compound 194 (2.0 g, 2.04 mmol) in Af, A -di methyl form am ide (10 mL) were added potassium bicarbonate (1.02 g, 10.21 mmol) and Compound 191 (1.6 g, 2.86 mmol) under N2. The reaction mixture was stirred at 65 °C for 12 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue was diluted with ethyl acetate (30 mL). The organic layer was washed with saturated aq. ammonium chloride solution (3 x 10 mL), saturated aq. sodium bicarbonate solution (3 x 10 mL), and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated and purified by column chromatography to afford Compound 195 (1.9 g, 68%) as a pale yellow oil. ESLMS m / z:

[1303] [M+H]+1371.69.

[1304] Preparation of Compound 196

[1305] To a solution of Compound 195 (1.8 g, 1.31 mmol) in methanol (12 mL) was added aq.

[1306] 1 NNaOH solution (6.56 mL, 6.56 mmol) at 0 °C under N2. After 7 hours, the reaction mixture was titrated with aq. 1 N HC1 solution to pH 3~4 at 0 °C, and the mixture was extracted with dichloromethane (3 x 30 mL). The combined organic layers were dried over anhydrous sodium 133

[1307] FH30010281.1Attorney Docket: LCH-04525

[1308] sulfate and filtered. The filtrate was concentrated under the reduced pressure and purified by column chromatography to afford Compound 196 (914 mg, 51%) as a yellow oil. ESI-MS m / z: [M+Na]+1379.60.

[1309] Preparation of Compound 197

[1310] To a solution of Compound 196 (190 mg, 0.14 mmol) in

[1311]

[1312] -di methyl form am ide (5 mL) were added Compound 151 (45 mg, 0.15 mmol), A, A, A’, A ’-tetramethyl - -(l 7 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 69 mg, 0.18 mmol), and N, N-diisopropylethylamine (0.06 mL, 0.42 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. ammonium chloride solution (30 mL), saturated aq. sodium bicarbonate solution (30 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 197 (140 mg, 61%). ES MS m / z: [M+H]+1645.04, [M / 2+H]+823.39.

[1313] Preparation of Compound 198

[1314] To a solution of Compound 197 (140 mg, 0.09 mmol) in methanol (5.0 mL) was added palladium / charcoal (10 wt. %, 15 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 198 (90 mg, 77%) as a yellow oil. ESLMS m / z:[M+H]+1376.80, [M / 2+H]+689.21.

[1315] Preparation of Compound 199

[1316] To a solution of Compound 152 (536 mg, 1.11 mmol) in AA-dimethylformamide (7 mL) were added 1 -(3 -dimethylaminopropyl)-3 -ethylcarbodiimide hydrochloride (290 mg, 1.51 mmol), 1 -hydroxybenzotriazole (204 mg, 1.51 mmol), Compound 198 (693 mg, 0.50 mmol), and A-m ethylmorpholine (0.33 mL, 3.02 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL) and saturated aq. ammonium chloride solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 199 (1.03 g, 89%). ESLMS m / z:

[1317] [M+H]+2310.86, [M / 2+H]+1155.88.

[1318] Preparation of Compound 200

[1319] To a solution of Compound 199 (670 mg, 0.29 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (286 mg, 0.725 mmol) and pyridine (0.093 mL, 1.16

[1320] 134

[1321] FH30010281.1Attorney Docket: LCH-04525

[1322] mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with di chloromethane (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL), 0.5 N aq. HC1 solution (50 mL), and 2% aq. NaOH solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 200 (995 mg, crude), which was used without further purification. ES MS m / z: [M / 2+H]+1364.73.

[1323] ^Preparation Example 18> Preparation of Compound 216

[1324]

[1325] Preparation of Compound 210

[1326] To a solution of Compound 195 (1.10 g, 0.802 mmol) in dichloromethane (2 mL) was added HC1 (4 M in 1,4-dioxane, 2.0 mL, 26.1 mmol) at 0 °C under N2. After 4 hours, the reaction mixture was concentrated under the reduced pressure to afford Compound 210 (1 g, 95%) as a brown oil, which was used for the next step without further purification. ESLMS m / z: [M+H]+1315.79.

[1327] Preparation of Compound 211

[1328] To a solution of Compound 210 (1 g, 0.760 mmol) in

[1329]

[1330] -di methyl form am ide (20 mL) were added l-( / c / 7-butoxycarbonyl)piperazine (170 mg, 0.912 mmol), 7V,7\ / 7V’,7V’-tetramethyl-O-(17 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 346 mg, 0.912 mmol), and

[1331] 135

[1332] FH30010281.1Attorney Docket: LCH-04525

[1333] 7V,7V-diisopropylethylamine (0.32 mL, 2.28 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. ammonium chloride solution (50 mL), saturated aq. sodium bicarbonate solution (50 mL) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 211 (835 mg, 74%). ES MS m / z:

[1334] [M+H]+1485.05.

[1335] Preparation of Compound 212

[1336] To a solution of Compound 211 (835 mg, 0.563 mmol) in methanol (5 mL) was added aq. 1 N NaOH solution (2.81 mL, 2.81 mmol) at 0 °C under N2. After 3 hours, the reaction mixture was titrated with aq. 1 N HC1 solution to pH 3~4 at 0 °C and extracted with ethyl acetate (2 x 30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under the reduced pressure to afford Compound 212 (748 mg, 90%) as a brown oil, which was used for the next step without further purification. ESLMS m / z: [M+H]+1471.00.

[1337] Preparation of Compound 213

[1338] To a solution of Compound 212 (975 mg, 0.66 mmol) and Compound 151 (405 mg, 1.32 mmol) in

[1339]

[1340] -di methyl form am ide (20 mL) were added 7V,7V,7V’,7V’-tetramethyl-O-(17 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 377 mg, 0.99 mmol) and N, N-diisopropylethylamine (0.35 mL, 1.99 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with saturated aq. ammonium chloride solution (25 mL), saturated aq. sodium bicarbonate solution (25 mL) and brine (20 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 213 (350 mg, 30%). ESLMS m / z: [M / 2+H]+879.01.

[1341] Preparation of Compound 214

[1342] To a solution of Compound 213 (349 mg, 0.20 mmol) in methanol (12 mL) was added palladium / charcoal (10 wt. %, 150 mg) under hydrogen atmosphere. After stirring at room temperature for 2 hours, the reaction mixture was filtered through a celite pad and concentrated under reduced pressure to afford Compound 214 (297 mg, 100%) as a pale yellow oil. ESLMS m / z: [M / 2+H]+745.61.

[1343] 136

[1344] FH30010281.1Attorney Docket: LCH-04525

[1345] Preparation of Compound 215

[1346] To a solution of Compound 152 (716 mg, 1.48 mmol) in A A-di methyl form am ide (15 mL) were added 1 -(3 -dimethylaminopropyl)-3 -ethylcarbodiimide hydrochloride (296 mg, 1.54 mmol), 1 -hydroxybenzotriazole (218 mg, 1.61 mmol), Compound 214 (1 g, 0.67 mmol), and A-methylmorpholine (0.44 mL, 4.03 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL) and saturated aq. ammonium chloride solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 215 (1 g, 61%). ES MS m / z: [M+H]+2420.39, [M / 2+H]+1210.84.

[1347] Preparation of Compound 216

[1348] To a solution of Compound 215 (1 g, 0.41 mmol) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (407 mg, 1.03 mmol) and pyridine (0.13 mL, 1.65 mmol) at 0 °C under N2. After stirring at room temperature for 18 hours, the reaction mixture was diluted with di chloromethane (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL), 0.5 N aq. HC1 solution (50 mL), and 2 % aq. NaOH solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 216 (1 g, crude), which was used without further purification. ESLMS m / z: [M+H]+2839.96, [M / 2+H]+1420.69.

[1349] ^Preparation Example 19> Preparation of Compound 238

[1350]

[1351] 137

[1352] FH30010281.1Attorney Docket: LCH-04525

[1353]

[1354] Preparation of Compound 226

[1355] To a solution of 2-(2-(2-chloroethoxy)ethoxy)ethan-l-ol (25 g, 148.26 mmol) inN, N-dimethylformamide (50 mL) was added sodium azide (14.5 g, 111.39 mmol) at 0 °C. After stirring at 100 °C for 16 hours, The reaction mixture was diluted with di chloromethane (300 mL) and washed with distilled water (200 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 226 (24.4 g, crude), which was used without further purification. 'H-NMR (400 MHz, CDC13) 6 3.74 (t, J= 5.0 Hz, 2H), 3.71-3.65 (m, 6H), 3.64 - 3.59 (m, 2H), 3.40 (t, J = 5.0 Hz, 2H), 2.34 (t, J= 6.2 Hz, 1H). ESLMS m / z: [M+Na]+198.25.

[1356] Preparation of Compound 227

[1357] To a solution of Compound 226 (23 g, 131.28 mmol) in tetrahydrofuran (300 mL) was added sodium hydride (60% dispersion in mineral oil, 6.85 mg, 170.67 mmol) at 0 °C. After stirring at 0 °C for 10 minutes, methyl bromoacetate (14.9 ml, 157.55 mmol) was added to the reaction mixture and stirred at room temperature for 5 hours. The reaction mixture was diluted with ethyl acetate (300 mL) and washed with brine (200 mL) and dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 227 (11.6 g, 37%). 'H-NMR. (400 MHz, CDCI3) 84.18 (s, 2H), 3.78 (s, 3H), 3.76-3.65 (m, 10H), 3.39 (t, J= 7.2 Hz, 3H).

[1358] 138

[1359] FH30010281.1Attorney Docket: LCH-04525

[1360] Preparation of Compound 228

[1361] To a solution of Compound 227 (3 g, 12.1 mmol) in 1,4-dioxane (15 mL) was added sodium hydroxide (1.45 mg, 36.4 mmol) in distilled water (5 mL) at 0 °C After stirring at room temperature for 3 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with 1 N hydrochloric acid solution (100 mL). The organic layer was dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to afford Compound 228 (2.3 g, crude), which was used without further purification • 'H-NMR (400 MHz, CDC13) 64.17 (s, 2H), 3.81 - 3.76 (m, 2H), 3.70 (m, 8H), 3.41 (t, J= 5.0 Hz, 2H). ESIMS m / z: [M+Na]+256.22.

[1362] Preparation of Compound 229

[1363] To a solution of Compound 228 (2.3 g, 9.69 mmol) in dichloromethane (25 mL) was added A-hydroxysuccinimide (1.67 g, 14.54 mmol) and l-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (EDC HC1, 2.8 g, 14.54 mmol) at room temperature. After stirring at room temperature for 5 hours under N2, the reaction mixture was diluted with dichloromethane (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 229 (3.2 g, crude), which was used without further purification. 'H-NMR (400 MHz, CDCI3) 84.53 (d, J= 1.6 Hz, 2H), 3.84-3.74 (m, 2H), 3.74-3.65 (m, 8H), 3.40 (t, J= 5.1 Hz, 2H), 2.86 (s, 4H). ESI-MS m / z: [M+Na]+353.26.

[1364] Preparation of Compound 230

[1365] To a solution of 2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol (6.4 g, 34.0 mmol) in tetrahydrofuran (40 mL) was added sodium hydride (60% dispersion in mineral oil, 897 mg, 37.4 mmol) at 0 °C. After the reaction mixture was stirred at 0 °C for 10 minutes, tert-butyl bromoacetate (6.5 ml, 44.20 mmol) was added to the reaction mixture and stirred at room temperature for 17 hours. The reaction mixture was diluted with ethyl acetate (200 mL) and washed with brine (100 mL) and dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 230 (4.2 g, 41%). 'H-NMR (400 MHz, CDCI3) 64.20 (s, 2H), 4.02 (s, 2H), 3.73-3.66 (m, 12H), 2.42 (q, J= 2.0 Hz, 1H) 1.45 (s, 9H). ESI-MS m / z:

[1366] [M+H]+303.18.

[1367] 139

[1368] FH30010281.1Attorney Docket: LCH-04525

[1369] Preparation of Compound 231

[1370] To a solution of Compound 230 (700 mg, 2.32 mmol) in dichloromethane (5 mL) was added HC1 (4 M in 1,4-di oxane solution, 2.4 mL). After stirring at room temperature for 5 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 231 (560 mg, crude), which was used without further purification. 'H-NMR (400 MHz, CDCh) 6 4.24-4.14 (m, 4H), 3.80-3.74 (m, 2H), 3.70 (m, 10H), 2.44 (q, J= 2.0 Hz, 1H). ESLMS m / z:

[1371] [M+H]+269.46.

[1372] Preparation of Compound 232

[1373] To a solution of Compound 231 (732 mg, 2.97 mmol) in dichloromethane (5 mL) was added A-hydroxysuccinimide (513 mg, 4.45 mmol) and l-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (EDC. HC1, 854 mg, 4.45 mmol) at room temperature. After stirring at room temperature for 5 hours under N2, the reaction mixture was diluted with dichloromethane (100 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to afford Compound 232 (822 g, crude), which was used without further purification. 'H-NMR. (400 MHz, CDCI3) 84.53 (d, J= 1.4 Hz, 2H), 4.21 (t, J = 1.9 Hz, 2H), 3.84-3.77 (m, 2H), 3.74-3.63 (m, 10H), 2.86 (s, 4H), 2.44 (q, J= 2.1 Hz, 1H). ESLMS m / z: [M+Na]+366.31.

[1374] Preparation of Compound 233

[1375] To a solution of H-Lys(Boc)-OMe (3.2 g, 12.35 mmol) and Compound 232 (4.2 g, 12.35 mmol) in dichloromethane (30 mL) were added AA’-diisopropylethylamine (6.5 mL, 37.04 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with dichloromethane (100 mL). The organic layer was washed with saturated aq. sodium bicarbonate solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 233 (4.7 g, 77%). ESIMS m / z: [M+H]+489.44, [M+Na]+511.40.

[1376] Preparation of Compound 234

[1377] To a solution of Compound 233 (4.7 g, 9.54 mmol) in dichloromethane (15 mL) was added HC1 (4 M in 1,4-di oxane solution, 15 mL). After stirring at room temperature for 3 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 234 (4.1 g, crude), which was used without further purification. ESLMS m / z: [M+H]+389.41.

[1378] 140

[1379] FH30010281.1Attorney Docket: LCH-04525

[1380] Preparation of Compound 235

[1381] To a solution of Compound 234 (4.1 g, 9.54 mmol) and Compound 229 (3.2 g, 9.54 mmol) in dichloromethane (30 mL) were added N, / f ’-diisopropylethylamine (5.1 mL, 28.98 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with di chloromethane (30 mL). The organic layer was washed with saturated aq. sodium bicarbonate solution (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 235 (4.7 g, 80%). ES MS m / z:

[1382] [M+H]+604.46, [M+Na]+626.42.

[1383] Preparation of Compound 236

[1384] To a solution of Compound 235 (4.7 g, 7.75 mmol) in methanol (10 mL) and water (5 mL) was added sodium hydroxide (620 mg, 15.51 mmol) in distilled water (5 mL) at 0 °C. After stirring at room temperature for 3 hours, the reaction mixture was diluted with dichloromethane (100 mL) and methanol (10 mL) and washed with 1 N HC1 solution (100 mL). The organic layer was dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to afford Compound 236 (4.6 g, crude), which was used without further purification. ESLMS m / z: [M+H]+590.44, [M+Na]+612.39.

[1385] Preparation of Compound 237

[1386] To a solution of Compound 236 (4.6 g, 7.78 mmol) in dichloromethane (30 mL) were added N-(3 -dimethylaminopropyl)-? / ’ -ethylcarbodiimide hydrochloride (EDC HC1, 1.9 g, 10.12 mmol), 1 -hydroxybenzotriazole (HOBt, 1.6 g, 11.68 mmol), tert-butyl N-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]carbamate (2.3 g, 8.56 mmol), and / A’-diisopropylethylamine (4.1 mL, 23.35 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL) and distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 237 (3.5 mg, 54%). ESLMS m / z: [M+H]+836.58, [M+Na]+858.55.

[1387] Preparation of Compound 238

[1388] To a solution of Compound 237 (800 mg, 0.96 mmol) in tetrahydrofuran (10 mL) were added triphenylphosphine (276 mg, 1.05 mmol) and distilled water (0.17 mL, 9.57 mmol) at 0 °C under N2. The reaction mixture was refluxed for 12 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure. The resulting residue was

[1389] 141

[1390] FH30010281.1Attorney Docket: LCH-04525

[1391] purified by column chromatography to afford Compound 238 (752 mg, 97%). ESI-MS m / z:

[1392] [M+H]+810.57, [M+Na]+832.54.

[1393]

[1394] Preparation of Compound 240

[1395] To a solution of Compound 238 (193 mg, 0.24 mmol) and Compound 239 (250 mg, 0.20 mmol; prepared by the method described in WO 2017 / 089895 Al, the content of which is hereby incorporated by reference) in A / f-di methyl form am ide (5 mL) were added 1- [bis(dimethylamino)methylene]-l / / -l,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 98 mg, 0.26 mmol) and AA’-diisopropylethylamine (0.10 mL, 0.60 mmol) at 0 °C under N2. at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL) and distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 240 (340 mg, 83%). ESLMS m / z: [M+H]+2049.16, [M / 2+H]+1025.16.

[1396] 142

[1397] FH30010281.1Attorney Docket: LCH-04525

[1398]

[1399] Preparation of Compound 242

[1400] To a solution of Compound 238 (730 mg, 0.90 mmol) and Compound 241 (923 mg, 0.75 mmol; prepared by the method described in WO2017 / 089895 Al, the content of which is hereby incorporated by reference) in A, AAi methyl form amide (5 mL) were added 1- [bis(dimethylamino)methylene]-U / -l,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 371 mg, 0.98 mmol) and AA’-diisopropylethylamine (0.39 mL, 2.25 mmol) at 0 °C under N2. at 0 °C under N2. After stirring at room temperature for 20 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with saturated aq. sodium bicarbonate solution (50 mL) and distilled water (50 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 242 (1.3 g, 90%). ESLMS m / z: [M+H]+2020.59, [M / 2+H]+1010.92.

[1401] 143

[1402] FH30010281.1Attorney Docket: LCH-04525

[1403]

[1404] Preparation of Compound 244

[1405] To a solution of Compound 243 (300 mg, 0.52 mmol; prepared by the method described in WO 2018 / 182341 Al, the content of which is hereby incorporated by reference) in dichloromethane (10 mL) were added bis(pentafluorophenyl)carbonate (417 mg, 1.06 mmol) and A, A’-diisopropylethylamine (0.27 mL, 1.58 mmol) at 0 °C under N2. After stirring at room temperature for 3 hours, the reaction mixture was diluted with di chloromethane (30 mL) and washed with distilled water (2 x 30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 244 (402 mg, 97%). ES MS m / z: [M+H]+777.54.

[1406] 144

[1407] FH30010281.1Attorney Docket: LCH-04525

[1408] Preparation of Compound 245

[1409] To a solution of Compound 42 (100 mg, 0.11 mmol) and Compound 244 (108 mg, 0.08 mmol) in A A -di methyl form am ide (1 mL) was added AA’-diisopropylethylamine (0.06 mL, 0.35 mmol) at 0 °C under N2. After stirring at room temperature for 6 hours, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. sodium bicarbonate solution (30 mL) and distilled water (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtering and concentrating under reduced pressure to afford Compound 245 (128 mg, crude), which was used without further purification. ES MS m / z:

[1410] [M+H]+1450.47.

[1411] Preparation of Compound 246

[1412] To a solution of Compound 245 (80 mg, 0.05 mmol) and Compound 240 (112 mg, 0.05 mmol) in ethanol (1 mL), distilled water (1 mL) were added tris(3-hydroxypropyltriazolylmethyl)amine (THPTA, 9.5 mg, 0.02 mmol), copper (II) sulfate pentahydrate (11 mg, 0.04 mmol) and sodium L-ascorbate (16 mg, 0.08 mmol) at 0 °C under N2. After stirring at room temperature for 6 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 246 (193 mg, crude), which was used without further purification. ESLMS m / z: [M / 2+H]+1166.50.

[1413] Preparation of Compound 247

[1414] To a solution of Compound 246 (193 mg, crude) in methanol (1 mL) and tetrahydrofuran (1 mL) was added lithium hydroxide monohydrate (23 mg, 0.5 mmol) in distilled water (1 mL) at -50 °C. After stirring for 2 hours at 0 °C, the reaction mixture was adjusted to pH 4~5 with acetic acid and concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 247 (50 mg, 28% for 3 steps). ESLMS m / z: [M / 3+H]+1068.97.

[1415] Preparation of Compound 248

[1416] To a solution of Compound 247 (50 mg, 0.02 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.2 mL) at 0 °C under N2. After stirring at room temperature for 2 hours under N2, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by HPLC to afford Compound 248 (15 mg, 27%). ESLMS m / z: [M / 2+H]+1552.41, [M / 3+H]+1035.24.

[1417] 145

[1418] FH30010281.1Attorney Docket: LCH-04525

[1419] ^Preparation Example 23> Preparation of Compound 272

[1420]

[1421] Preparation of Compound 269

[1422] To a solution of Compound 268 (5 g, 8.70 mmol; prepared by the method described in WO 2017 / 089894 Al, the content of which is hereby incorporated by reference) in dichloromethane (100 mL) were added bis(pentafluorophenyl)carbonate (4.11 g, 10.44 mmol) and MA-diisopropylethylamine (1.35 ml, 10.44 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with di chloromethane (30 mL) and washed with distilled water (2 x 70 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 269 (6.4 g, 94%). ES MS m / z:

[1423] [M+Na]+806.79.

[1424] Preparation of Compound 270

[1425] To a solution of Compound 269 (6.4 mg, 8.16 mmol) in A Mdi methyl form am ide (20 mL) were added Exatecan mesylate (5.20 g, 9.79 mmol), AA’-diisopropylethylamine (3.41 mL, 19.58 mmol). After stirring at room temperature for 1 hour, the reaction mixture was diluted with ethyl acetate (100 mL) and washed with distilled water (2 x 70 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 270 (7.66 g, 90%). ESLMS m / z: [M+H]+1035.85.

[1426] 146

[1427] FH30010281.1Attorney Docket: LCH-04525

[1428] Preparation of Compound 271

[1429] To a solution of Compound 270 (6.6 g, 6.37 mmol) in dichloromethane (5 mL) and methanol (20 mL) were added 10% palladium / charcoal (330 mg) under hydrogen. After stirring at room temperature for 2 hours, the reaction mixture was filtered through Celite and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 271 (4.7 g, 77%).1H-NMR(400 MHz, DMSO-de), 68.07 (d, J= 8.4 Hz, 1H), 7.77 (d, J= 11.2 Hz, 1H), 7.65 (s, 1H), 7.58 (d, J= 8.8 Hz, 1H), 7.31 (s, 1H), 7.22 (d, J= 8.4 Hz, 1H), 6.52 (s, 1H), 5.76 (s, 1H), 5.61 (d, J= 8.0 Hz, 1H), 5.49-5.39 (m, 3H), 5.31-5.22 (m, 3H), 5.18-5.03 (m, 4H), 4.74 (d, = 9.6 Hz, 1H), 3.63 (s, 3H), 3.3-3.05 (m, 3H), 2.38 (s, 3H), 2.35-2.15 (m, 2H), 2.02 (s, 3H), 1.98 (s, 6H), 0.88 (t, J= 7.2 Hz, 3H). ESLMS m / z: [M+H]+945.78.

[1430] Preparation of Compound 272

[1431] To a stirred mixture of Compound 238 (138 mg, 0.17 mmol) and Compound 271 (176 mg, 0.19 mmol) in A A-dimethylformamide (5 mL) were added M M A’, A’-tetramethyl-(9-(l7 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 81 mg, 0.21 mmol) and N, N’~ diisopropylethylamine (0.12 mL, 0.71 mmol) under N2. After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (50 mL) and washed with distilled water (2 * 30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 272 (225 mg, 76%). ESLMS m / z: [M+H]+1738.90.

[1432] 147

[1433] FH30010281.1Attorney Docket: LCH-04525

[1434]

[1435] Preparation of Compound 277

[1436] To a solution of the crude Compound 276 (2.10 g, 4.33 mmol; prepared by the method described in WO 2017 / 089895 Al, the content of which is hereby incorporated by reference) in N, A-dimethylform amide (50 mL) were added potassium carbonate (1.79 g, 13.01 mmol) and allyl bromide (0.41 mL, 4.76 mmol) at room temperature. After stirring at room temperature for 3 hours, the reaction mixture was diluted with 2 N aq. HC1 (100 mL). The resulting mixture

[1437] 148

[1438] FH30010281.1Attorney Docket: LCH-04525

[1439] was extracted with ethyl acetate (200 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered and concentrated. The resulting residue was purified by column chromatography to afford Compound 277 (1.55 g, 70%). 'H-NMR (400 MHz, CDCh) 6 7.74 (s, 1H), 7.45 (dd, J= 8.0 Hz, 2.0 Hz, 1H), 7.16 (d, J= 8.8 Hz, 1H), 6.02 (m, 1H), 5.40-5.26 (m, 5H), 5.16 (m, 1H), 4.76 (m, 2H), 4.66 (s, 2H), 4.19 (m, 1H), 3.73 (s, 3H), 2.07-2.05 (m, 9H), 1.68 (t, 1H).

[1440] Preparation of Compound 278

[1441] To a solution of Compound 277 (5 g, 9.53 mmol) in dichloromethane (50 mL) were added bis(pentafluorophenyl)carbonate (5.34 g, 14.30 mmol) and AA-diisopropylethylamine (4.98 mL, 28.60 mmol) at 0 °C under N2. After stirring at room temperature for 5 hours, the reaction mixture was diluted with dichloromethane (40 mL) and washed with distilled water (2 x 70 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 278 (6.57 g, 94%). ESLMS m / z: [M+Na]+756.98.

[1442] Preparation of Compound 280

[1443] To a solution of Compound 278 (1.5 g, 2.06 mmol) and Compound 279 (1.18 g, 3.09 mmol; prepared by the method described in the Organic and Biomolecular Chemistry, 2008, vol. 6, # 15, p. 2669) in AA-dimethylformamide (5 mL) were added l-hydroxy-7-azabenzotriazole (HOAt, 0.14 mg, 1.03 mmol) and A, A’-diisopropylethylamine (1.08 mL, 6.18 mmol) at 0 °C under N2. After stirring at room temperature for 4 days, the reaction mixture was diluted with ethyl acetate (40 mL) and washed with distilled water (3 * 30 mL). The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 280 (1.1 g, 58%). ESLMS m / z: [M+H]+932.65.

[1444] Preparation of Compound 281

[1445] To a solution of Compound 280 (1.11 g, 1.19 mmol) in methanol (35 mL) was added (1 S)-(+)-10-camphorsulfonic acid (110 mg, 0.48 mmol) at 0 °C under N2. After stirring at room temperature for 2 hours, the reaction mixture was neutralized with triethylamine. After concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 281 (763 mg, 91%). 'H-NMR. (400 MHz, CDCI3) 87.98 (bs, 1H), 7.93 (d, J= 6.0 Hz, 1H), 7.82 (s, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.31 (d, J= 8.4 Hz, 1H), 7.21 (s, 1H), 7.17 (d, J= 8.8 Hz, 1H), 6.07-5.97 (m, 1H), 5.41-5.27 (m, 5H), 5.18-5.14 (m, 3H), 4.78 (d, J= 5.2 Hz, 2H), 4.72 (d, J= 5.2 Hz, 2H), 4.65 (d, J= 4.8 Hz, 2H), 4.19 (d, J = 8.4 Hz, 2H), 4.15-4.10 (m, 1H), 3.74 (s, 3H), 2.07-2.01 (m, 12H), 1.25 (bs, 2H).

[1446] 149

[1447] FH30010281.1Attorney Docket: LCH-04525

[1448] Preparation of Compound 282

[1449] To a solution of Compound 281 (233 mg, 0.33 mmol) in dichloromethane (3 mL) were added pyridine (0.11 mL, 1.33 mmol) and bis(pentafluorophenyl)carbonate (392 mg, 0.99 mmol) at 0 °C under N2. After stirring at room temperature for 16 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford Compound 282 (185 mg, 50%). 'H-NMR (400 MHz, CDCI3) 59.48 (s, 1H), 7.73 (s, 1H), 9.65-7.55 (m, 4H), 7.50 (d, J= 8.4 Hz, 1H), 7.23 (d, J= 8.4 Hz, 1H), 6.04-5.95 (m, 1H), 5.67 (d, J= 8.0 Hz, 1H), 5.25 (d, J= 10.4 Hz, 1H), 3.78-4.71 (m, 3H), 35.15 (s, 3H), 5.12-5.04 (m, 1H), 3.64 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H). ESI-MS m / z:

[1450] [M+Na]+1146.37.

[1451] Preparation of Compound 283

[1452] To a solution of Compound 282 (238 mg, 0.21 mmol) in A A-dimethylformamide (5 mL) was added exatecan mesylate (226 mg, 0.42 mmol) and 7V,7V-diisopropylethylamine (0.25 mL, 1.48 mmol). After stirring at room temperature for 16 hours, the reaction mixture was diluted with ethyl acetate (5 mL), washed with distilled water (5 mL x 3), and then dried with anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 283 (195 mg, 56.5%). ESLMS m / z: [M / 2+l]+814.02, [M+H]+1626.30.

[1453] Preparation of Compound 284

[1454] To a solution of Compound 283 (195 mg, 0.12 mmol) in A, A-dimethylformamide (5 mL) was added tetrakis(triphenylphosphine)palladium(0) (6.93 mg, 0.006 mmol) and pyrrolidine (0.015 ml, 0.18 mmol). After stirring at room temperature for 10 hours, the reaction mixture was diluted with dichloromethane (5 mL) and washed with distilled water (2 x 5 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 284 (160 mg, 84%). ESLMS m / z: [M+H]+1586.98.

[1455] 150

[1456] FH30010281.1Attorney Docket: LCH-04525

[1457]

[1458] Preparation of Compound 289

[1459] To a solution of Compound 186 (2.0 g, 6.51 mmol) in dichloromethane (15 mL) were added triethylamine (1.37 mL, 9.76 mmol) and -toluenesulfonyl chloride (1.49 g, 7.81 mmol) at 0 °C. After stirring at room temperature for 4 hours, the reaction mixture was diluted with dichloromethane (50 mL) and washed with saturated aq. ammonium chloride (3 x 30 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 289 (2.04 g, 70%) as pale yellow oil. 'H-NMR (400 MHz, CDC13) 8 7.80 (m, J= 8.1, 4.3 Hz, 2H), 7.35 (m, J= 7.6, 4.2 Hz, 2H), 4.16 (d, J= 5.5

[1460] 151

[1461] FH30010281.1Attorney Docket: LCH-04525

[1462] Hz, 2H), 3.84-3.48 (m, 21H), 3.39 (d, J= 5.3 Hz, 2H), 2.45 (d, J= 4.0 Hz, 3H). ESLMS m / z:

[1463] [M+Na]+484.243.

[1464] Preparation of Compound 290

[1465] To a solution of pentaethylene glycol (150 g, 629 mmol) in tetrahydrofuran (900 mL) was added potassium tert-butoxide (1.7 M in tetrahydrofuran, 180 mL, 307 mmol) at 0 °C. After stirring at 0 °C for 30 minutes under N2, propargyl bromide solution (80% in toluene, 34.8 mL, 315 mmol) was added dropwise at 0 °C. The mixture was then gradually warmed up to 50 °C and stirred for 16 hours. The reaction mixture was concentrated under reduced pressure, and the resulting residue was purified by column chromatography to afford Compound 290 (57 g, 65%). ESLMS m / z: [M+H]+277.39, [M+Na]+299.39.

[1466] Preparation of Compound 291

[1467] Compound 290 (57 g, 206 mmol), 4-dimethylaminopyridine (5.0 g, 41 mmol) and p-toluenesulfonyl chloride (79 g, 412 mmol) were dissolved in dichloromethane (300 mL). Triethylamine (58 mL, 412 mmol) was added dropwise at 0 °C. The reaction mixture was then gradually warmed up to room temperature and stirred for 16 hours. The reaction mixture was diluted with dichloromethane (200 mL) and washed with water (200 mL), and brine (200 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The resulting residue was purified by column chromatography to afford Compound 291 (75 g, 85%). ESLMS m / z: [M+H]+431.43, [M+Na]+453.42.

[1468] Preparation of Compound 292

[1469] To a solution of Compound 185 (7.0 g, 16.04 mmol) in dichloromethane (50 mL) was added imidazole (2.4 g, 35.28 mmol) and triisopropylsilylchloride (4.08 mL, 19.24 mmol) at 0 °C. After stirring at room temperature for 18 hours under N2, the reaction mixture was diluted with dichloromethane (200 mL) and washed with water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 292 (14.6 g, 91%). 'H-NMR (400 MHz, CDCI3) 8 7.79 (d, J= 8.0 Hz, 2H), 7.34 (d, J= 8.0 Hz, 2H), 4.16 (t, J= 4.8 Hz, 2H), 3.83 (t, J= 5.6 Hz, 2H), 3.69-3.58 (m, 20H), 2.45 (s, 3H), 1.12-1.06 (m, 21H).

[1470] Preparation of Compound 293

[1471] To a solution of Compound 192 (72 g, 157.7 mmol) in A Mdi methyl form am ide (1 L) were added potassium bicarbonate (31 g, 315.5 mmol), Compound 289 (96 g, 315.5 mmol), and potassium iodide (1 g, 7.9 mmol) under N2. The reaction mixture was stirred at 60 °C for 2 days and concentrated under reduced pressure. The resulting mixture was diluted with water 152

[1472] FH30010281.1Attorney Docket: LCH-04525

[1473] (300 mL) and extracted with ethyl acetate (300 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 293 (62 g, 66%) as pale yellow oil. 'H-NMR (400 MHz, CDC13) 87.32 (d, J= 8.0 Hz, 2H), 7.23 (s, 1H), 7.20 (s, 1H), 6.87 (dd, J= 8.4, 2.3 Hz, 2H), 5.71 (d, J= 2.3 Hz, 1H), 5.15 (d, J= 2.3 Hz, 2H), 4.26 (t, J= 4.5 Hz, 2H), 3.96-3.70 (m, 11H), 3.70-3.57 (m, 19H), 3.41-3.35 (m, 2H). ESI-MS m / z: [M+Na]+616.53.

[1474] Preparation of Compound 294

[1475] To a solution of Compound 293 (62 g, 104.4 mmol) in A A -di methyl form am ide (200 mL) were added cesium carbonate (68 g, 208.9 mmol), potassium iodide (346 mg, 2.0 mmol), and Compound 291 (49 g, 114.9 mmol) under N2. After stirring at room temperature for 19 hours, the reaction mixture was concentrated under reduced pressure. The resulting mixture was diluted with water (300 mL) and extracted with ethyl acetate (300 mL x 2). The combined organic layers were dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 294 (70 g, 78%) as pale yellow oil. ESI-MS m / z: [M+Na]+874.75.

[1476] Preparation of Compound 295

[1477] To a solution of Compound 294 (40 g, 46.9 mmol) in dichloromethane (100 mL) were added anisole (76 mL, 704.3 mmol) and trifluoroacetic acid (18 mL) at 0 °C under N2. After stirring at room temperature for 1 hour under N2, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford a Compound 295 (30 g, 87.3%) as pale yellow oil. ESI-MS m / z: [M+H]+732.68.

[1478] Preparation of Compound 296

[1479] To a solution of Compound 295 (1.6 g, 2.19 mmol), potassium iodide (18 mg, 0.11 mmol) and potassium bicarbonate (440 mg, 4.37 mmol) in A, A-di methyl form am ide (10 mL) was added Compound 292 (1.51 g, 2.40 mmol) in A / V-dimethylformamide (5 mL). After stirring at 60 °C for 1 day under N2, the reaction mixture was diluted with EtOAc (300 mL) and washed with water (100 mL), and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 296 (2.28 g, 88%). ESI-MS m / z: [M+H]+1151.97, [M+Na]+1173.98.

[1480] Preparation of Compound 297

[1481] To a solution of Compound 296 (2.35 g, 1.98 mmol) in tetrahydrofuran / methanol (15 mL / 10 mL) was added aq. 1 N NaOH solution (19 mL, 19 mmol) at 0 °C under N2. After stirring 153

[1482] FH30010281.1Attorney Docket: LCH-04525

[1483] at room temperature for 3 hours, the reaction mixture was adjusted to pH 6 using aq. 3 N HC1 solution and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford Compound 297 (2.2 g, 95%), which was used without further purification.1H-NMR. (400 MHz, CDC13) 6 7.27 (s, 2H), 4.22-4.10 (m, 6H), 3.84 (d, J= 5.3 Hz, 6H), 3.81-3.54 (m, 50H), 3.37 (s, 2H), 2.49-2.43 (m, 1H), 1.18-1.00 (m, 21H).

[1484] Preparation of Compound 298

[1485] To a solution of Compound 297 (2.27 g, 1.93 mmol) and tert-butyl {2-[2-(2-aminoethoxy)ethoxy]ethoxy}carbamate (561 mg, 2.12 mmol) in A -di methyl form am ide (2 mL) were added HBTU (880 mg, 2.32 mmol) and M / f-diisopropylethylamine (1.01 mL, 5.80 mmol) at 0 °C. After stirring at room temperature for 3 hours under N2, the reaction mixture was diluted with ethyl acetate (200 mL), washed with distilled water (100 mL) and brine (100 mL), and dried over anhydrous Na2SO4. The organic layer was filtered, concentrated under reduced pressure, and purified by column chromatography to afford Compound 298 (1.76 g, 66%). ESLMS m / z: [M+H]+1385.11.

[1486] Preparation of Compound 299

[1487] To a solution of Compound 298 (300 mg, 0.22 mmol) in tetrahydrofuran (4 mL) was added triphenylphosphine (68 mg, 0.26 mmol) at room temperature. After stirring for 30 minutes under N2, water (0.078 mL, 4.33 mmol) was added, and the reaction mixture was refluxed for 4 hours. The reaction mixture was concentrated under reduced pressure and purified by column chromatography to afford Compound 299 (170 mg, 58%). ESLMS m / z:

[1488] [M+H]+1359.19.

[1489] Preparation of Compound 300

[1490] To a solution of Compound 299 (170 mg, 0.12 mmol) and Compound 271 (124 mg, 0.13 mmol) in A( A -di methyl form am ide (3 mL) were added 7V,7V,7V’,7V’-tetramethyl-O-(17 / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 62 mg, 0.16 mmol) and N, N-diisopropylethylamine (0.065 mL, 0.38 mmol) at 0 °C. After stirring at room temperature for 3 hours under N2, the reaction mixture was diluted with ethyl acetate (200 mL), washed with distilled water (100 mL) and brine (100 mL). The organic layer was dried over anhydrous sodium sulfate. After filtration and concentration under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 300 (200 mg, 69%). ESLMS m / z: [M+H]+2285.51, [M / 2+H]+1143.44.

[1491] 154

[1492] FH30010281.1Attorney Docket: LCH-04525

[1493]

[1494] Preparation of Compound 312

[1495] To a solution of Compound 295 (30 g, 50 mmol) in

[1496]

[1497] -di methyl form am ide (500 mL) were added Compound 191 (28 g, 49.2 mmol), cesium carbonate (11 g, 81.9 mmol) and potassium iodide (340 mg, 2.0 mmol) under N2. After stirring at 40 °C for 1 days, the reaction mixture was concentrated under reduced pressure. The resulting residue was diluted with ethyl acetate (300 mL) and washed with water (200 mL) and brine (200 mL). The organic layer was dried sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 312 (33 g, 71%) as pale yellow oil. ES MS m / z: [M+Na]+1147.02.

[1498] Preparation of Compound 313

[1499] To a solution of Compound 312 (28 g, 24.9 mmol) in isopropanol (30 mL) was added aq. 1 N NaOH solution (37.3 mL, 37.3 mmol) at 0 °C under N2. After stirring at room

[1500] 155

[1501] FH30010281.1Attorney Docket: LCH-04525

[1502] temperature for 4 hours, the reaction mixture was adjusted to pH 3~4 with aq. 1 N HC1 solution. The mixture was diluted with ethyl acetate (300 mL) and washed with water (200 mL) and brine (200 mL). The organic layer was dried over sodium sulfate and filtered. The filtrate was concentrated under the reduced pressure and purified by column chromatography to afford Compound 313 (14 g, 50%) as yellow oil. ESLMS m / z: [M+Na]+1134.02.

[1503] Preparation of Compound 314

[1504] To a solution of Compound 313 (11 g, 9.9 mmol) in A'A -di methyl form am ide (50 mL) were added {2-[2-(2-aminoethoxy)ethoxy]ethoxy}carbamate (3.3 g, 10.9 mmol), N, N, N’, N’~ tetramethyl-O-(U / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU 4.5 g, 11.9 mmol), and A, A-diisopropylethylamine (8.6 mL, 49.5 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was diluted with ethyl acetate (200 mL) and washed by saturated aq. ammonium chloride solution (300 mL), saturated aq. sodium bicarbonate solution (200 mL) and brine (200 mL). The organic layer was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford Compound 314 (13.2 g, 95%) as yellow oil. ESLMS m / z: [M+H]+1398.31.

[1505] Preparation of Compound 315

[1506] To a solution of Compound 314 (434 mg, 0.31 mmol) in tetrahydrofuran (5 mL) were added triphenylphosphine (98 mg, 0.37 mmol) and distilled water (0.11 mL, 6.21 mmol) at 0 °C under N2. The reaction mixture was stirred at 60 °C for 20 hours. After concentrating under reduced pressure, the resulting residue was purified by column chromatography to afford Compound 315 (187 mg, 44%) as pale yellow oil. ESLMS m / z: [M+H]+1371.21.

[1507] Preparation of Compound 316

[1508] To a solution of Compound 241 (160 mg, 0.13 mmol; prepared by the method described in WO 2017 / 089895 Al, the content of which is hereby incorporated by reference) in A'A -di methyl form am ide (3 mL) were added Compound 315 (170 mg, 0.12 mmol), A, A, A’, A’-tetramethyl-O-(U / -benzotriazol-l-yl)uronium hexafluorophosphate (HBTU, 56 mg, 0.15 mmol), and A, A-diisopropylethylamine (0.04 mL, 0.25 mmol) under N2. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was purified by reverse phase column chromatography to afford Compound 316 (144 mg, 45%) as a white solid. ESLMS m / z: [M / 2+H]+1291.35.

[1509] Preparation of Compound 317

[1510] To a solution of Compound 316 (144 mg, 0.06 mmol) and Compound 245 (85.7 mg, 0.06 mmol) in dichloromethane (1 mL) and ethanol (1.5 mL) were added a solution of tris(3- 156

[1511] FH30010281.1Attorney Docket: LCH-04525

[1512] hydroxypropyltriazolymethyl)amine (THPTA, 10 mg, 0.02 mmol), copper (II) sulfate pentahydrate (28 mg, 0.11 mmol) and sodium L-ascorbate (44 mg, 0.22 mmol) in distilled water (1.5 mL) under N2. After stirring at room temperature for 4 hours, the reaction mixture was concentrated under reduced pressure to afford Compound 317 (230 mg, 100%), which was used for the nex...

Claims

1. Attorney Docket: LCH-04525We claim:

1. A conjugate having a structure represented by General Formula I, or a pharmaceutically acceptable salt thereof:[General Formula I]Ab-[LAb-(B)i]mwherein,Ab is an anti-Lewis Y antibody or antigen-binding fragment thereof, comprising a variable heavy chain complementarity determining region 1 (CDRH1), a variable heavy chain complementarity determining region 2 (CDRH2), a variable heavy chain complementarity determining region 3 (CDRH3), a variable light chain complementarity determining region 1 (CDRL1), a variable light chain complementarity determining region 2 (CDRL2), and a variable light chain complementarity determining region 3 (CDRL3); whereinCDRH1 comprises an amino acid sequence of SEQ ID NO: 2,CDRH2 comprises an amino acid sequence of SEQ ID NO: 4,CDRH3 comprises an amino acid sequence of SEQ ID NO: 6,CDRL1 comprises an amino acid sequence of SEQ ID NO: 11,CDRL2 comprises an amino acid sequence of SEQ ID NO: 13, andCDRL3 comprises an amino acid sequence of SEQ ID NO: 15;each LAbis, independently, a linker;each B is, independently an active agent; and1 and m are each independently 1 to 20.

2. The conjugate of claim 1, wherein Ab comprises:(i) a heavy chain variable region (VH) comprising:the amino acid sequence of SEQ ID NO: 8;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 8 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; or258FH30010281.1Attorney Docket: LCH-04525a sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 8 while maintaining the CDRH1 comprising the amino acid sequence of SEQ ID NO: 2, the CDRH2 comprising the amino acid sequence of SEQ ID NO: 4, and the CDRH3 comprising the amino acid sequence of SEQ ID NO: 6; and(ii) a light chain variable region (VL) comprising:the amino acid sequence of SEQ ID NO: 17;a sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 17 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 11, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 13, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 15; ora sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 17 while maintaining the CDRL1 comprising the amino acid sequence of SEQ ID NO: 11, the CDRL2 comprising the amino acid sequence of SEQ ID NO: 13, and the CDRL3 comprising the amino acid sequence of SEQ ID NO: 15.

3. The conjugate of claim 1 or 2, wherein Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 8 and a light chain variable region (VL) comprising the amino acid sequences of SEQ ID NO: 17.

4. The conjugate of any one of claims 1-3, wherein Ab specifically binds to Lewis Y.

5. The conjugate of any one of claims 1-4, wherein Ab is a humanized antibody or a human antibody.

6. The conjugate of any one of claims 1-5, wherein Ab is selected from a monoclonal antibody, a single chain antibody (scAb), a Fab fragment, a Fab' fragment, aF(ab')2 fragment, an scFab fragment, an Fv fragment, a dsFv fragment, a single chain variable fragment (scFv), an scFv-Fc fragment, a variant antibody, a multimeric antibody, a minibody, a diabody, a bispecific antibody, and a multispecific antibody.259FH30010281.1Attorney Docket: LCH-045257. The conjugate of any one of claims 1-6, wherein Ab comprises an IgA, IgG, IgM, IgE, or IgD constant domain or is an IgA, IgG, IgM, IgE, or IgD antibody.

8. The conjugate of claim 7, wherein Ab comprises an IgG constant domain or is an IgG antibody; optionally wherein Ab comprises an IgGl, IgG2, IgG3, or IgG4 constant domain or is an IgGl, IgG2, IgG3, or IgG4 antibody.

9. The conjugate of claim 8, wherein Ab comprises an IgGl constant domain or is an IgGl antibody.

10. The conjugate of any one of claims 7-9, wherein(i) Ab comprises LAL A mutations in a heavy chain constant domain, and the LAL A mutations comprise L234A and L235A substitutions according to EU numbering convention; or(ii) Ab comprises leucine-to-alanine substitutions in a heavy chain constant region in place of amino acids corresponding to amino acids 233-234 in SEQ ID NO: 9.

11. The conjugate of any one of claims 7-10, wherein(i) Ab comprises a P329G substitution according to EU numbering convention; or(ii) Ab comprises a proline-to-glycine substitution in a heavy chain constant region in place of an amino acid corresponding to amino acid 328 in SEQ ID NO: 9.

12. The conjugate of any one of claims 7-11, wherein Ab comprises(a) L234A, L235A, and P329G substitutions according to EU numbering convention; or (b) leucine-to-alanine substitutions in a heavy chain constant region in place of amino acids corresponding to amino acids 233-234 in SEQ ID NO: 9 and a proline-to- glycine substitution in the heavy chain constant region in place of an amino acid corresponding to amino acid 328 in SEQ ID NO: 9.

13. The conjugate of any one of claims 1-12, wherein Ab at the C-terminus comprises an amino acid motif that is recognized by an isoprenoid transferase; optionally wherein the isoprenoid transferase is farnesyl protein transferase (FTase) or geranylgeranyl transferase (GGTase).260FH30010281.1Attorney Docket: LCH-0452514. The conjugate of claim 13, wherein LAbis covalently bonded to Ab by a thioether bond and the thioether bond comprises a sulfur atom of a cysteine of the amino acid motif.

15. The conjugate of claim 13 or 14, wherein the amino acid motif comprises a CYaYaX sequence, wherein:C is cysteine;each Yais independently an aliphatic amino acid, optionally wherein each Yais independently selected from alanine, isoleucine, leucine, methionine, and valine; and X is selected from glutamine, glutamate, serine, cysteine, methionine, alanine, and leucine.

16. The conjugate of any one of claims 13-15, wherein the amino acid motif comprises a CVIM (SEQ ID NO: 22) or CVLL (SEQ ID NO: 23).

17. The conjugate of any one of claims 13-16, wherein at least one of the 1 to 20 amino acids preceding the amino acid motif is glycine.

18. The conjugate of any one of claims 13-17, wherein the amino acid motif has the sequence GGGGGGGCVIM (SEQ ID NO: 24).

19. The conjugate of claim 1, wherein Ab comprises:(a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 19;(b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and a light chain comprising the amino acid sequence of SEQ ID NO: 19;(c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 21, and a light chain comprising the amino acid sequence of SEQ ID NO: 19;(d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 9, and a light chain comprising the amino acid sequence of SEQ ID NO: 18;(e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 20, and a light chain comprising the amino acid sequence of SEQ ID NO: 18; or(f) a heavy chain comprising the amino acid sequence of SEQ ID NO: 21, and a light chain comprising the amino acid sequence of SEQ ID NO: 18.261FH30010281.1Attorney Docket: LCH-0452520. The conjugate of claim 19, wherein Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 20 or 21, and a light chain comprising the amino acid sequence of SEQ ID NO: 18.

21. The conjugate of any one of claims 1-20, wherein the conjugate has a structure represented by Formula la or a pharmaceutically acceptable salt thereof:Formula lawhereineach instance of G is independently a sugar or a sugar acid (e.g., a glucuronic acid or galactoside);R1and R2are each independently hydrogen, Ci-s alkyl, or C3-8 cycloalkyl; or R1and R2combine to complete a (Cs-Cs) cycloalkyl ring;each instance of W is independently -C(O)-, -C(O)N(R’)-, -C(O)O-, -SO2N(R’)-, -P(O)(R”)N(R’)-, -SON(R’)-, or -PO2N(R’)-;each instance of R’ and R” is independently H, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl or aryl;each instance of Z is independently alkyl, halo, cyano, or nitro;nl and n2 are each independently 1 to 20;each instance of n3 is independently 0, 1, 2, or 3; andY1is absent, C1-C50 alkylene, C1-C50 alkenylene, 1-50 atom heterocyclylene, or 1-50 atom heteroalkylene.

22. The conjugate of claim 21, wherein R1is H or methyl.

23. The conjugate of claim 21 or 22, wherein R2is H or methyl.262FH30010281.1Attorney Docket: LCH-0452524. The conjugate of any one of claims 21-23, wherein G has a structure represented by Formula II or a pharmaceutically acceptable salt thereof:whereinR3and each R4is independently H, alkyl, aralkyl, or an oxygen protecting group;R3ais H or alkyl;R3bis H or alkyl; orR3aand R3bcombine to form an oxo;R3Ais H or a hydroxyl protecting group; andR3Bis H or a carboxyl protecting group.

25. The conjugate of claim 24, wherein R3is H or methyl.

26. The conjugate of any one of claims 21-25, wherein W is -C(O)N(R’)- and the C(O) is bonded to the phenyl ring and N(R’) is bonded to Y1.

27. The conjugate of any one of claims 21-26, wherein each R’ and R” is H.

28. The conjugate of any one of claims 21-27, wherein Z is halo (e.g., bromo) or cyano.

29. The conjugate of any one of claims 21-28, wherein n3 is 0 or 1.

30. The conjugate of any one of claims 21-29, wherein Y1comprises a C1-50 alkylene or Ci-50 heteroalkylene wherein the C1-50 alkylene or C1-50 heteroalkylene comprises one or more of:(i) one or more unsaturated bonds;(ii) a heteroarylene (e.g., a heteroarylene in the alkylene or heteroalkylene chain);(iii) at least one Cl -20 alkyl substituent; and263FH30010281.1Attorney Docket: LCH-04525(iv) at least one isoprenyl group having a structure represented by Formula III:wherein n4 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.

31. The conjugate of claim 30, wherein n4 is 1, 2, 3, or 4.

32. The conjugate of any one of claims 21-31, wherein Y1comprises a peptide comprising at least one hydrophilic amino acid.

33. The conjugate of claim 32, wherein the peptide comprises an amino acid having a side chain having a moiety that bears a charge at neutral pH in aqueous solution (e.g., an amine, guanidine, or carboxyl moiety).

34. The conjugate of claim 32 or 33, wherein the peptide comprises an amino acid selected from alanine, aspartate, asparagine, glutamate, glutamine, glycine, lysine, ornithine, proline, serine, histidine, arginine and threonine.

35. The conjugate of any one of claims 21-34, wherein Y1comprises a unit having a structure represented by Formula IVa or IVb:-(CH2)r(V(CH2)P)q- Formula IVa,-(CH2CH2X)W- Formula IVb;whereinV is a single bond, -O-, -S-, -NR5-, -C(O)NR6-, -NR7C(O)-, -NR8SO2-, or -SO2NR9-, preferably-O-;X is -O-, Ci-8 alkylene, or -NR5-, preferably -O-;R5to R9are each independently H, Ci-6 alkyl, Ci-6 alkyl Ce-2o aryl, or Ci-6 alkyl Cs-2o heteroaryl;r is an integer of 1 to 10, preferably 2;264FH30010281.1Attorney Docket: LCH-04525p is an integer of 0 to 12, preferably 2;q is an integer of 1 to 20, preferably 2, 5, or 11; andw is an integer of 1 to 20, preferably 6 to 20.

36. The conjugate of claim 35, wherein V is -O-.

37. The conjugate of claim 35 or 36, wherein X is -O-.

38. The conjugate of any one of claims 35-37, wherein each R5, R6, R7, R8, and R9is H.

39. The conjugate of any one of claims 35-38, wherein r is 2; p is 2; q is 2, 5, or 11; and w is 6 to 20.

40. The conjugate of any one of claims 21-39, wherein Y1further comprises a binding unit formed by a reaction between an alkyne and an azide or between an aldehyde or ketone group and hydrazine or hydroxylamine.

41. The conjugate of any one of claims 21-39 wherein Y1further comprises a unit having a structure represented by Formula Va, Vb, Vc, Vd, or Ve:whereinL1is a single bond or C1-30 alkylene; andR10is H or Ci-10 alkyl.

42. The conjugate of any one of claims 21-41, wherein Y1comprises an oxime.

43. The conjugate of claim 42, wherein the oxygen atom of the oxime is on the side of Y1that is linked to W and the carbon atom of the oxime is on the side of Y1that is linked to Ab.265FH30010281.1Attorney Docket: LCH-0452544. The conjugate of claim 42, wherein the carbon atom of the oxime is on the side of Y1that is linked to W and the oxygen atom of the oxime is on the side of Y that is linked to Ab.

45. The conjugate of any one of claims 42-44, wherein the oxime has a structure represented by Formula Via:ViawhereinR11is H, alkyl or cycloalkyl; andR12is H, alkyl or cycloalkyl; or R11and R12combine to form a cycloalkyl.

46. The conjugate of claim 45, wherein each R11and R12is independently H or alkyl, preferably methyl.

47. The conjugate of claim 45, wherein R11and R12combine to form a cycloalkyl, preferably cyclobutyl.

48. The conjugate of any one of claims 42-47, wherein the oxime has a structure represented by formula VIb:VIbwhereinR11and R12are independently H, alkyl or cycloalkyl; or R11and R12combine to form a cycloalkyl;X1and X2are each independently N(R13), O, or S; andR13is H, alkyl, aryl, or aralkyl.

49. The conjugate of claim 48, wherein X1is N(R13), further wherein R13is H.

50. The conjugate of claim 48 or 49, wherein X2is O.266FH30010281.1Attorney Docket: LCH-0452551. The conjugate of any one of claims 21-50, wherein Y1further comprises an oligoethylene glycol.

52. The conjugate of claim 51, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties represented by, optionally wherein the oligoethylene glycol comprises 1, 2, 3, or 4 ethylene glycol moieties.

53. The conjugate of claim 51 or 52, wherein Y1comprises an oxime and the oligoethylene glycol covalently bonds the oxime to W.

54. The conjugate of any one of claims 21-53, wherein Y1is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido.

55. The conjugate of any one of claims 21-53, wherein Y1is substituted with an oligoethylene glycol.

56. The conjugate of claim 55, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

57. The conjugate of any one of claims 51-56, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino e.g, dimethylamino).

58. The conjugate of any one of claims 21-57, wherein Y1further comprises at least one amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties).

59. The conjugate of any one of claims 21-58, wherein Y1further comprises an amino acid (e.g., a hydrophilic amino acid), preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.267FH30010281.1Attorney Docket: LCH-0452560. The conjugate of claim 59, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine, preferably from arginine, aspartate, glutamate, histidine, lysine, and ornithine, more preferably from aspartate, glutamate, and sarcosine.61 The conjugate of any one of claims 21-60, wherein Y1is linear.

62. The conjugate of any one of claims 21-60, wherein Y1is branched.

63. The conjugate of claim 62, wherein Y1comprises:i) a branching unit covalently coupled to Ab by a primary linker;ii) a first branch which couples a first B to the branching unit; andiiia) a second branch which couples a second B to the branching unit; oriiib) a second branch comprising an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) is covalently coupled to the branching unit.

64. The conjugate of claim 63, wherein Y1comprises a second branch which couples a second B, via a cleavage group, to the branching unit.

65. The conjugate of claim 63, wherein Y1comprises a second branch which couples an alkyl or heteroalkyl (e.g., a polyethylene glycol monomer or a polyethylene glycol oligomer) to the branching unit.

66. The conjugate of any one of claims 63-65, wherein the branching unit comprises an amino acid, preferably a lysine residue.

67. The conjugate of any one of claims 62-65, wherein the branching unit has a structure represented by Formula Vila, Vllb, Vile, or Vlld:268FH30010281.1Attorney Docket: LCH-04525whereinG1, G2, G3are each independently a bond,R14is H or alkyl;R15is H, alkyl or L5-CO2R16R16is H or alkyl; andL2, L3, L4, and L5are each independently a bond or alkylene.

68. The conjugate of any one of claims 63-65, wherein the branching unit has a structure represented by Formula Vlllb:Vlllbwherein R14is H or alkyl.

69. The conjugate of any one of claims 63-68, wherein the cleavage group has a structure represented by Formula IX or a pharmaceutically acceptable salt thereof:269FH30010281.1Attorney Docket: LCH-04525IXwhereinBw is an active agent;each Rw2, Rw3, Rw4, and Rw5is independently H, alkyl, aralkyl, or an oxygen protecting group;each Rw6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkyl sulfonyl, or sulfonamido;each Ww1is independently*(CH2)twiN(Rw7)C(O)-, -*C(O)O-, -*S(O2)N(RW7)-, -*P(O)( RW8)N(RW7)-, - *S(O)N(Rw7)-, or -*P(O2)N(RW7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula IX;Rw7and Rw8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;twl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nwl is 0, 1, 2, or 3;Jw1is H or alkyl;Jw2is H or alkyl; orJw1and Jw2combine to form an oxo; andAw2represents a linkage to the secondary linker.

70. The conjugate of any one of claims 62-69, wherein:at least one branched linker is covalently coupled to Ab; andat least two B are covalently coupled to the branched linker.270FH30010281.1Attorney Docket: LCH-0452571. The conjugate of claim 70, wherein the conjugate comprises 1, 2, 3, or 4 branched linkers and each branched linker comprises two B.

72. The conjugate of any one of claims 1-71, wherein the conjugate comprises a structurerepresented by:, oror a pharmaceutically acceptable salt thereof; whereinB' and B" are each an active agent;nil, n22, and n33 are each independently 0 to 30;AA is an amino acid group (e.g., a lysine); andthe wavy bond represents a connection to Ab.

73. The conjugate of any one of claims 1-20, wherein the conjugate comprises a structure represented by Formula X or a pharmaceutically acceptable salt thereof:271FH30010281.1Attorney Docket: LCH-04525Formula XL6comprises an alkylene;Y2and Y4are each independently O, N(R17), or S;Yxis H;X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-,-OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, -N(R19)P(O)(R18)-, -P(O)2N(R19)-, or -N(R19)P(O)2-;R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;V1and V3are each independently a bond, N, NH, C, CH, or CH2;L7and L9each independently comprise an alkylene;T1and T3are each independently a bond, -O-, or a self-immolative moiety;B1and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; orV1, T1and B1or V3, T3and B3together represent a branched moiety; andml and m3 are each independently 1, 2, or 3.

74. The conjugate of any one of claims 1-20, wherein the conjugate comprises a structure represented by Formula XI or a pharmaceutically acceptable salt thereof:272FH30010281.1Attorney Docket: LCH-04525Formula XIwhereinL6comprises an alkylene;Y2, Y3, and Y4are each independently O, N(R17), or S;X1is -N(R18)C(O)-, -C(O)N(R18)-, -C(O)N(R18)(CH2)Z-, -(CH2)ZC(O)N(R18) -, -C(O)-, - C(O)O-,-OC(O)-, -S(O2)N(R18)-, -N(R18)S(O2)-, -P(O)(R18)N(R19)-, -N(R19)P(O)(R18)-, - P(O)2N(R19)-, or -N(R19)P(O)2-;each z is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;R17, R18, and R19are each independently H, alkyl, aryl, or aralkyl;L7, L8, and L9each independently comprise an alkylene;V1, V2, and V3are each independently a bond, N, NH, C, CH, or CH2;T1, T2, and T3are each independently a bond, -O-, or a self-immolative moiety;B1, B2, and B3are each independently an active agent (e.g., a drug or a toxin), H, alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, alkylamino, guanidinyl, amido, cyano, azido, alkylthio, cycloalkyl, alkylsulfonyl, sulfonamido, aryl, heteroaryl, or heterocyclyl; orV1, T1and B1; V2, T2and B2; or V3, T3and B3together represent a branched moiety; and ml, m2, and m3 are each independently 1, 2, or 3.

75. The conjugate of claim 74, wherein each of Y2, Y3, and Y4is O.

76. The conjugate of claim 74 or 75, wherein X1is -C(O)N(R18)-, further wherein R18is H.

77. The conjugate of any one of claims 74-76, wherein L6comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.

78. The conjugate of any one of claims 74-77, wherein L6further comprises an oligoethylene glycol.

79. The conjugate of claim 78, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, 4, 5, or 6 ethylene glycol moieties, more preferably 5 ethylene glycol moieties.273FH30010281.1Attorney Docket: LCH-0452580. The conjugate of any one of claims 74-79, wherein L6is substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkylsulfonyl, or sulfonamido.

81. The conjugate of any one of claims 74-80, wherein L6further comprises a structure represented by Formula Xia or Formula Xlb:XlbwhereinA1represents a linkage to X1;A2represents a linkage to Ab;X3and X4are each independently O, S, or N(R23);R20and R21are each H or alkyl; or R20and R21combine to form a cycloalkyl;R22is H or alkyl; andR23is H, alkyl, aryl, or aralkyl.

82. The conjugate of claim 81, wherein X3is N(R23), further wherein R23is H.

83. The conjugate of claim 81 or 82, wherein X4is O.

84. The conjugate of any one of claims 81-83, wherein each of R20and R21is independently alkyl (e.g., methyl).274FH30010281.1Attorney Docket: LCH-0452585. The conjugate of any one of claims 82-84, wherein R20and R21combine to form a cycloalkyl (e.g., cyclobutyl).

86. The conjugate of any one of claims 73-85, wherein L6further comprises a heteroaryl (e.g., pyrazolyl, triazolyl).

87. The conjugate of claim 86, wherein L6further comprises a structure represented by Formula Xllla or Xlllb:Xllla Xlllbwhereineach A1represents a linkage to X1; andeach A2represents a linkage to Ab.

88. The conjugate of any one of claims 74-87, wherein L6further comprises a structure represented by Formula XIV:XIVwherein n5 is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, preferably wherein n5 is 1, 2, 3, 4, or 5;each A1represents a linkage to X1; andeach A2represents a linkage to Ab.

89. The conjugate of any one of claims 74-88, wherein L6is substituted with an oligoethylene glycol.

90. The conjugate of claim 89, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties (e.g., 1, 2, 3, or 4 ethylene glycol moieties).

91. The conjugate of claim 89 or 90, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino e.g., dimethylamino).275FH30010281.1Attorney Docket: LCH-0452592. The conjugate of any one of claims 74-91, wherein L6further comprises an amido moiety (e.g., 1, 2, 3, 4, 5, or 6 amido moieties, preferably 1 or 2 amido moieties).

93. The conjugate of claim 92, wherein L6comprises 1 or 2 amido moieties substituted with alkyl (e.g., carboxyalkyl).

94. The conjugate of any one of claims 74-93, wherein L6further comprises an amino acid (e.g., a hydrophilic amino acid), preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.

95. The conjugate of any one of claims 74-94, wherein L6further comprises a polypeptoid (e.g., polysarcosine).

96. The conjugate of claim 94, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine, serine, and threonine, preferably from arginine, aspartate, glutamate, histidine, lysine, and ornithine, more preferably from aspartate, glutamate, and sarcosine.

97. The conjugate of any one of claims 74-96, wherein each of L7, L8and L9independently comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.

98. The conjugate of any one of claims 74-97, wherein each of L7, L8and L9independently further comprises an oligoethylene glycol.

99. The conjugate of claim 98, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 5 ethylene glycol moieties.

100. The conjugate of any one of claims 74-99, wherein each of L7, L8and L9independently further comprises an amido moiety, preferably 1, 2, 3, 4, 5, or 6 amido moieties, more preferably 1 or 2 amido moieties.

101. The conjugate of any one of claims 74-99, wherein each of L7, L8and L9independently further comprises 1 or 2 optionally substituted amido moieties (e.g., heterocyclylamido, such as piperazinylamido or carboxyl ami do).276FH30010281.1Attorney Docket: LCH-04525102. The conjugate of any one of claims 74-101, wherein each of L7, L8and L9independently further comprises a heteroaryl (e.g., pyrazolyl or triazolyl).

103. The conjugate of claim 102, wherein each of L7, L8and L9independently further comprises a structure represented by Formula XVa or XVb:XVa XVbwherein:each Ax1represents a linkage to V1, V2or V3; andeach Ax2represents a linkage to Y2, Y3or Y4.

104. The conjugate of any one of claims 74-103, wherein each of L7, L8and L9is independently substituted with an oligoethylene glycol.

105. The conjugate of claim 104, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.

106. The conjugate of claim 104 or 105, wherein the oligoethylene glycol is substituted with carboxyalkyl (e.g., carboxyethyl) or amino (e.g., dimethylamino).

107. The conjugate of any one of claims 74-106, wherein each of L7, L8and L9is independently substituted with alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino (e.g., hydroxylamino), amido, cyano, nitro, azido, alkylthio, alkenyl, alkynyl, cycloalkyl, alkyl sulfonyl, or sulfonamido.

108. The conjugate of any one of claims 74-107, wherein each of L7, L8and L9independently further comprises an amino acid (e.g, a hydrophilic amino acid), preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.

109. The conjugate of claim 108, wherein the amino acid(s) are selected from arginine, aspartate, asparagine, glutamate, glutamine, histidine, lysine, ornithine, proline, sarcosine,277FH30010281.1Attorney Docket: LCH-04525serine, and threonine, preferably from arginine, aspartate, glutamate, histidine, lysine, and ornithine, more preferably from aspartate, glutamate, and sarcosine.

110. The conjugate of any one of claims 74-109, wherein V1is a bond.

111. The conjugate of any one of claims 74-109, wherein V1is N and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIa or a pharmaceutically acceptable salt thereof:XVIawherein:Ax3represents a linkage to L7;Lx1and Lx2each independently comprise an alkylene;Tx1and Tx2are each independently a bond or a self-immolative moiety; andBx1and Bx2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

112. The conjugate of any one of claims 74-109, wherein V1is CH or C, valence permitting, and V1, T1, and B1together represent a branched moiety having a structure represented by Formula XVIb, Formula XVIc, or Formula XVId, or a pharmaceutically acceptable salt thereof:XVIc,278FH30010281.1Attorney Docket: LCH-04525XVId,wherein:Ax3represents a linkage to L7;Lx1, Lx2, and Lx3each independently comprise an alkylene;Gx1, Gx2, and Gx3are each independently an alkylene,each Rx1is independently H, alkyl, or aralkyl;Tx1, Tx2, and Tx3are each independently a bond or a self-immolative moiety; andBx1, Bx2, and Bx3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

113. The conjugate of any one of claims 110-112, wherein each of Lx1, Lx2, and Lx3independently comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.

114. The conjugate of any one of claims 110-113, wherein each of Lx1, Lx2, and Lx3independently further comprises an oligoethylene glycol.

115. The conjugate of claim 114, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.

116. The conjugate of any one of claims 111-115, wherein T1, Tx1, Tx2, or Tx3has a structure represented by Formula XVII or a pharmaceutically acceptable salt thereof:279FH30010281.1Attorney Docket: LCH-04525wherein,each Rx2, Rx3, Rx4, and Rx5is independently H, alkyl, aralkyl, or an oxygen protecting group;each Rx6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;Wx1is -*C(O)-, -*C(O)N(Rx7)-, -*N(RX7)C(O)-, -*(CH2)tx1N(Rx7)C(O)-, -*C(O)O-, -*S(O2)N(Rx7)-, -*P(O)(Rx8)N(Rx7)-, -*S(O)N(Rx7)-, or -*P(O2)N(Rx7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XVII, Rx7and Rx8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Ja1is H or alkyl;Ja2is H or alkyl; orJa1and Ja2combine to form an oxo;tx1is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nxl is 0, 1, 2, or 3;Ax4represents a linkage to B1, Bx1, Bx2, or Bx3; andAx5represents a linkage to L7, Lx1, Lx2, or Lx3.

117. The conjugate of claim 116, wherein each of Rx2, Rx3,:4, and Rx5is H.

118. The conjugate of claim 116 or 117, wherein nxl is 0.280FH30010281.1Attorney Docket: LCH-04525119. The conjugate of any one of claims 116-118, wherein Wx1is -*C(O)N(Rx7)-, further wherein Rx7is H.

120. The conjugate of any one of claims 116-119, wherein Ja1and Ja2combine to form oxo.

121. The conjugate of any one of claims 74-120, wherein V2is a bond.

122. The conjugate of any one of claims 74-121, wherein V2is N and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XIXa or a pharmaceutically acceptable salt thereof:XIXawherein:Ay3represents a linkage to L8;Ly1and Ly2each independently comprise an alkylene;Ty1and Ty2are each independently a bond, or a self-immolative moiety; andBy1and By2are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

123. The conjugate of any one of claims 74-121, wherein V2is CH or C, valence permitting, and V2, T2, and B2together represent a branched moiety having a structure represented by Formula XlXb, Formula XIXc, or Formula XlXd, or a pharmaceutically acceptable salt thereof:281FH30010281.1Attorney Docket: LCH-04525XIXc,XlXd,wherein:Ay3represents a linkage to L8;Ly1, Ly2, and Ly3each independently comprise an alkylene;Gy1, Gy2, and Gy3are each independently an alkylene,each Ry1is independently H, alkyl, or aralkyl;Ty1, Ty2, andTy3are each independently a bond or a self-immolative moiety; and By1, By2, and By3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

124. The conjugate of claim 122 or 123, wherein each of Ly1, Ly2, and Ly3independently comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.

125. The conjugate of any one of claims 122-124, wherein each of Ly1, Ly2, and Ly3independently further comprises an oligoethylene glycol.

126. The conjugate of claim 125, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.

127. The conjugate of any one of claims 74-126, wherein T2, Ty1, Ty2, or Ty3has a structure represented by Formula XX or a pharmaceutically acceptable salt thereof:282FH30010281.1Attorney Docket: LCH-04525XXwherein,each Ry2, Ry3, Ry4, and Ry5is independently H, alkyl, aralkyl, or an oxygen protecting group;each Ry6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;each Wy1is independently - -*C(O)O-, -*S(O2)Nwherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XX;Ry7and Ry8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jb1is H or alkyl;Jb2is H or alkyl; orJb1and Jb2combine to form an oxo;tyl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nyl is 0, 1, 2, or 3;Ay4represents a linkage to B2, By1, By2, or By3; andAy5represents a linkage to L8, Ly1, Ly2, or Ly3.

128. The conjugate of claim 127, wherein each of Ry2, Ry3, Ry4, Ry5is H.283FH30010281.1Attorney Docket: LCH-04525129. The conjugate of claim 127 or 128, wherein each nyl is 0.

130. The conjugate of any one of claims 127-129, wherein each Wy1is -*C(O)N(Ry7)-, further wherein Ry7is H.

131. The conjugate of any one of claims 127-130, wherein Jb1and Jb2combine to form oxo.

132. The conjugate of any one of claims 74-131, wherein V3is a bond.

133. The conjugate of any one of claims 74-131, wherein V3is N and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIa or a pharmaceutically acceptable salt thereof:XXIIawherein:Az3represents a linkage to L9;Lz1and Lz2each independently comprise an alkylene;Tz1and Tz2are each independently a bond or a self-immolative moiety; andBz1and Bz2are each independently an active agent (e.g., a drug or a toxin).

134. The conjugate of any one of claims 74-131, wherein V3is CH or C, valence permitting, and V3, T3, and B3together represent a branched moiety having a structure represented by Formula XXIIb, Formula XXIIc, or Formula XXIId, or a pharmaceutically acceptable salt thereof:XXIIb,284FH30010281.1Attorney Docket: LCH-04525XXIId,wherein:Az3represents a linkage to L9;Lz1, Lz2, and Lz3each independently comprise an alkylene;Gz1, Gz2, and Gz3are each independently an alkylene,each Rz1is independently H, alkyl, or aralkyl;Tz1, Tz2, and Tz3are each independently a bond or a self-immolative moiety; andBz1, Bz2, andBz3are each independently an active agent (e.g., a drug or a toxin), amido, carboxyl, ester, urea, substituted amido, or heteroaryl.

135. The conjugate of claim 133 or 134, wherein each of Lz1, Lz2, and Lz32independently comprises a Ci-Cioo alkylene, preferably a C1-C50 alkylene.

136. The conjugate of any one of claims 133-135, wherein each of Lz1, Lz2, and Lz3independently further comprises an oligoethylene glycol.

137. The conjugate of claim 136, wherein the oligoethylene glycol comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 ethylene glycol moieties, preferably 1, 2, 3, or 4 ethylene glycol moieties.285FH30010281.1Attorney Docket: LCH-04525138. The conjugate of any one of claims 136-137, wherein T3, Tz1, Tz2, or Tz3have a structure represented by Formula XXIII or a pharmaceutically acceptable salt thereof:XXIIIwhereineach Rz2, Rz3, Rz4, and Rz5is independently H, alkyl, aralkyl, or an oxygen protecting group; each Rz6is alkyl, alkenyl, alkynyl, halo, hydroxyl, carboxyl, acyl, acetyl, ester, thioester, alkoxy, phosphoryl, amino, amido, cyano, nitro, azido, alkylthio, cycloalkyl, alkylsulfonyl, or sulfonamido;Wz1is -*C(O)-, -*C(O)N(Rz7)-, -*N(RZ7)C(O)-, -*(CH2)tziN(Rz7)C(O)-, -*C(O)O-, -*S(O2)N(RZ7)-, -*P(O)( RZ8)N(RZ7)-, -*S(O)N(RZ7)-, or -*P(O2)N(RZ7)-, wherein the C(O), N, CH2, S, or P marked with an * is bonded to the phenyl ring of Formula XXIII,Rz7and Rz8are each independently hydrogen, alkyl, cycloalkyl, alkoxy, alkylthio, alkylamino, heteroaryl, or aryl;Jc1is H or alkyl;Jc2is H or alkyl; orJc1and Jc2combine to form an oxo;tzl is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;nzl is 0, 1, 2, or 3;Az4represents a linkage to B3, Bz1, Bz2, or Bz3; andAz5represents a linkage to L9, Lz1, Lz2, or Lz3.

139. The conjugate of claim 138, wherein each of Rz2, Rz3, Rz4, and Rz5is H.286FH30010281.1Attorney Docket: LCH-04525140. The conjugate of claim 138 or 139, wherein nzl is 0.

141. The conjugate of any one of claims 138-140, wherein Wz1is -*C(O)N(Rz7)-, further wherein Rz7is H.

142. The conjugate of any one of claims 138-141, wherein Jc1and Jc2combine to form oxo.

143. The conjugate of any one of claims 1-142, wherein the conjugate comprises144. The conjugate of any one of claims 74-143, wherein each B1, B2, and B3is independently an active agent.

145. The conjugate of any one of claims 74-143, wherein each B1, B2, and B3is independently H, hydroxyl, amino (e.g., dimethyl amino), phosphoryl, sulfonamido, carboxyl, amido (e.g., piperazineamide), alkoxy, or heterocyclyl (e.g., a glucuronidyl or morpholinyl).

146. The conjugate of any one of claims 74-145, wherein each T1, T2, and T3is independently a bond.

147. The conjugate of any one of claims 1-146, wherein each active agent is independently a chemotherapeutic agent or a toxin.

148. The conjugate of any one of claims 1-146, wherein each active agent is independently a chemotherapeutic compound, a cytotoxic compound, an immunomodulatory compound, an anticancer agent, an antiviral agent, an antibacterial agent, an antifungal agent, or an antiparasitic agent.287FH30010281.1Attorney Docket: LCH-04525149. The conjugate of any one of claims 1-146, wherein each active agent is independently selected from:(a) a microtubule targeting agent (e.g., maytansinoid, maytansine, DM1, DM4, maytansinol, auristatin, dolastatin 10, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), eribulin, Halichondrin B, tubulysin, cryptophycin, EG5 inhibitors, SB-715992 (ispinesib), orfilanesib (ARRY-520));(b) a DNA damaging agent (e.g., enediyne, calicheamicin, uncialamycin, topoisomerase inhibitors, topotecan, camptothecin, SN-38, irinotecan (CPT-11), exatecan, Dxd, FL118, pyrrolobenzodiazepine (PBD), PBD dimer, duocarmycin, Duocarmycin A, CC-1065);(c) an RNA targeting agent (e.g., thailanstatin, amatoxin, a-amanitin, P-amanitin);(d) an affinity ligand (e.g., the affinity ligand is a substrate, inhibitor, active agent, neurotransmitter, radioactive isotope, or mixtures thereof);(e) a radioactive label (e.g., 32P or 35S), a fluorescent dye, an electron dense reagent, an enzyme, an immunogenic protein, a nucleic acid molecule with a sequence complementary to a target, or mixtures thereof;(f) an immunomodulatory compound, an anti-cancer agent, an anti-viral agent, an antibacterial agent, an anti-fungal agent, an anti-parasitic agent, or mixtures thereof; (g) an estrogen receptor modulator (e.g., tamoxifen, raloxifene, droloxifene, 4- hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone or toremifene); (h) an aromatase inhibitor(e.g., 4(5)-imidazole, aminoglutethimide, megestrol acetate, exemestane, letrozole or anastrozole);(i) a nonsteroidal antiandrogen (NSAA) (e.g., flutamide, nilutamide, bicalutamide); (j) an aromatase inhibitor;(k) a protein kinase inhibitor;(l) a lipid kinase inhibitor;(m) an antisense oligonucleotide;(n) a ribozyme;(o) a vaccine;(p) an anti -angiogenic agent;(q) a Bcl-xL inhibitor;(r) a NAMPT inhibitor; and(s) a Carmaphycin.288FH30010281.1Attorney Docket: LCH-04525150. The conjugate of any one of claims 1-146, wherein each active agent is independently selected from: Calicheamicin, Monomethyl auristatin E(MMAE), Monomethyl auristatin F(MMAF), Mertansine (DM1), Ravtansine (DM4), SN-38, Deruxtecan (Dxd), FL118, exatecan, pyrrolobenzodiazepines (PBD), PBD dimers, duocarmycin, Duocarmycin A, and Auristatin E.

151. The conjugate of any one of claims 1-19, wherein the conjugate comprises a structure selected from:289FH30010281.1Attorney Docket: LCH-04525290FH30010281.1Attorney Docket: LCH-04525291FH30010281.1Attorney Docket: LCH-04525292FH30010281.1Attorney Docket: LCH-04525293FH30010281.1Attorney Docket: LCH-04525294FH30010281.1Attorney Docket: LCH-04525295FH30010281.1Attorney Docket: LCH-04525296FH30010281.1Attorney Docket: LCH-04525297FH30010281.1Attorney Docket: LCH-04525298FH30010281.1Attorney Docket: LCH-04525299FH30010281.1Attorney Docket: LCH-04525300FH30010281.1Attorney Docket: LCH-04525301FH30010281.1Attorney Docket: LCH-04525302FH30010281.1Attorney Docket: LCH-04525303FH30010281.1Attorney Docket: LCH-04525wherein indicates a connection point to Ab.304FH30010281.1Attorney Docket: LCH-04525152. A pharmaceutical composition comprising the conjugate of any one of claims 1-151 and a pharmaceutically acceptable excipient.

153. A pharmaceutical composition for use in preventing or treating a cancer, the composition comprising the conjugate of any one of claims 1-151.

154. The pharmaceutical composition for use of claim 153, wherein the cancer is selected from lung cancer, colon cancer, colorectal cancer, breast cancer, ovarian cancer, gastric cancer, leukemia, lymphoma, multiple myeloma, head and neck cancer, pancreatic cancer, liver cancer, prostate cancer, and bladder cancer, and combinations thereof.

155. A method of treating or preventing a cancer in a subject in need thereof comprising administering a conjugate of any one of claims 1-151 or a pharmaceutically acceptable salt thereof to the subject.

156. The method of claim 155, wherein the cancer is selected from lung cancer, colon cancer, colorectal cancer, breast cancer, ovarian cancer, gastric cancer, leukemia, lymphoma, multiple myeloma, head and neck cancer, pancreatic cancer, liver cancer, prostate cancer, and bladder cancer, and combinations thereof.305FH30010281.1